Expression of nuclear-acting early-response genes in the rat heart : implications for cardiac hypertrophy by Hannan, R
Expression of Nuclear-Acting 
Early-Response Genes in the Rat Heart: 
implications for cardiac hypertrophy. 
Cl.°)‘'-00(%°(% 
	by 
R. D. Hannan, B.Sc. (HONS) 
submitted in fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
Molecular Biology Unit 
Biochemistry Department 
University of Tasmania (March, 1994) 
STATEMENT 
This thesis contains no material which has been used for the award of any other degree 
or diploma in any tertiary institution and to the best of my knowledge and belief, this 
thesis contains no copy or paraphrase previously published by another person, except 
where due reference is made. 
R.D. Hannan
Authority of Access 
This thesis may be made available for loan and limited copying in accordance with the 
Copyright Act 1968. 
R.D. Hannan
ACKNOWLEDGMENTS 
I would like to express my sincere gratitude to my supervisor, mentor and friend, 
Dr. Adrian K. West, not only for his excellent guidance throughout my doctoral training 
but also for his continuing support and confidence in my ability to succeed in my 
postdoctoral career. He took on that which most others would not have done. 
Also special thanks to my fellow Ph.D. students and members of the 
Biochemistry department including Dr. Steve Richards, Fiona Stennard, Jenny 
Hamilton, Scott Ragg, Ros Thomson and Drs. Kim and Steve Rattigan. Without you all 
my Ph.D. would have been far far duller. 
Finally, I would like to thank Professor Michael G. Clark for allowing me to 
enter into a research career in his department and for providing such a stimulating and 
high class environment in which to do so. 
This thesis is dedicated to my wife and best friend Kate. You kept me going 
where I otherwise would have faltered. All in here I owe to you. 
PUBLICATIONS FROM THIS THESIS 
1. Adrenergic agents, but not triiodo-L-thyronine induce c-fos and c-myc expression in 
the rat heart. R.D. Hannan and A.K. West. Basic Research in Cardiology, 86;154-164 
(1991) 
2. Localization of c-fos and related gene expression in the rat heart following 
norepinephrine expression. R.D. Hannan, F.A. Stennard and A.K. West. Journal of 
Molecular and Cellular Cardiology, 25; 1137-1148 (1993) 
3. Localization of c-myc proto-oncogene expression in the rat heart in vivo and in the 
isolated, perfused heart following treatment with norepinephrine. R.D. Hannan, F.A. 
Stennard and A.K. West. Biochimica et Biophysica Acta, 1217;281-290 (1994) 
iv 
ABBREVIATIONS 
a-SkA: a-skeletal actin 
ABC: avidin-biotin complex 
aFGF: acidic fibroblast growth factor 
ANG angiotensin 
ANP: atrial natriuretic peptide/factor 
AP-1: activating protein 1 
APAAP: alkaline phosphatase-antialkaline phosphatase 
ATF: activating factor 1 
bFGF: basic fibroblast growth factor 
BSA: bovine serum albumin 
cAMP: cyclic AMP 
Cd: cadmium chloride 
CRE: cAMP response element 
CREB: cAMP response element binding protein 
DAB: diaminobenzidine 
DEX: dexamethasone 
DMSO: dimethyl sulfoxide 
EPI: epinephrine 
ET-1: endothelin-1 
FLI: Fos like immunostaining 
HLH: helix-loop-helix 
i.p: intraperitoneal 
IP3 : inositol phosphate 
LAB: labeled avidin-biotin 
LR: leucine repeat 
MHC: myosin heavy chain 
MLC: myosin light chain 
MOPS: morpholinopropane sulfonic acid 
MT metallothionein 
NE: norepinephrine 
PAP: peroxidase-antiperoxidase 
PBS: phosphate buffered saline 
PCNA: proliferating cell nuclear antigen 
PDC: 4a-phorbol 12b, 13a,-didecanoate 
PDGF: platelet derived growth factor 
PI: phosphatidyl inositol 
PICA: protein kinase A 
PKC: protein kinase C 
PLC: phospholipase C 
PMA: phorbol 12 myristate 13 acetate 
SD: standard deviation 
SDS: sodium dodecyl sulphate 
SHR: spontaneously hypertensive rats 
SR: sarcoplasmic reticulum 
SRE: serum response element 
SRF: serum response factors 
T3 : triiodine-L-thyroxine 
TBS: tris-buffered saline 
TGF-0 1 : transforming growth factor 13, 
TNFoc: tumor necrosis factor a 
TPA: 12-0-tetradecanoylphorbol-13-acetate 
TRE: thyroid response element 
TrM: tropomyosin 
vi 
Expression Of Nuclear-acting Early-Response Genes in the Rat Heart: 
Implications 
for Cardiac Hypertrophy 
Post-natal growth of the mammalian heart is characterized by an increase in size of pre-existing 
cardiomyocytes (hypertrophy) rather than an increase in their number (hyperplasia). The primary stimuli 
for this growth process are not clearly understood but seem to involve both hemodynamic and hormonal 
factors. A major challenge to researchers has been to clearly define the signals that activate and regulate 
cardiac hypertrophy and to elucidate the intracellular transducing mechanisms which couple the 
hypertrophic stimuli to the long term changes in cardiac phenotype and function. Of the most likely 
candidate molecular signals the nuclear-acting early-response genes are of particular interest since their 
protein products are thought to play key roles in linking extracellular signals with terminal patterns of 
gene expression during growth and differentiation. The work in this thesis has examined the ability of 
various hypertrophic stimuli to modulate the expression of nuclear acting early response genes in the rat 
heart both in vivo and in vitro. A single injection of norepinephrine (2.5 jig/kg to 2.5 mg/kg) transiently 
increased mRNA levels of the nuclear acting early-response genes c-myc, c-fos, c-fun, fra-1 and fra-2 in 
the rat heart. Similar responses were also observed following chronic infusion of norepinephrine (100 
gg/kg/h) but not in response to treatment with the hypertrophic hormone triiodo-L-thyroxine. 
Hybridization histochemistry and immunocytochemistry techniques were used to localize early response 
genes to particular cell types and regions of the heart. Following norepinephrine administration (2.5 
mg/kg) Fos protein transiently accumulated in the cardiac myocytes and to a much lesser extent other cell 
types. In direct contrast, little Myc immunostaining was observed in the cardiac myocytes with greatest 
expression being localized to the cardiac non-myocyte population, presumably fibroblasts and cells of 
the vasculature system. The observed responses for both genes was not uniform but appeared greatest in 
the left atrium and left ventricle with lesser expression elsewhere. In order to differentiate the complex 
systemic interactions of norepinephrine from its direct actions upon the heart an isolated perfused heart 
system was employed. Both elevated perfusion pressure (60-120 mmHg) and the inclusion of 
norepinephrine (1 nM to 1 1.tM) in the perfusion buffer (60 mmHg) led to elevated mRNA levels of 
c-myc , c-fos, fra-1 and fra-2. These findings demonstrate the utitlity of the isolated perfused heart system 
as a model to study separately the effects of pressure load and NE on gene expression during the early 
stages of cardiac hypertrophy. Taken together with the in vivo results they lend further support to the 
notion that the products of early-response genes structurally or functionally related to c-fos may mediate 
the hypertrophic actions of norepinephrine and pressure overload. In contrast, c-myc expression may be 
associated with the proliferation of cardiac non-myocyte cells which occurs concomitant with cardiac 
hypertrophy. 
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CHAPTER 1 
INTRODUCTION 
1.1 DEVELOPMENT OF THE HEART: A BRIEF OVERVIEW 
1.1.1 Myocyte Formation 
Cardiac myocytes develop by active proliferation of a population of 
undifferentiated myogenic cells (presumptive myoblasts) which are derived from the 
splanchnic mesoderm of the early embryo (Manasek, 1970; Zak 1974A, 1974B). 
Initially the myoblasts are indistinguishable from their parent presumptive myoblasts 
(Bugaisky and Zak, 1986), however synthesis of myofibrillar protein is slowly initiated 
and accumulates in the cells which become distinguishable as those of muscle (Zak 
1974A, 1974B). This contrasts significantly with skeletal muscle development in which 
proliferation of skeletal myoblasts is mutually exclusive with the activation of muscle 
specific genes (Endo and Nadal-Ginard, 1986; Nguyen et al., 1983; Schneider and 
Olson, 1988). 
In the initial stages of cardiac morphogenesis the primitive heart consists 
only of myocytes, there being no fibroblasts, blood vessels or neuronal tissue (Manasek, 
1970). These non-myocyte components of the myocardium have different origins, 
thought to be the epicardium region of the mesoderm (Manasek, 1968). They invade the 
myocardium later in its development but due to their rapid and continual proliferation 
they eventually outnumber the myocytes by 3 to 1 (Morkin and Ashford, 1968; Grove et 
al., 1969; Bugaisky and Zak, 1986). Even so, myocytes account for more than 75% of 
the adult heart by volume as a result of their hypertrophic postnatal growth. 
As growth of the heart continues and myofibrillar protein accumulates, 
myocytes change from the round or oval shape of the early fetal stage to become 
progressively more elongated and this event parallels development of intraluminal 
pressure (Bishop, 1990). However it is not until shortly after birth when cell division 
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ceases that cardiac myocytes rapidly assume all aspects (with the exception of size) of 
the adult cell. The external shape of the cell develops from the simple neonatal spindle 
cell to a complex structure containing fully developed laterally aligned sarcomeres, 
T-tubules, numerous intercalated disc regions and a cross sectional shape which is 
irregular in order to accommodate adjacent cells and blood vessels (Bishop, 1990). At 
this stage the previously immature vasculature cells, neuronal cells and connective 
tissue become fully developed and functional (Bishop, 1990). 
1.1.2 Postnatal Development 
Prenatal growth of heart occurs primarily as a result of an increase in cell 
number (hyperplasia) but shortly after birth myocyte cell division ceases and further 
myocardial enlargement stems largely from an increase in the size of pre-existing 
myocytes (hypertrophy) and to a lesser extent hyperplasia of nonmuscle cells (Clubb 
and Bishop, 1984; Zak 1974A, 1974B). The exact time of conversion from hyperplastic 
to hypertrophic growth varies from species to species. In the rat an early postnatal 
period of approximately 20 days (birth to time of weaning) (Mattfeldt and Mall, 1987) is 
characterized by both cell division and cell enlargement whilst in the late postnatal 
period (weaning onwards) further increase in cardiac myocyte mass occurs solely from 
hypertrophy of existing myocytes and hyperplasia of non-muscle cell types (Sasaki et 
al., 1968; Claycomb, 1975; Korecky and Rakusan, 1978; Bing et al., 1971; Spann et al., 
1971; Skosey et al., 1972). This growth transition period is characterized by the 
appearance of multinucleate myocytes due to nuclear division which is not accompanied 
by cellular division (Clubb and Bishop, 1984). For example, in rats approximately 90% 
of adult ventricular myocytes have 2 or more nuclei (Bishop and Drummond, 1979; 
Clubb and Bishop, 1984; Muir, 1957; Challice and Edwards, 1961; Bugaisky and Zak, 
1986 ) whilst in pigs adult myocytes contain as many as 4 to 16 nuclei (Grabner and 
Pfitzer, 1974). In contrast, during skeletal muscle development karyokinesis is not 
uncoupled from cytokinesis and formation of multinucleate myotubes occurs via cell 
fusion (Clubb and Bishop, 1984). Furthermore, postnatal growth of skeletal muscle 
differs in that it is mediated in part by recruitment of "satellite" precursor cells in 
addition to hypertrophy (Campion, 1984). 
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Postnatal growth of the heart is also associated with increasing circulatory 
demands of a rapidly growing animal and rather abrupt changes in the patterns of flow 
and circulatory resistance occur shortly after birth (Rudolph, 1979). There is a 
progressive increase in volume load on both sides of the heart whilst pressure load in the 
left ventricle is markedly altered, increasing from about 20-25 mmHg at birth to over 
120 mmHg by several weeks of age (Bishop, 1990). This latter change correlates with 
faster hypertrophic growth of the left ventricular myocardium which is probably 
responsible for the relatively larger mass of this chamber in the adult heart (Rudolph, 
1979; Bishop, 1990). Concomitant with cardiac myocyte development and the 
subsequent transition to hypertrophic growth is the coordinated shift in the expression of 
specific contractile genes and genes involved in cardiac metabolism and energetics 
(Katz, 1990; Nadal-Ginard and Mandavi, 1989; Schneider and Parker, 1990). Generally 
these transitions involve selective transcription within multigene families or alternative 
mRNA splicing within the one gene (Breithart and Nadal-Ginard, 1987). Such "gene 
plasticity" results in a new cardiac phenotype whose functional properties differ from 
those of the fetal heart (Nadal-Ginard and Mandavi, 1989). It is proposed that such 
changes allow the newly developed heart to better cope with the altered hemodynamic 
demand, circulating hormonal levels and higher oxygen dependence characteristic of the 
adult animal (Bishop, 1990). 
1.2 CARDIAC HYPERTROPHIC STIMULI 
The adult heart structure and composition are not, however, a fixed postnatal 
property, but can be modified even further in response to alterations in cardiovascular 
demand, altered circulating hormone levels and following ischemia. For instance, 
certain forms of exercise training or pulmonary artery stenosis are often associated with 
significant myocyte hypertrophy and heart growth beyond that normally expected. 
Altered levels of various circulatory hormones and neurotransmitters such as thyroxine, 
angiotensin II (ANG II) and norepinephrine (NE) are also associated with the 
hypertrophic growth process. However, since many of these agents affect 
cardiovascular hemodynamics in addition to interacting with their corresponding 
receptors within the myocardium, it has often been difficult to ascertain whether they 
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affect myocardial growth directly or whether their trophic actions are mediated by 
complex systemic interactions 
1.2.1 Pressure and Volume Overload 
Increased work placed upon the heart as a result of hemodynamic changes is 
one of the major factors associated with the initiation and maintenance of cardiac 
hypertrophy during both physiological growth and disease states. 
Hemodynamic stimuli which may modulate cardiac growth are traditionally 
differentiated into two broad groups: those that result in pressure overload of the heart 
in which the ventricle must pump against a greater afterload (Batra and Rakusan, 1991) 
and those which give rise to volume overload of the heart in which the output is 
increased, often against a reduced peripheral resistance (Batra and Rakuson, 1991). 
Pressure overload following aortic (Schwartz et al., 1978; Hess et al., 1981; Caspari et 
al., 1977; Oldershaw et al., 1980; ICrayenbuehl et al., 1983) or pulmonary artery 
stenosis (Marino et al., 1985; Cooper et al., 1981) and renovascular or genetic 
hypertension is a major determinant of left ventricular hypertrophy in humans. This 
form of cardiac growth is generally associated with increased ventricular wall thickness 
and myocyte cross sectional area (Grossman et al., 1975; Anversa et al., 1986; Smith 
and Bishop, 1985) without chamber dilation and is termed "concentric" hypertrophy. 
Volume overload in humans is associated with certain forms of strenuous exercise 
training or a number of disease states including aortic insufficiency, arteriovenous 
fistula, tarsal septal defect or with hyperthyroidism (Grossman et al., 1975; Ford, 1976; 
Hutchins et al., 1973; Linzbach, 1960; Carabello et al., 1989; Papadimitriou et al., 
1974; Thomas, et al., 1984; Newman, et al., 1982; Ross, 1974; Hultgren and Bove, 
1981). In contrast to pressure overload, volume overload generally results in an 
enlargement of the ventricular circumference due to an increase in myocyte cell length 
(Grossman et al., 1975; Anversa et al., 1986; Gerdes et al., 1988) with variable changes 
in relative wall thickness (Linzbach, 1960; Grossman et al., 1975) and is thus termed 
"eccentric" hypertrophy. Increased work load on the heart may also occur in response to 
a large variety of myocardial conditions such as ischemic cardiomyopathy or acute 
myocardial infarction in which muscle is lost in a diffuse or focal manner (Sonnenblick 
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et al., 1983). Events such as these may evoke significant hypertrophy of the remaining 
myocardium (reactive hypertrophy) which must assume the load of the tissue lost due to 
the cell death (Sonnenblick et al., 1983). Myocyte growth in response to ischemia can 
be the result of either increased cell diameter and/or length (i.e. eccentric or concentric 
hypertrophy) and this appears to be largely dependent on the region and extent of cell 
damage, the precipitating cause and the status of the heart prior to the event (Anversa et 
al., 1985; Rubin et al., 1983). 
1.2.1.1 Overload hypertrophy: an adaptive response 
At least in the initial stages of cardiac hypertrophy, myocyte growth is 
viewed in terms of an adaptive response of the heart at the cellular and subcellular levels 
of organization which effectively minimizes the increase in pressure and volume 
overload (Rakusan, 1984). It is thought that the adaptive response may be attributed, at 
least in part, to changes in the relative amounts of cardiac specific isocontractile genes 
and enzymes of myocardial metabolism. For instance, rodent models of pressure 
overload are associated with an increase in cardiac mass and re-expression of genes 
associated with the neonatal heart such as 0-myosin heavy chain (0-MHC) (Litten et al., 
1982; Lompre et al., 1979; Martin et al., 1983). The diminished actin-activated ATPase 
activity of 0-MHC decreases the maximum velocity of shortening in unloaded muscle 
fibers (Schwartz et al., 1981) and the lower energetic cost of developed work is 
proposed to be advantageous during high oxygen demand (Katz, 1990; Nadal-Ginard 
and Mandavi, 1989). Other neonatal specific isocontractile genes which are also 
re-expressed include a-skeletal actin (a-SkA), 0-tropomyosin (0-TrM) (Izumo et al., 
1988) and atrial myosin light chain-1 (MLC-1) (Katoh et al., 1989). Similarly the 
neonatal isogenes encoding enzymes associated with myocardial metabolism such as the 
non-muscle subunits of creatine kinase (Ingwall et al., 1985), lactate dehydrogenase 
(Hammond et al., 1976) and the a3-isoform of the sarcolemmal Na+/K+ ATPase (Zahler 
et al., 1989) are up-regulated or reinduced during pressure overload hypertrophy and 
thus contribute to the inerease in the glycolytic potential of the tissue (Bishop, 1990). 
Other genes whose expression is modulated positively or negatively during pressure 
overload hypertrophy include those encoding the sarcoplasmic reticulum (SR) 
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slow/cardiac Ca' ATPase (Komuro et al., 1989) and atrial natriuretic peptide (ANP) 
(Izumo et al., 1988) respectively. It is possible that down regulation of the SR Ca' 
ATPase may explain the alterations in function of the SR and the impairment of Ca" 
movements in the hypertrophic myocardium (Schwartz et al., 1986). 
However re-expression of fetal isogenes is not a characteristic of all forms 
of cardiac hypertrophy and does not appear to occur during cardiac growth associated 
with volume overload as elicited by hyperthyroidism or arteriovenous fistula 
(Swynghdauw, 1986). In fact in these forms of hypertrophy the relative amounts of 
isocontractile genes associated with the adult phenotype are increased (for review see 
Morkin et al., 1983). 
Isocontractile protein shifts also occur in the human heart, but they have 
been less well characterized and appear to differ in many cases from those in rodent 
hearts (Parker and Schneider, 1991). For instance 13-MHC constitutes a major 
proportion of MHC in the adult human ventricle in contrast with rodents in which 
fl-MHC is down-regulated. A comparison of some of the cardiac-specific genes in 
rodent and human ventricle and their alterations following hypertrophic stimulus are 
outlined in Table 1. Further application of molecular techniques such as polymerase 
chain reaction (PCR) will allow for better characterization of muscle-specific gene 
changes within the adult myocardium in the future. (Feldman et al., 1991; Ito et al., 
1991 B). 
Table 1.1 Expression of cardiac isocontractile genes in normal and pressure overloaded 
adult rat and human ventricles. 
Rat 	Human 
a 	 Normal 	 +-1-4- + 
Pressure Overload 	 ++ 
MHC 
Normal 	 -H-+ 
Pressure Overload 
	 +-H- 	1111 
Cardiac 	Normal 	 -H-+ 	-H-+ 
Pressure Overload 	 -H-+ 
a-Actin 
Skeletal 	Normal 	 -/+ 
Pressure Overload 	 +-H- 
(-): not expressed; (+,++,+++): relative expression; (?): unknown or conflicting results. Adapted from 
Parker and Schneider (1991). 
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1.2.1.2 Experimental induction of overload hypertrophy 
A number of experimental models have been developed in order to better 
characterize the effect of altered hemodynamic load on cardiac hypertrophy in vivo. 
Generally these models of hypertrophy are designed to mimic the changes in pressure 
and/or volume load observed clinically in animals during normal development and 
adaptation or in response to disease states. 
Particular forms of physical activity involving dynamic exercise such as 
swimming or running endurance trials are common models used to study hypertrophic 
growth during volume overload. Typically, a moderate or strenuous exercise regimen 
imposed on rats results in 22% and 30% hypertrophy respectively of the right ventricle 
after 8 weeks (Anversa et al., 1982; Loud et al., 1984; Anversa et al., 1984). It is worth 
noting however, that significantly increased adrenergic activity has been associated with 
swimming-exercised rats which may contribute to hypertrophy in its own right (Rupp, 
1989) and may account for the observed increased proportion of oc-MHC levels (Rupp 
and Wahl, 1990; Rupp, 1989; Rupp et al., 1984; Schaible et al., 1987; Pagani and 
Solaro, 1983). Other models of volume overload hypertrophy include chronic 
aortocaval fistula which can result in 20% to 100% increases in heart weight at 1-5 
months compared to sham operated animals (Grossman et al., 1975; Flaim et al., 1987; 
Zimmer, 1983; Batra and Rakusan, 1991). 
Cardiac hypertrophy following pressure overload can be rapidly induced in 
experimental animals by a wide variety of techniques, including abdominal aortic 
banding with right renal ischemia (Doering et al., 1988; Jalil et al., 1988; Jalil et al., 
1989), coarcation of 1 renal artery (Averill et al., 1976; Marino et al., 1985; Sen et al., 
1981; Thiedemann et al., 1983; Sen and Bumpus, 1979), suprarenal abdominal aortic 
banding (Folkman and Klagsbrun, 1987; Slack et al., 1987) and pulmonary artery 
vasoconstriction (Yoshida et al., 1987). For instance, within 8 days following 
constriction of the abdominal aorta there is an approximate 50% increase in size of the 
left ventricle and cardiomyocyte transverse area (Anversa et al., 1986). Spontaneously 
hypertensive rats (SHR) also develop cardiac hypertrophy and there is a gradual increase 
in cardiac mass as a function of an age-related rise in pressure. At 20 weeks of age both 
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hypertension and hypertrophy are established (Okamoto and Aoki, 1963; Okamoto et 
al., 1966; Pfeffer et al., 1979 A; Sen et al., 1974). 
Reactive cardiac hypertrophy may be induced experimentally by occlusion 
of a coronary artery. For instance complete ligation of the left anterior descending 
coronary artery in rats leads to transmural ischemia and a subsequent increase in 
myocardial volume of the surviving cardiac tissue (Zimmer et al., 1990; Pfeffer et al., 
1979 B; Anversa et al., 1984). In addition many models that induce acute cardiac 
overloading such as banding of the pulmonary artery of adult animals may result in 
multifocal areas of necrosis (Bishop and Melsen, 1976) and consequently reactive 
hypertrophy ensues. 
1.2.1.3 Load: a primary and sufficent stimulus for cardiac hypertrophy 
Changes in cardiac gene plasticity, metabolism and work parameters are 
readily characterized during experimentally-induced overload hypertrophy. In contrast 
it has proven very difficult to establish with any degree of certainty whether increased 
load itself is a direct and sufficient cause of cardiac hypertrophy in whole animals. 
Alterations in load are often accompanied by reflex changes in the levels of growth 
factors and neurotransmitters both locally and in circulation which may subsequently 
modulate heart growth. 
i) models of load in vivo 
One in vivo model which has proven particularly useful in dissecting the 
various parameters involved in overload hypertrophy is the heterotopical isotransplanted 
heart (Korecky et al., 1987; Klein and Hong, 1986; Advani et al., 1990; Klein et al., 
1990). In this model a heart is transplanted into the abdomen of a recipient animal of 
the same strain by attaching the stumps of aorta and pulmonary artery to the abdominal 
aorta and inferior vena cava respectively (Korecky and Masika, 1991). The transplant in 
effect functions as a denervated "non-working" Langendorff heart and is exposed to the 
same hormonal stimuli as the endogenous heart but does not support a hemodynamic 
load (Korecky and Masika, 1991). Several days following surgery an onset of atrophy 
is observed and this can not be reversed by the addition of growth-promoting hormones 
or neurotransmitters such as thyroxine or NE although expected shifts in the isomyosin 
spectrum due to these agents can be observed (Korecky and Masika, 1991; Klein and 
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Hong, 1986; Korecky et al., 1987). In addition, moderate swimming exercise does not 
attenuate atrophy of isotransplanted hearts even though mild hypertrophy is observed in 
the endogenous heart (Advani et al., 1990). In contrast, increased load placed upon the 
transplanted heart as a result of aortic insufficiency and/or stenosis of the aortic valve 
significantly attenuates the atrophy observed in the left ventricle (Korecky and Masika, 
1991). 
The papillary muscle, because of its easily dissectable, elongated form and 
highly oriented histological structure is• another model often used for examining the 
direct effect of load on cardiac growth (Anversa et al., 1986). In one study the tethering 
chordae tendineae of a single papillary muscle was cut to remove the load on this region 
of an otherwise normally loaded ventricle. This treatment very rapidly led to atrophy of 
the unloaded muscle (Cooper and Tomanek, 1982) even when the surrounding 
ventricular chamber was subjected to increased load secondary to aortic constriction and 
despite the influence of hormones supplied by the muscle's blood and nerve supply 
(Cooper et al., 1985). The only means by which the mass could be returned to the 
atrophied papillary muscle was by surgical restoration of the original load (Thompson et 
al., 1984; Kent et al., 1985). 
In vivo experiments such as these provide indirect evidence that increased 
work load is a major and sufficient factor contributing to the initiation and maintenance 
of cardiac hypertrophy following hemodynamic overload. Alternatively, these studies 
might simply indicate that load prevents atrophy, which might be an altogether 
different process to hypertrophy. 
ii) models of load in vitro 
In an attempt to better determine whether load itself is a primary and 
sufficient determinant for myocyte hypertrophy and cardiac growth a number of in vitro 
models have been developed including isolated superfused papillary muscle, 
Langendorff perfused hearts and cardiomyocyte cultures. These models have an 
advantage over their in vivo counterparts in that the complex systemic interactions of a 
given hypertrophic stimulus can be removed. Increased ventricular pressure has been 
shown to increase protein synthesis in isolated heart preparations (Hjalmarson and 
Isaksson, 1972; Morgan et al., 1980; Schreiber et al., 1966) and similarly, exposure of 
Langendorff perfused and working hearts to elevated aortic pressure increased the rate 
9 
of cardiac protein synthesis due to faster rates of both peptide chain initiation and 
elongation (Kira et al., 1984). When ventricular pressure development was prevented 
by ventricular draining and hearts were arrested with tetrodotoxin, protein synthesis still 
increased as a function of perfusion pressure (Kira et al., 1984). Further experiments 
demonstrated that oxygen consumption, glucose-6-phosphate levels and energy 
availability could be dissociated from the stimulatory effect of higher aortic pressure 
(Kira et al., 1984). Taken together these results indicate that stretch of the ventricular 
wall in response to elevated aortic pressure is the parameter most closely related to 
increased protein synthesis in vitro (Kira et al., 1984). In support of this other groups 
have demonstrated increased rates of protein synthesis in the left atrium of the perfused 
heart when the filling pressure of the chamber was elevated with respect to controls 
(Smith and Sugden, 1983). Similarly in isolated denervated papillary muscle 
preparations, an enhanced protein synthesis rate was found to be proportional to the load 
or tension applied to the muscle (Kent et al., 1989). 
The importance of load or stretch in the maintenance of cardiac muscle 
structure and function has become even more apparent from experiments with 
cardiomyocyte cell cultures. Unattached and thus externally unloaded feline 
cardiomyocytes maintained in cell suspension rapidly lose internal structure and 
organizational characteristics of differentiated striated muscle and come to resemble 
undifferentiated neonatal myocytes (Cooper et al., 1989). In contrast, adult 
cardiomyocytes externally loaded by attachment to a laminin-coated substrate exhibited 
only a very gradual loss of their characteristic structural, biochemical and functional 
properties (Cooper et al., 1986). Furthermore, linear deformation resulting in 
approximately 10% increase in cardiomyocyte cell length increased incorporation of 
[31-1]-uridine into nuclear RNA and [ 311]-phenylalanine into cytoplasmic protein (Mann 
et al., 1989; Cooper et al., 1989). Other studies have demonstrated that contractile 
arrest produced by either membrane depolarization or L-channel blockade inhibits not 
only growth of neonatal myocytes in culture but also expression of 13-MHC (Samarel 
and Engelmann, 1991). 
Thus in vitro experiments indicate that increased load itself is sufficient 
stimulus to accelerate RNA and protein synthesis and are supportive of the notion that 
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increased cardiac loading is one form of stimulus that is capable of initiating the 
biochemical events that form the basis of cardiac hypertrophy in vivo. 
1.2.2 Hormones and Growth Factors 
Although increased load or stretch of myocytes has been strongly implicated 
in the initiation and maintenance of cardiac hypertrophy, this does not obviate the 
possible importance to cardiac growth of other potential trophic factors such as 
norepinephrine (NE), thyroid hormones, angiotensin II (ANG II), adrenocorticoids and 
insulin. For many of these, it has been difficult to establish precisely what their 
contribution is to the hypertrophic growth process since they may modulate cardiac 
growth directly or as a secondary response via the alterations in hemodynamic 
parameters which they cause. In addition, recent studies have presented strong evidence 
that specific growth factors formed in the heart (Parker and Schneider, 1991; Schunkert 
et al., 1990) or changes in the intracardiac activity of systems such as the 
renin-angiotensin system (Schunkert et al., 1990; Baker et al., 1990), may play an 
autocrine or paracrine role in the hypertrophic response of the myocardium. 
It is possible that although the final result may be the same (i.e. increased 
cardiac muscle mass), different growth-promoting stimuli may accomplish this via 
alternative signaling pathways resulting in distinct changes in myocyte composition and 
cardiac design. By this means it is hypothesized that the heart may be better able to 
adapt to altered functional demand placed upon it during normal growth and disease 
states. 
1.2.2.1 Catecholatnines 
The catecholamines, NE from the sympathetic nerves and epinephrine (EPI) 
from the adrenal medulla, have been identified as likely non-mechanical growth factors 
which may modulate the development of cardiac hypertrophy. Early evidence for this 
notion has stemmed from both clinical observations and from in vivo experiments but 
even stronger lines of evidence are now emerging from studies with isolated cardiac 
myocyte cultures. 
i) in vivo studies 
Numerous studies have been published documenting that chronic 
administration of NE in vivo rapidly leads to increases in myocardial mass and 
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hypertrophy of the cardiac myocytes (Laks et al., 1973; Harri, 1978; King et al., 1987). 
However the establishment of a direct causal relationship between adrenergic-receptor 
occupation and subsequent changes in myocardial metabolism in vivo have been 
difficult due to the complex cardiac and systemic effects that this hormone exerts. For 
instance, cardiac hypertrophy observed following chronic treatment with high doses of 
catecholamines is physiologically similar to that observed in pressure-overloaded hearts 
secondary to aortic stenosis since both models exhibit preferential hypertrophy of the 
left ventricle which is often accompanied by an increase in connective tissue (Marino et 
al., 1985; Benjamin et al., 1989). The similarity between these two forms of cardiac 
growth may be partly interpreted as the effect of high circulating levels of NE leading to 
increased vascular resistance ((l c-mediated vasoconstriction) and subsequent 
pressure-overload of the heart. Thus these findings argue for a secondary pressure 
component in the mediation of NE induced cardiac hypertrophy in vivo. Interpretation 
of results derived from animals treated with high doses of catecholamines in vivo may 
be further complicated due to their ability to cause myocardial damage (reviewed in 
Jiang and Downing, 1990). For instance it is well documented that acute high-dose 
administration of isoproterenol ( a 13-adrenergic agonist) can lead to significant cardiac 
cell necrosis (Stanton et al., 1969) and thus a significant proportion of the cardiac 
enlargement observed under these conditions may be due to reactive hypertrophy and/or 
growth of connective tissue (Jiang and Downing, 1990) rather than a direct trophic 
effect of these drugs (Morgan and Baker, 1991). 
However, direct evidence in vivo for a role of catecholamines in modulating 
cardiac hypertrophy independent of pressure comes from experiments in which cardiac 
hypertrophy is induced by levels of NE that do not alter hemodynamic parameters or in 
which changes in hemodynamics are reduced by peripherally-acting drugs. For instance 
chronic infusion or repeated injections of rats with subhypertensive doses of NE or 
isoproterenol results in significant cardiac hypertrophy (Laks et al., 1973; Tse et al., 
1979; Chiba et al., 1989; Marino etal., 1991). Furthermore it has been shown that these 
changes in cardiac mass occur without concomitant cellular necrosis or fibrosis (Lin, 
1973; Marino et al., 1991). Similarly either infusion or repeated injections of 
hypertensive doses of either a- or P-adrenergic agonists rapidly and independently 
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induce cardiac hypertrophy and increase total RNA concentration even when 
hemodynamic parameters are normalized by co-infusion with the calcium channel 
blocker verapamil (Zierhut and Zimmer, 1989). Thus these experiments demonstrate 
that low doses of catecholarnines can modulate cardiac hypertrophy independent of 
pressure load. In respect to this it is interesting to note that the morphological changes 
produced by low doses of NE appear to be different to those observed in response to 
hypertensive levels of this hormone. For instance subhypertensive doses of NE have 
been reported to lead to similar increases in both left and right ventricular mass which 
are directly paralleled by increases in left and right ventricular muscle cell 
cross-sectional area (Marino et al., 1991). Furthermore, increased muscle mass is 
accompanied by proportional increases in interstitial volume and that of the vascular 
compartment of the heart but not with increased density of connective tissue (Marino et 
al., 1991). In short it appears that low doses of NE produce morphological changes in 
the heart similar to those produced by volume-overload hypertrophy, while higher doses 
of NE can produce morphological growth and abnormalities similar to those produced 
by pressure-overload hypertrophy (Marino et al., 1991). 
In addition to the effect of NE on the heart described above, it appears that 
the adrenergic system may indirectly regulate other models of cardiac enlargement. For 
example a number of studies have reported that cardiac a,- and 13-adrenergic receptor 
numbers are increased during aortic stenosis and consequently it has been hypothesized 
that increased catecholamine sensitivity may play a mediator role in pressure-overload 
hypertrophy (Karliner et al., 1980; Limas, 1979; Tamai et al., 1989). For instance, 
pressure-overload of guinea pig hearts elicits an increase in myocardial a cadrenoceptor 
density and this occurs before the onset of cardiac hypertrophy. Furthermore a,- but not 
n-blockade could prevent the observed development in hypertrophy (Tamai et al., 
1989). However, since a 1 -blockade also decreased left ventricular pressure it was not 
possible to determine whether it affected cardiac metabolism directly or secondary to 
reducing after load. Other groups have demonstrated that long term treatment of 
spontaneously hypertensive rats with a l -adrenergic blockers reduces blood pressure, 
leads to regression of cardiac hypertrophy and shifts the myosin isoenzyme pattern 
towards a-MHC (Takeda et al., 1991). In contrast a number of other studies, a 
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reduction in sympathetic activity was only moderately successful or unsuccessful in 
reducing cardiac mass (Cooper et al, 1985; Prasad et al., 1984; Zimmer and Gerlach, 
1982; Cutilletta et al., 1977; Oparil and Cutilletta, 1979; Tomanek et al., 1982) 
In a number of physiological and pathological conditions leading to 
hypertrophy, sympathetic nervous activity is enhanced and the subsequent augmentation 
of catecholamine release has been implicated in the cardiac growth process. For 
instance patients with congestive heart failure invariably exhibit elevated plasma levels 
of catecholamines (Cohn et al., 1984), whilst certain forms of exercise-induced 
hypertrophy in rats can be ameliorated by chemical sympathectomy and P -adrenergic 
blockade (Rupp and Wahl, 1990). 
In summary, experiments with subhypertensive doses of NE are highly 
supportive of a direct metabolic role for catecholamines in the initiation and 
maintenance of cardiac hypertrophy in vivo. However interpretation of results derived 
from studies conducted with higher doses of catecholamines are less clear due to the 
accompanying hemodynamic and cardiotoxic effects that these hormones cause. 
Whether altered catecholamine and receptor levels modify the development of 
hypertrophy in response to mechanical overload is a controversial subject which is yet 
to be resolved. It is likely that the model of overload and the animal species under study 
are important factors in these instances (Booth and Thomason, 1991). 
ii) in vitro studies 
In an attempt to circumvent the complicating systemic effects of 
catecholamines, investigators have turned to the isolated perfused heart and other in 
vitro myocardial preparations. Early studies demonstrated that pretreatment with 
catecholamines in vivo enhanced protein synthesis in ventricular slices subsequently 
incubated in vitro, but there was no acute effect of EPI on protein synthesis in slices in 
vitro (Malloy, 1973). A number of groups have demonstrated that catecholamines can 
modulate protein synthesis in isolated perfused heart preparations. For instance NE, EPI 
and isoproterenol (selective n-agonist) added in vitro to perfused hearts caused a 
dose-dependent increase in the incorporation of ["C]-phenylalanine into heart protein 
during the first 60 min of perfusion but only EPI was effective in increasing protein 
synthesis after 90 min of perfusion (Kallfelt et al., 1976). In fact other groups have 
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detected inhibition of protein synthesis by 13-adrenergic agonists and other agents which 
raise intracellular cyclic AMP (cAMP) concentrations in the perfused heart during 
sustained perfusion (Fuller and Sugden, 1988). This apparent lack of effect or decrease 
in protein synthesis during extended perfusion periods with catecholamines has been 
postulated to be the result of decreased cardiac ATP levels. It has been demonstrated 
that catecholamines perfused in vitro decrease cardiac ATP levels and total adenosine 
nucleotide contents (Fuller and Sugden, 1988; Chua et al., 1978), probably due to 
insufficient 02  delivery by the simple physiological saline solutions used in perfusion 
buffers, in the face of positive chronotropy and inotropy. Furthermore, since protein 
synthesis is an endogonic process, decreased nucleoside triphosphate contents may 
explain the apparent decrease in protein synthesis elicited by P-adrenergic agents during 
the second hour of perfusion (Fuller and Sugden, 1988). Other groups have avoided 
problems of a-receptor-mediated reduction in cardiac ATP by using hearts arrested with 
tetrodotoxin and in these preparations drugs that increased cAMP content such as 
glucagon and forskolin did not reduce cardiac ATP levels but were able to increase 
protein synthesis after 90 min of perfusion (Xenophontos etal., 1989). 
In addition to 13-agonists, increased protein synthesis has also been 
demonstrated in isolated perfused hearts in response to selective oc cadrenergic agents 
and this has been shown to be due to faster rates of translation of pre-existing mRNA 
(Fuller et al., 1990). 
In contrast to perfused heart preparations, in vitro models using cardiac cell 
culture permit the direct analysis of a single variable at the myocyte level. The most 
inclusive studies examing the effects of catecholamines on cardiomyocyte hypertrophy 
in vitro have been undertaken by Paul Simpson's group (Simpson, 1983; Simpson, 
1985; Simpson, 1989; Henrich and Simpson, 1988; Bishopric et al., 1987; Waspe et al., 
1990) using isolated neonatal cardiocyte cultures and have subsequently been 
confirmed by a number of other groups (Meidell et al., 1986; Inuzuka, 1986). With 
these preparations it has been demonstrated that quiescent neonatal myocytes 
maintained in serum-free medium respond equipotentially to NE and EPI with an 
increase in protein content, cell surface area or cell volume, with no associated cell 
division. Furthermore, cardiac growth was not restricted to non-specific increases in 
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proteins since inRNAs encoding for the muscle-specific isocontractile genes a-skeletal 
actin (a-SkA), 13-MHC (Waspe et al., 1990; Bishopric et al., 1987) and MLC-2 (Lee et 
al., 1988) were also up-regulated. Thus the growth of these cells, both in terms of 
phenotypic changes and cellular enlargement, in response to NE appears to closely 
model cardiac hypertrophy observed in vivo in response to pressure overload. The 
growth-promoting effect of NE in these cell cultures was demonstrated to be mainly 
mediated via the acadrenergic receptors since both - and specific blockers failed to 
inhibit hypertrophic growth whilst 13-adrenergic agonists did not result in increased cell 
size (Simpson, 1983). In addition it was demonstrated that the growth response could 
be regulated independently of beating since growth inhibition with cyclohexamide did 
not prevent induction of beating by NE and conversely inhibition of beating with 
13-antagonists did not prevent stimulation of hypertrophy by NE or EPI (Simpson, 
1985). These experiments provided the first direct evidence that catecholamines could 
modulate cardiac growth independent of changes in cardiac mechanics. 
The notion that the NE growth response of neonatal cells is specific to 
acadrenergic agents may have to be revised since Simpson's group have subsequently 
demonstrated that the 13-adrenergic receptor is linked to myocyte hypertrophy although 
it has a 1000-fold lower EC50, is dependent on certain culture conditions, may require 
contractility and may not activate transcription (Simpson et al., 1991). 
The trophic actions of catecholamines have also been investigated in 
myocyte cultures isolated from adult animals and they appear to differ markedly from 
those observed in neonatal myocyte preparations. For example p- but not a-adrenergic 
stimulation increased a-MHC expression in contracting adult myocytes (Rupp et al., 
1991) and this response was shown not to be linked to the high mechanical activity 
induced by 13-adrenergic agents since no differences in expression were observed 
between contracting and arrested myocytes. The finding that a-MHC expression is 
increased in these experiments rather than 13-MHC, as was demonstrated in neonatal 
myocytes treated with NE, is intriguing but not unexpected since I3-adrenergic 
administration in adult rats has been shown to lead to an increased proportion of 
a-MHC (Sreter et al., 1982; Rupp et al., 1983; Buttrick et al., 1988; Rupp et al., 1991). 
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However, since 13-adrenergic stimulation increases NE release from presynaptic nerve 
terminals (Mueller and Axelrod, 1968) it is difficult to determine whether 0-agonists act 
primarily via 0- or a-adrenergic mechanisms in vivo. In direct contrast, others have 
shown that 13-adrenergic agonists do not stimulate contractile protein synthesis in 
quiescent adult myocytes but instead give rise to a general augmentation of 
non-contractile protein levels (Dubus et al., 1990). Interestingly in another study of 
adult rat myocyte preparations, elevated rates of protein synthesis (20-30%) were 
induced by acute administration of a cagonists and this was shown to be due to faster 
rates of translation of pre-existing inRNA (Fuller et al., 1990). However, Cooper et al 
(1986 and 1987) showed no trophic response was observed in adult feline 
cardiomyocytes treated with NE (Cooper et al., 1986) and thus the growth promoting 
effects of NE may be species-specific or the significant differences in the experimental 
culture conditions may be critical (Rupp et al., 1991). 
The above results clearly demonstrate that adrenergic agents can directly 
mediate hypertrophy and isocontractile gene expression in neonatal cardiac myocytes. 
However, despite recent advances in the preparation and culture of adult cardiac 
myocytes (Bugaisky and Zak, 1989), studies concerning the effect of catecholamines on 
myocyte hypertrophy with these cells are less conclusive and appear to differ from those 
observed in neonatal myocytes. It has been suggested that this discrepancy could result 
from differences in the animal developmental stage from which the myocytes were 
obtained. In the heart of adult mammals the sensitivity of acagents is decreased with 
respect to neonatal hearts (Graham and Lannier, 1986; Schaffer and Williams, 1986) 
whilst cardiac responsiveness to 13-adrenergic agents is increased (Longabaugh et al., 
1986). Alternatively it is possible that growth stimulation in adult myocytes is more 
dependent on the inotropic (Watanabe and Lindemann, 1984; Winegrad, 1984) and 
chronotropic effects (Watanabe and Lindemann, 1984) of adrenergic stimulation than in 
neonatal cells. Importantly, recent studies indicate that growth factor(s) released from 
cardiac non-myocytes that act in a paracrine fashion may be important for hypertrophy 
of adult hearts (Parker and Schneider, 1991; Long et al., 1991) and thus future in vitro 
experiments will need to investigate the effects of adrenergic agents on adult myocytes 
in the presence of other myocardial cell types. 
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In conclusion, in vivo studies indicate that adrenergic agents can stimulate 
cardiac hypertrophy independent of hemodynamic changes and these findings are 
supported by experiments with isolated neonatal myocytes. However when adult 
myocytes are removed from their complex three dimensional surrounds and cultured in 
vitro the effect of adrenergic agents on their growth is less conclusive. It is likely that 
cardiac non-myocytes may play an important role in mediating the effects of NE on 
hypertrophic growth of adult myocytes in situ and that this may be mediated by the 
release of specific paracrine growth factor(s). 
1.2.2.2 Angiotensin 
The vasoactive octapeptide hormone ANG H is the major circulatory 
component of the renin-angiotensin system, an important hormone system that regulates 
volume and fluid homeostasis in humans and other animals. In addition to these well 
established actions, recent studies indicate that ANG H may directly increase protein 
synthesis and cardiac hypertrophy by coupling to its cardiac membrane receptor. 
Furthermore, evidence has mounted recently suggesting that a locally active, 
intracardiac renin-angiotensin system may have an autocrine or paracrine influence on 
myocyte growth and cardiac hypertrophy during pressure overload. 
i) in vivo studies 
ANG II may indirectly affect cardiac growth by causing increased blood 
pressure and total vascular resistance due to coupling to its receptors in the vasculature 
system. However, direct in vivo evidence for a role of ANG H in modulating 
myocardial growth has come from studies in which animals administered 
subhypertensive doses (Morgan and Baker, 1991) or hypertensive doses of ANG H in 
which the pressor activity of the drug was inhibited, (Khairallah and Kanabus, 1983), 
still developed marked cardiac hypertrophy. From these studies it has been suggested 
that ANG H stimulates protein synthesis and cell growth in cardiac tissue by direct 
coupling to its cardiac reeceptors including those on the cardiomyocytes (Baker et al., 
1984; Baker and Khosla, 1986; Wright et al., 1983). However the mechanism by which 
occupation of its receptor is coupled to protein synthesis is not known. 
In addition to a role for circulating ANG II in cardiac growth, evidence 
supporting the presence of local renin-angiotensin systems in the heart (Jin et al., 1988; 
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Dzau, 1988) has recently accrued. Studies indicate that both angiotensinogen (the 
substrate for angiotensin converting enzyme) and renin mRNA are found in the 
myocardium and are developmentally regulated in this tissue (Chemin et al., 1990; Jin 
et al., 1988; Dzau et al., 1987; Kanapuli and Kumar, 1987; Ohlcubu, et al., 1986). For 
instance, both renin and angiotensinogen mRNA are present in all chambers of the 
neonatal heart but soon after birth, expression is localized to the left and right atria 
(Chernin et al., 1990). Furthermore, the angiotensin converting pathway appears to be 
amplified during pressure-overload hypertrophy since in hypertensive rats 
angiotensinogen levels are several-fold higher in the left ventricle than in normotensive, 
non-hypertrophic rats (Li et al., 1989). Similarly, aortic constriction results in 
up-regulation of angiotensinogen and angiotensin converting enzyme mRNA levels in 
the hypertrophying left ventricle (Baker et al., 1990; Schunkert et al., 1990). It has been 
suggested that this may represent a regression of the ventricular myocyte toward the 
neonatal cell type exemplified by cardiac specific isocontractile proteins shifts (Chernin 
et al., 1990). This developmental regulation and re-expression during pressure overload 
is similar to that observed for ANP mRNA (Chemin et al., 1990; Wei et al., 1987). 
The exact physiological roles of the local ANG II generating pathways have 
not been defined but within the heart it has been suggested that in addition to effects on 
cardiac contractility, coronary vasomotor tone and arrhythmogenesis, they may play a 
permissive role in modulating cardiac growth and development (Dzau, 1988; 
Lindpaintner et al., 1988). For instance, treatment with angiotensin converting enzyme 
inhibitors resulted in prevention or reversal, of left ventricular hypertrophy brought 
about by aortic stenosis in rats (Schunkert et al., 1990; Kromer and Riegger, 1988) and 
in response to chronic pressure overload in humans (Wakashima et al., 1984; Devereaux 
et al., 1987). Furthermore, this occurred even when the levels of angiotensin converting 
enzyme inhibitors did not decrease peripheral resistance (Schunkert et al., 1990). 
These data indicate ANG II may directly affect myocardial growth by 
coupling to its cardiac receptors and that this may occur independently of the well 
established endocrine functions such as increased peripheral vascular resistance and 
arterial pressure, that this hormone can produce. In addition it appears that locally 
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generated ANG II may have an important role in mediating cardiac cell growth and 
hypertrophy in vivo during pressure-overload hypertrophy. 
ii) in vitro studies 
A number of studies have demonstrated that ANG II can stimulate protein 
synthesis and hypertrophy in cultured vascular smooth muscle cells (Berk et al., 1989; 
Geisterfer et al., 1988). More recently a direct trophic role for angiotensin has been 
demonstrated in cardiac tissue. Cultured embryonic chick myocytes treated with ANG 
H for 3 h exhibited increased total RNA levels, total cellular protein (32%) and 
enhanced cellular hypertrophic growth within 5 to 6 days compared to untreated cells 
(Baker and Aceto, 1990). The growth-related effects of ANG H could be prevented by 
ANG H antagonists but not adrenergic antagonists and were accompanied by increased 
cytosolic Ca' influx. In addition the hypertrophic effects of ANG II were not dependent 
on the chronotropic state of the cells since increases in cellular protein were not 
inhibited by 1(4" depolarization (Baker and Aceto, 1990). In contrast studies with adult 
myocyte cultures found that ANG II did not increase protein synthesis except under 
• high Ca' conditions (Fuller et al., 1990). It is possible that the discrepancy in results 
between these culture systems stems from quantitative and/or qualitative differences in 
the ANG II receptors. Further studies are needed to fully characterize the role of 
components of the renin angiotensin system in both adult and neonatal cell cultures. 
In summary, both in vivo and in vitro data indicate that ANG H may 
modulate cardiac hypertrophy by direct activation of its cardiomyocyte receptors. In 
addition ANG H may indirectly affect cardiac growth during hypertension by either 
paracrine and/or autocrine functions related to a locally-acting intracardiac 
renin-angiotensin system. 
1.2.2.3 Endothelin-1 
Endothelin-1 (ET-1) is a 21-residue vasoconstrictive peptide derived from 
the endothelium that induces a potent and sustained vasoconstrictive effect on a number 
of blood vessel types (Yanagisawa et al., 1988; Moravec et al., 1989). It is considered 
to play an important role in the regulation of blood pressure and local blood flow (Ito et 
al., 1991 A) and possesses powerful inotropic and chronotropic actions on isolated atria 
in a number of species (Moravec et al, 1989; Ishikawa et al., 1988; Hu et al., 1988). 
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ET-1 receptors in cardiac membrane (Gu et al., 1989) and in cultured cardiomyocytes 
have been recently characterized and it now appears that ET-1, in addition to its 
vasopressor activity, may act as a myocyte growth factor in a similar fashion to 
acadrenergic agonists. 
Direct support linking ET-1 activity to cardiac growth has come from in 
vitro experiments with neonatal myocytes cultured in serum-free medium. In this 
system ET-1 has been shown to augment protein synthesis and hypertrophy in cardiac 
neonatal myocytes (Suzuki etal., 1990; Ito etal., 1991 A) with concomitant increases in 
mRNA transcripts (2-5 fold) of the muscle specific genes MLC-2, a-SlcA and 
troponin-1 within 6 h (Ito et al., 1991 A). Run-on transcription assays indicated that 
contractile isogene expression was regulated by increases at the level of transcription. 
Furthermore, similar responses were observed following treatment with TPA or 
ionomycin (Ito et al., 1991 A) and were blocked by protein lcinase C (PKC) inhibitors 
(Suzuki et al., 1990) indicating that activation of PKC and calcium ion influx may 
mediate ET-1 induced myocyte hypertrophy. Recent studies indicate that the addition of 
ET-1 to cultured adult myocytes more than doubles the rate of protein synthesis 
(Neyses et al., 1991). 
These results indicate that ET-1 is a potential modulator of hypertrophy in 
neonatal myocytes and protein synthesis in adult myocytes, however its relevance to 
pathophysiological hypertrophy in vivo has not been determined. It is possible that 
ET-1 may act in a paracrine fashion to mediate pressure overload hypertrophy in certain 
models of hypertension as is hypothesized for the renin angiotensin system. In support 
of this, plasma ET-1 levels have been reported to be increased in patients with 
hypertension (Shichiri et al., 1990) and acute myocardial infarction (Miyauchi et al., 
1989). 
1.2.2.4 Thyroid hormones 
The heart is a major target organ of thyroid hormone action and clinical 
symptoms associated with thyroid dysfunction indicate that this hormone exerts 
multiple effects on cardiac structure and function. In particular, the ability of thyroid 
hormone to modulate cardiac hypertrophic growth during disease states and in 
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experimental studies in vivo and in vitro has received considerable attention from both 
clinicians and researchers alike. 
i) in vivo studies 
It is well documented that the administration of thyroid hormones (T 4 and 
T3) to rodents produces rapid and reversible cardiac hypertrophy (Bonnin et al., 1983; 
Carter et al., 1982; Crie et al., 1983; Sandford et al., 1978; Siehl et al., 1985; Zahringer 
et al., 1984; Yazalci and Raben, 1975). For instance, repeated injections or chronic 
infusion of T3 results in a significant increase in RNA concentrations (approximately 
20% within 1 day) (Morgan et al., 1978; Kao et al., 1977), protein synthesis (46% 
within 3 days) and myocardial mass (45% within 7 days) (Clarke and Ward, 1983). 
This has been shown to be largely due to faster rates of protein synthesis rather than 
decreased rates of protein degradation (Sandford et al., 1978; Cohen et al., 1966; 
Wildenthal et al., 1978). 
In addition to non-specific changes in protein synthesis, increased thyroid 
hormone levels are associated with specific alterations in expression of genes coding for 
isocontractile proteins. Hypothyroid states in the rat results in a complete switch in the 
normal a/f3-MHC distribution (Hoh et al., 1978; Lompre et al., 1984) by inducing the 
progressive disappearance of a-MHC mRNA and the appearance of f3-MHC mRNA 
(Talafih et al., 1984). Conversely, thyroxine replacement has the opposite effect, 
suggesting that the a- and P-MHC genes are regulated by thyroid hormone in an 
antithetic fashion (Mandavi et al., 1984) and directly opposed to the isoform shifts 
observed during pressure-mediated cardiac hypertrophy. As with pressure-overload 
hypertrophy, it is thought that alterations in myosin composition during hypo- and 
hyper-thyroidism are physiologically significant, since the relative proportions of the 
isoforms seem to be directly related to the intrinsic speed of contraction (Barany, 1967; 
Schwartz et al., 1981). 
The mode by which thyroid hormone affects cardiac metabolism is a 
contentious issue. Convincing evidence exists that a significant proportion of the 
physiological action of thyroid hormone depends on its interaction with nuclear 
receptors with which it has high affinity (Oppenheimer et al., 1972; Lazar and Chin, 
1990). Following occupation of its receptor, it is internalized where the complex binds 
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to sites on sensitive DNA known as thyroid-response elements, and mediates or 
modulates both positively and negatively transcriptional processes. Thus thyroid 
hormone responsiveness of cardiac a-MHC has been implicated by the identification of 
a thyroid response elements within the 5' flanking region of this gene (for reviews see 
Mandavi et al., 1989; Nadal-Ginard and Mandavi, 1989). By analogy it is possible that 
other changes in gene expression characteristic of thyroid hormone-induced cardiac 
hypertrophy may mediated by direct binding of the thyroid receptor to the appropriate 
sites on DNA. 
Alternatively, the trophic actions of thyroid hormones may be the result of 
secondary alterations in hemodynamic and metabolic parameters since increased cardiac 
rate, left ventricular systemic pressure, CO, output and decreased peripheral resistance 
are all associated with hyperthyroidism (Buccino et al., 1967; Morlcin et al., 1983). The 
observation that many of these changes are mimicked by the stimulated sympathetic 
nervous system has led to the hypothesis that alterations in adrenergic neurotransmitter 
sensitivity may have an importance in thyroid hormone-induced hypertrophy. In 
support of this, changes in cardiac NE levels (Levin et al., 1982) and in NE turnover 
(Coulombe et al., 1977) have been found in hypo- and hyperthyroidism. In addition, 
direct receptor binding studies have demonstrated that thyroid hormone administration 
leads to up-regulation of 13-receptors (Williams et al., 1977) by directly controlling the 
rate of transcription of the 13,-adrenergic receptor gene (Bahouth, 1991). Conversely 
a-receptor numbers are down regulated in cardiac tissue under these conditions (Ishac et 
al., 1983; Williams and Leflcowitz, 1979). Clinically, 13-adrenoceptor blockade has been 
used in combination with anti thyroid drugs for the treatment of thyrotoxicosis, and 
I3-adrenoceptor antagonists have been shown to be partially effective in reducing 
Is-mediated hypertrophy in animal experiments (Eliades and Harvey, 1989). However 
not all studies support this mode of therapy. For instance, reserpine treatment does not 
reduce cardiac hypertrophy during thyrotoxicosis (Malcolm, 1972). Furthermore, 
co-infusion of either a- and/or p-adrenergic blockers during thyroid hormone 
administration was found not to reduce cardiac hypertrophy even when left ventricular 
mechanical parameters were reduced (Zeihut and Zimmer, 1989). These studies 
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indicate that thyroid hormones can modulate cardiac hypertrophy independently of a-
and 13-adrenergic stimuli or changes in mechanical parameters of the heart. 
In contrast, in vivo studies with heterotopically transplanted hearts (Korecky 
et al., 1987; Klein et al., 1990) or papillary muscle (Cooper and Tomanek, 1982; 
Cooper et al., 1985) indicate that changes in myocardial mechanics are the more likely 
mediators of thyroid hormone-induced cardiac hypertrophy rather than direct metabolic 
effects (for a more detailed discussion see section 1.2.1.3) 
ii) in vitro studies 
Studies with in vitro preparations are generally supportive of a direct effect 
of thyroid hormones on protein synthesis. In hearts from T s injected rats that were 
perfused as working preparations with blood simulants, an increase in the number of 
ribosomes was associated with faster rates of protein synthesis (Siehl et al., 1985). 
Similar results were obtained from investigations using fetal mouse hearts in organ 
culture and in addition, increased protein synthesis was demonstrated in absence of the 
usual systemic metabolic and hemodynamic effects associated with thyroid hormone 
administration in vivo (Crie et al., 1983). In chicken cardiomyocyte cultures, both 
augmented protein synthesis and myocyte growth were observed following T, treatment 
(Carter et al., 1985). Similarly, the addition of T, to K*-depolarized noncontracting 
myocytes increased rates of protein synthesis by approximately 35% (unpublished from 
Morgan and Baker, 1991). In feline and rodent fetal cardiomyocyte cultures, thyroid 
hormone treatment increased a-MHC gene expression and down regulated p-MHC 
expression (Gustafson et al., 1987; Nag and Cheng, 1984). Thus in vitro studies support 
a direct action of thyroid hormones on cardiac growth and isocontractile gene 
expression which does not seem to be dependent on secondary changes in contractile 
properties of these cells. 
In summary it seems likely that both peripheral and direct effects of thyroid 
hormones contribute to the cardiac hypertrophy observed in vivo. However the relative 
contribution to these two trophic components of thyroid action has proven difficult to 
determine and further investigation is required. 
1.2.2.5 Other myocardial hypertrophic factors 
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In addition to the afore mentioned trophic factors, other circulatory 
substances such as adrenocorticoids, insulin and growth hormone have been implicated 
to some degree in the initiation or maintenance of cardiac hypertrophy. It is likely 
however that in the majority of cases these substances play a permissive role as opposed 
to an initiatory role in this trophic process (Morgan and Baker, 1991). Even so, 
evidence is accumulating that cardiac myocytes may be the targets for the action of a 
number of peptide growth factors which may act in an autocrine or paracrine manner to 
mediate hypertrophic growth during cardiac overload. For instance when pressure load 
was applied to the right ventricle of an in vitro perfused rabbit heart, increased 
incorporation of [ 31-1]-1ysine into cardiac contractile protein was observed not only in the 
right but also the left ventricle where pressure load was not applied (Kira et al., 1982). 
Furthermore, perfusate washout from a heart with a pressure-loaded right ventricle 
stimulated increased [ 31-1]-1ysine incorporation into both left and right ventricular 
chambers of a co-perfused unloaded heart (Kira et al., 1982). More recently it was 
demonstrated that extracts from hypertrophied left ventricle of dogs with experimentally 
induced renal hypertension increased [314]-uridine uptake in cultured rat cardiac 
myocytes. These experiments suggest that growth factor(s) are released from pressure 
loaded ventricle which can initiate hypertrophy in unloaded ventricles and isolated 
myocytes (Honda et al., 1988). Such trophic factor(s) may not be species-specific since 
water soluble extracts from pressure-loaded hypertrophying dog hearts can cause 
increased mRNA synthesis and initiate hypertrophy in unloaded rat hearts (Hammond et 
al., 1982). The nature of these putative growth factor(s) is unknown but recently a 
number of known growth factors have been localized to cardiac tissue including acidic 
fibroblast growth factor (aFGF), basic FGF (bFGF), platelet-derived growth factor 
(PDGF), tumor necrosis factor a (TNFa) and transforming growth factor 13, (TGF 13,) 
(for a review see Parker and Schneider, 1991). Furthermore, the administration of these 
growth factors to cardiac myocyte cultures stimulated reexpression of neonatal specific 
contractile genes similar to those observed in pressure overloaded hearts in vivo (see 
Table 1.2). In addition to these well characterized growth factors a novel growth factor 
has been isolated from cardiac non-myocyte cells which stimulates hypertrophy but not 
hyperplasia of neonatal cardiac myocytes maintained in serum free medium (Long et al., 
1991). 
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Thus considerable evidence is accumulating to suggest that cardiac 
non-myocytes may modulate myocyte growth during normal development and in 
response to hypertrophic stimuli by the production of an array of growth factors which 
act in a paracrine fashion. Such findings further emphasize the complexity of the 
hypertrophic growth response in vivo and underline the need to consider all cell types of 
the heart when investigating this growth phenomena. 
Table 1.2 Changes in the expression of cardiomyocyte genes in response to peptide 
growth factors. 
Gene/isoform 	 Growth Factor 
MHC 
a 	 aFGF, bFGF, TGFP1 
bFGF, TGFii i 
a-actin 
Cardiac 	 bFGF, TGF[3 1 
Skeletal bFGF, TGFP, 
Smooth 	 aFGF, bFGF, TGF[3 1 
ANF 	 aFGF, bFGF, 
Slow/cardiac Ca' ATPase 	 aFGF, bFGF, TGF13 1 
aFGF: acidic fibroblastic growth factor; bFGF: basic fibroblastic growth factor; TGFb t.transforming 
growth factor 	. Adapted from Parker and Schneider (1991). 
1.3 HYPERTROPHIC SIGNAL TRANSDUCTION PATHWAYS AND GENE 
TRANSCRIPTION 
1.3.1 Gene Transcription 
The data presented clearly illustrates that cardiac hypertrophy is a 
heterogeneous process involving both quantitative changes in general protein synthesis 
and also qualitative alterations in the levels of specific isocontractile and metabolic 
proteins. In the majority of studies the observed changes in myocyte size and phenotype 
were attributed to increased protein synthesis rather than decreased protein degradation 
(Kira et al., 1984; Xenophontos et al., 1989; Fuller et al., 1990; Simpson, 1983). 
Theoretically a number of potential sites for the regulation of protein synthesis exist 
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including transcription and translation. However, during cardiac hypertrophy, changes 
in myocyte levels of contractile and non-contractile proteins were generally preceded by 
corresponding alterations in the level of their appropriate mRNA (Waspe et al., 1990; 
Bishopric et al., 1987; Lee et al., 1988). Thus gene plasticity during cardiac 
hypertrophy appears to be the result of changes above the level of translation. 
Furthermore, using nuclear run-on assays to quantify the initiation of transcription it 
was shown that an increased rate of DNA transcription rather than increased RNA 
stability was responsible for selective increases in isocontractile mRNA (Lee et al., 
1988; Ito et al., 1991 B; Simpson, 1990). 
Considered together these studies demonstrate that extracellular 
hypertrophic stimuli are able to effect changes in gene expression within the nuclei of 
cardiac myocytes and establish that gene transcription is a critical regulatory event 
during cardiac hypertrophy. 
1.3.2 Signal Transduction Pathways 
The intracellular transducing mechanisms which couple hypertrophic stimuli 
to long term changes in cardiac gene transcription have yet to be clearly elucidated. In 
other systems it has been shown that growth promoting stimuli regulate gene expression 
via intracellular pathways (second messenger systems) which culminate in the increased 
activity of a number of protein transcription factors (third messenger systems) which 
subsequently interact with the promoter elements of target genes (for review see 
Lenardo and Baltimore, 1989; Mitchell and Tjian, 1989; Yamamoto, 1985). It is likely 
then that a similar regulatory strategy occurs during hypertrophic growth following 
mechanical load or exposure to hormones such as NE. In accordance with this 
hypothesis there are a number of general but distinct second messenger systems which 
have been tentatively implicated in the transduction of these hypertrophic stimuli from 
the myocyte cell membrane to the nucleus including (1) cAMP formation, (2) PKC 
activation and (3) increases in ion fluxes. Thyroid hormone is able to affect gene 
transcription directly by binding to thyroid response element target sites in DNA and 
this has been discussed previously, however evidence also exists that this hormone may 
mediate hypertrophy indirectly through some of the above pathways. 
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1.3.2.1 cAMP 
Intracellular content of cAMP may play a significant role in mediating 
cardiac hypertrophy in response to a variety of trophic stimuli. A number of studies 
indicate that cellular stretch or deformation of cardiac muscle increases cAMP as well as 
protein synthesis and ribosome formation (Morgan et al., 1989; Watson, 1989). 
Elevated levels of adenyl cyclase have been reported in guinea pig hearts 10 min 
following hemodynamic overload (Schreiber et al., 1971). Furthermore, elevated aortic 
pressure increased protein synthesis, cAMP concentration and cAMP dependent protein 
kinase activity in isolated perfused rat hearts (Xenophontos et al., 1989, Haneda et al., 
1990; Watson et al., 1989). Occupation of 13-adrenergic receptors by catecholamines 
has been reported to increase adenyl cyclase activity, lead to cardiac hypertrophy in 
vivo, and increased protein synthesis and cell growth in adult myocyte cell cultures. The 
thyroid hormone T, has been shown to increase cAMP levels in the heart within 12 h of 
administration (Zimmer and Peffer, 1986) and accordingly it has been suggested that 
this may be an intracellular transducing signal for cardiac hypertrophy induced in 
response to this hormone (Zimmer and Peffer, 1986). 
1.3.2.2 PKC 
PKC activity has been strongly implicated in myocyte hypertrophy in 
response to catecholamine, ANG II or ET-1 administration or following stretch. For 
instance, PKC activity has been associated with increased general protein synthesis, 
isocontractile gene transcription and myocyte hypertrophy in isolated neonatal myocyte 
cultures following acadrenergic or ET-1 stimulation (Henrich and Simpson, 1988; 
Suzuki et al., 1990). Secondly, phorbol myristate (PMA) activates PKC and also gives 
rise to trophic responses similar to those seen in response to a cadrenergic and ET-1 
administration (Henrich and Simpson, 1988; Suzuki et al., 1990). Whether PKC 
activity is coupled to cardiac hypertrophy mediated by these hormones, in adult 
myocytes, is still uncertain since it has proven difficult to establish whether growth in 
isolated adult cardiomyocytes responds to a cadrenergic stimulation (Rupp et al., 1991; 
Dubus et al., 1990). 
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Although not formally demonstrated in cardiac myocyte cultures, ANG II 
has been shown to elevate PKC translocation and induce phosphorylation of nuclear 
laminae in cultured vascular smooth muscle (Tsuda and Alexander, 1990). It is possible 
therefore that increased translocation of PKC may be a means by which increased 
intracardiac renin-angiotensin system activity may directly modulate cardiac growth 
independent of hemodynamic changes. PKC has also been implicated in 
stretch-induced hypertrophy since atrial distention causes increased phosphatidylinositol 
(PI) turn-over and this has been shown not to be the result of NE or acetylcholine • 
release (Von Harsdorf et al., 1989). 
1.3.2.3 Ion fluxes 
Changes in ion fluxes, particularly altered calcium ion current (Keung, 
1989; Kleiman and Houser, 1988), NW-Ca' exchange and calcium release from SR 
(Lecarpentier et al., 1987; Lore11 et al., 1986) have been reported in hypertrophic 
myocardium. Increased aortic pressure has been shown to significantly increase [Cali 
in isolated perfused hearts (Schreiber et al., 1977) although elevation of Ca 2+ in the 
perfusate did not alter rates of protein synthesis (Haneda et al., 1989). The mechanism 
by which [Cali increases in response to perfusion pressure is not known but it is likely 
to be modulated through stretch-activated ion channels which have been identified in the 
lumen of adult and neonatal cardiac myocytes (Bustamante et al., 1991). Furthermore, 
stretch of myocytes in culture increases protein synthesis, alters isocontractile protein 
content and elevates Ca2+ influx (Komuro et al., 1989 A). It has also been demonstrated 
that activated 13-adrenergic receptors can increase Ca' flux through cardiac calcium 
channels via direct G-protein interaction or by phosphorylation of cAMP-dependent 
protein lcinases (Haung et al., 1990; Yatawi and Brown, 1989). Finally, occadrenergic 
agonists, ANG H, ET-1 and stretch stimulate calcium ion release from the endoplasmic 
reticulum via increased phosphoinositide-phospholipase C (PI PLC) turnover and 
inositol phosphate (IP) formation (Brown et al., 1985; Suzuki et al., 1990; Baker and 
Aceto, 1989). Thus increased [Ca21i due to mobilization from intracellular stores in 
addition to influx through membrane channels, may be a means by which hypertrophic 
stimuli may modulate cardiac growth. 
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Sodium ion flux has been associated with growth processes in cardiac tissue. 
Deformation of cardiocytes increases Na+ flux through a stretch-activated ion channel in 
the SR (Bustamante et al., 1991). The normal influx of Na` induced by spontaneous 
contraction in neonatal rat myocytes is associated with increased general protein and 
isocontractile protein synthesis, compared to non-contracting cells (McDermott and 
Morgan, 1989). Partial block of this mechanotransducer by the polycationic antibiotic 
streptomycin (Ohmori, 1985) reduces both Na+ uptake in stretched myocardium and 
isolated cardiocytes by 15% and reduces contractile protein synthesis (Kent et al., 
1991). In differentiated avian skeletal myotubles both increased sodium influx and 
protein synthesis have been observed in response to mechanical stretch (Guharay and 
Sachs, 1984). 
1.3.2.4 Other mechanisms of transduction 
In addition to the cellular messengers described above it is possible that 
rapidly activated, unknown molecular signals, secondary to trophic stimuli could bind 
directly to DNA and regulate cellular growth and phenotype (Komuro et al., 1990). It 
has also been postulated that stretch-dependent plasmalemma alterations could be 
translated directly into changes in nuclear structure via transmission of mechanical 
forces across cytoskeletal structures that physically link the plasma membrane to the 
nuclear envelope (Georgatos and Blobel, 1987). The importance of the cytoskeleton 
and the interaction of the cytoskeleton with intracellular matrix in regulation of cell 
growth has been the subject of a number of reviews (Lazarides, 1980; Lazarides, 1985 
A; Craig, 1985; Lazarides, 1985 B; Bissel et al., 1982). Furthermore, it was recently 
demonstrated that during cardiac hypertrophy a number of cytoskeletal networks are 
modified (Rappaport and Samuel, 1988; Samuel et al., 1990). 
1.3.2.5 Molecular mechanisms by which PKC, cAMP and ion flux may 
modulate gene transcription. 
Mechanisms by which increased PKC activity, cAMP levels, ion flux or 
mechanical transducers may regulate hypertrophic growth processes are not known but 
it is well established that protein phosphorylation by kinases is one key regulatory 
mechanism for signal transduction pathways that link cell surface events to alterations in 
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gene expression (see Schonthal et al., 1991). For instance increased cardiac cAMP 
levels or increased membrane phospholipid turnover following hypertrophic stimuli can 
activate cAMP dependent protein kinase A (PICA) or PKC respectively. In turn, 
activation of these lcinases may result in the modulation of nuclear transcription factors 
which could then bind to regulatory regions of the target genes (e.g. an isocontractile 
gene) or to another protein bound to a regulatory region, and thereby activate RNA 
polymerase II (Simpson et al., 1989). Activation of transcription factors by PKC in 
other systems has been previously demonstrated (Elsholtz et al., 1986; Sen and 
Baltimore, 1986; Angel et al., 1987; Bohmann et al., 1987) and often involves 
12-0-tetradecanoylphorbol-13-acetate (TPA) response elements (TREs) (Angel et al., 
1987). Genes that are regulated by cAMP have also been identified (Roesler et al., 
1988) and usually contain a cAMP response element (CRE) in their 5' control regions 
(Franza et al., 1987). For a more detailed discussion of the above see section 13.3. 
Increased [Cal may also regulate transcription during hypertrophy via kinase activity 
since increased ion flux or release from intracellular stores following trophic stimuli, 
may cause phosphorylation of a variety of cellular proteins including transcription 
factors (Morgan and Curran, 1986), by Ca 2+ activated, calmodulin-independent PKC 
(Colbran et al., 1989) or by PKC (Blinks et al., 1982; Rasmussen and Barrett, 1984). 
Alternatively Ca2+ may bind and activate a transcription factor directly in a similar 
manner to which it activates calmodulin. At present no second messenger system is 
known to be dependent on Na+ uptake but it is possible that increased [Nali may be 
acting by secondary alterations in [Cali via Ne-Ca 2+ exchange (Reeves, 1985). 
Mechanisms by which mechanotransducers may activate transcription in nucleus are not 
yet known although protein dephosphorylation may be important in these instances. 
1.3.3 Cardiac Gene Transcription Factors: A Possible Role for the Nuclear-Acting 
Early-Response Genes 
Transcriptional regulation of genes mediated through second messenger 
systems appears to be a pivotal control point for the development and regression of 
many forms of cardiac hypertrophy. Accordingly, significant effort has been channeled 
into elucidating the nature of the implied transcription factors and the possible 
mechanisms by which they interact with trophic signals to regulate cardiac gene 
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plasticity. It has been suggested that hypertrophic-specific changes in gene expression 
are exerted by the products of a limited number of critical regulatory genes (Simpson, 
1988 A). If this is true, then the products of such genes would likely to be located 
within the nucleus where they could bind to specific DNA sequence elements embedded 
in promoters, enhancers and silencers and where they could interact with other proteins 
to initiate or block RNA transcription. Furthermore they would be likely to exist in low 
levels compared to other gene products, but be rapidly inducible for instance following a 
phosphorylation cascade by specific lcinases so that they could couple short term signals 
elicited at the cell surface to long term alterations in cellular phenotype and function. At 
present the best candidates for such regulatory factors would appear to be the products 
of a number of nuclear acting early-response genes including c-tnyc, c-fos and c-jun 
(reviewed in Herich and Ponta, 1989). 
c-myc, c-fos and c-jun belong to families of nuclear acting, DNA binding 
genes whose expression, whilst normally low in quiescent cells, is induced rapidly and 
transiently in response to a great variety of extracellular signals including mitogenic and 
differentiation-inducing factors and agents that cause depolarization of neuronal cells. 
Classically these genes are characterized by their ability to respond rapidly with 
increased transcription rates following stimulation with phorbol esters in a sequential 
manner: c-fos mRNA is detected within the first few minutes followed by increased 
c-myc mRNA (Greenberg and Ziff 1984; Muller 1984). Although originally termed 
proto-oncogenes due to their involvement in neoplasia, many of these genes also appear 
to play vital roles during normal mitosis and cell growth and perhaps memory formation 
and the term immediate-early or nuclear-acting early-response genes has become more 
appropriate. 
1.3.3.1 c-fos and c-jun families 
The c-fos gene was originally found as the cellular homologue of oncogenes 
carried by two murine retroviruses, FBR and FBJ that were involved in the generation 
of radiation-induced osteosarcoma (for review see Curran, 1988). The c-jun gene was 
discovered independently from c-fos as the cellular homologue of v-jun, the 
transforming gene of avian sarcoma virus 17 (Maki et al., 1987). The protein products 
of c-fos (Fos) and c-jun (Jun) interact together via a region of periodically repeated 
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leucine zippers to form a heterodimeric complex named activator protein 1 (AP-1) (for 
review see Curran and Franza, 1988). Jun, unlike Fos, also forms homodimers which 
appear to be less stable than Fos/Jun heterodimers (Nakabeppu and Nathans, 1991; 
Rauscher et al., 1988). In response to a variety of extracellular signals AP-1 binds to, 
and activates transcription from nanonucleotide sequences within promoter regions of 
target genes. These sequences are often components of complex regulatory elements 
containing binding sites for multiple transcription factors that are responsive to 
extracellular stimuli (Lee et al., 1987 B; Distel et al., 1988; Sonnenberg et al., 1989). 
These include the TPA response element located in the promoter of a number of genes 
responsive to elevated levels of PKC such as collagenase and also both c-fos and c-jun 
themselves (Angel et al., 1987; Lee et al., 1987 A; Lee et al., 1987 B). Another such 
site is the cAMP response element (CRE) that binds transcription factor CRE binding 
protein (CREB) and confers the response to adenyl cyclase and PICA pathways (Franza 
et al., 1987; Sassone-Corsi et al., 1990). Furthermore, c-fos and c-jun products form 
heterodimeric complexes with certain members of the CRE/Activating factor 1 (ATF) 
families that interact preferentially with CRE sites (Benbrook and Jones, 1990). The 
CRE site is also a target for transcription factors activated by second messengers other 
than cAMP, for example calcium (Sheng et al., 1990). AP-1 proteins have also been 
shown to be involved in the regulation of the cis-acting motif, serum response element 
(SRE) of c-fos and other serum growth factor-inducible genes that binds a different class 
of transcription factor, the serum response factors (SRF) (for reviews see Treisman, 
1990; Rivera and Greenberg, 1990). 
Several genes related to c-fos and c-jun have also been isolated including 
fra-1, fra-2 and fos-b (Cohen and Curran, 1988; Nishina et al., 1990; Zerial et al., 1989) 
(related to c-fos), and junB and junD (Ryder et al., 1988; Ryder et al., 1989) (related to 
c-jun). The protein products in these families contribute to an array of mono- . and 
heterodimeric complexes that bind AP-1 and CRE sites (Cohen etal., 1989; Nakabeppu 
et al., 1988; Hai and Curran, 1991; Curran, 1991) but have different binding affinities 
and trans-activation properties (Chiu, 1989; Hirai et al., 1989; Schutte et al., 1989; 
Lucibello et al., 1990; Ryseck and Bravo, 1991). In addition junB is involved in the 
negative regulation of c-jun expression (Chiu et al., 1989). It is possible then that 
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differential expression of these proteins may be one mechanism to ensure diversity and 
specificity of cellular responses to extracellular stimuli and allow for target gene 
selectivity (Angel and Karin, 1991). Recently, interactions of Fos and Jun with several 
members of the steroid receptor family have been described and these observations and 
those described above indicate that Fos and Jun can regulate transcription cooperatively 
with other transcription factor families (Schule et al., 1990; Yang-Yen et al., 1990). 
The products of these genes have been implicated as nuclear "third messenger" 
molecules in signal transduction processes and thus may contribute to the coupling of 
short term signals elicited by cell-surface stimulation to alterations in cellular phenotype 
by regulating expression of target genes (Curran, 1991). 
1.3.3.2 c-myc 
c-myc was first identified as the mammalian homologue of the transforming 
gene of an avian retrovirus, myelocytomatosis (Roussel et al., 1979) and its expression 
appears to be critical for determining the proliferative, differentiative and oncogenic 
potential of a wide variety of cell types (Reviewed by Cole, 1986; Luscher and 
Eisenman, 1990). Regulation of the c-myc gene is complex and occurs at the 
transcriptional and post-transcriptional level and appears to be tissue and stimulus 
specific (Dean 1986; Greenburg and Ziff, 1984; Kelly and Siebenlist, 1988; Siebenlist, 
1988). Like c-fos and c-fun, c-myc is rapidly induced in response to growth factors and 
it is possible that they may share common regulatory elements since all are induced in 
the absence of protein synthesis (Kelly et al., 1983; Lau and Nathans 1987; Muller, 
1984). 
c-myc is one of a family of nuclear phosphoproteins including N-myc (Kohl 
et al., 1986; De Pinto et al., 1986), L-myc (Nau et al., 1985), R-myc, P-myc and B-myc 
(Ingvarsson et al., 1988) which have similar exon structures and appear to be 
differentially regulated during development (for a review see Marcu et al., 1992). The 
protein products of the c-myc family have long been thought to be involved in the 
regulation of gene expression because of their nuclear localization and ability to bind 
DNA via either basic/helix-loop-helix (HLH) (Mure et al., 1989) or basic/leucine repeat 
(LR) structures common to several binding proteins (Landschulz et al., 1988). However 
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a convincing demonstration of this has remained elusive until the recent cloning of a 
heterodimeric partner of Myc, called Max, that facilitates sequence-specific 
DNA-binding activity (Blackwood and Eisenman, 1991). Max like Myc contains 
adjacent HLH and LR domains and forms heterodimers with c-, N- and L-myc but not , 
with other HLH proteins (Beckmann et al., 1990; Gregor etal., 1990; Hu et al., 1990). 
c-myc expression is generally higher in proliferating cells than quiescent 
cells and is activated in quiescent cells by mitogenic stimuli (Dean et al., 1986; Campisi 
et al., 1984; Kelly et al., 1983) including PDGF in Balb/c-3T3 fibroblasts and this 
increased expression is associated with entry into, and progression through the cell cycle 
(Armelin et al., 1984, Kaczmareck et al., 1985, Kelly et al., 1983). During terminal 
differentiation of cells, when proliferation ceases, there is concurrent reduction in 
expression of the c-myc gene (Endo and Nadal-Ginard, 1986; Schneider et al., 1987). 
Furthermore, constitutive c-myc expression has been shown to block differentiation of 
mouse cell lines (Coppola and Cole 1986). Current opinion is that the differential or 
combinatorial expression of the myc gene family has a role in regulating multiple 
differentiation pathways (Luscher and Eisenman, 1990). 
1.4 NUCLEAR-ACTING EARLY-RESPONSE GENE EXPRESSION IN HEART 
AND CARDIAC MYOCYTES 
Although the expression of nuclear-acting early-response genes has been 
traditionally linked with hyperplasia in a number of settings, they have more recently 
become the focus of considerable attention in the context of cardiac growth and 
hypertrophy. For instance, the loss of proliferative capacity and altered isogene 
expression of myocytes during myocardial development is paralleled by decreased 
expression in the cardiac levels of c-myc (Schneider et al., 1986). Similarly, other 
members of the myc family including N-myc and B-myc are also down regulated in the 
maturing heart (Schneider and Parker, 1990; Parker and Schneider, 1991; Claycomb and 
Lanson, 1987) and this is perhaps not surprising given the role these genes are 
hypothesized to play in cellular differentiation processes. Down regulation of c-myc is 
an early event during skeletal muscle differentiation (Endo and Nadal-Ginard, 1986; 
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Schneider et al., 1987) which fails to occur in muscle cell lines that cannot differentiate 
(Payne et al., 1987; Sejersen et al., 1985). Whilst decreased expression of c-myc is not 
obligatory for muscle development, autonomous expression of c-myc can delay or 
partially inhibit the myogenic phenotype (Caffrey et al., 1987; Schneider et al., 1987). 
Furthermore, v-myc can inhibit differentiation in skeletal muscle cells (Falcone et al., 
1985), impair cardiac differentiation and produce cardiac rhabdosarcomas in avian 
embryos (Saule et al., 1987). 
In contrast to c-myc, constitutive expression of c-fos appears not to be 
detectable (Barka et al., 1987) or is extremely low in neonatal or adult heart tissue in 
vivo (Claycomb and Lanson, 1987; Izumo et al., 1988; Schneider et al., 1986) although 
it has been localized to specific regions of the myocardium during embryogenesis (T. 
Curran, personal communication) and thus may play a role in the early development of 
the heart. However, c-fos expression seems to be sensitive to cell isolation procedures 
since it is abundantly expressed in freshly isolated neonatal and adult cardiocytes 
(Claycomb and Lanson, 1987). The potential for c-fos to play a role in cardiomyocyte 
differentiation is highlighted by the increased expression of this gene associated with the 
decreased expression of several muscle specific genes and the subsequent loss of several 
differentiated traits in skeletal muscle (Lassar et al., 1989 B). 
However, c-myc and c-fos expression, like the expression of 
neonatal-specific isocontractile genes, do not appear to be irreversibly repressed in 
terminally differentiated cardiac myocytes since their expression can be elicited by a 
number of interventions including some that provoke hypertrophic growth both in vivo 
and in vitro. For instance, in 28 day old rats, constriction of the abdominal aorta results 
in approximately 10% increase in cardiac mass and increased c-myc expression in both 
atria and the left ventricle 48 h following imposition of the overload (Mulvagh et al., 
1987). However aortic constriction in 80 day old rats results in increased c-myc inRNA 
in the atria alone indicating that up regulation of c-myc during pressure overload is both 
age- and tissue-dependent (Mulvagh et al., 1987). In another study acute aortic 
constriction resulted in increased cardiac c-fos and c-myc mRNA levels within 30 min 
and 2 h respectively (Komuro et al., 1988). Maximal levels were observed after 8 h and 
had returned to baseline by 48 h following surgery. Direct mechanical load also appears 
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to modulate early response gene expression in neonatal cardiocytes since stretching of 
these cells in vitro increases total cell RNA content, protein content and mRNA levels 
of c-fos (15 fold after 30 min) and the fetal specific isocontractile gene a-SkA (Komuro 
et al., 1991). Thus cardiocyte stretching in vitro may mimic hemodynamic load in vivo 
in terms of hypertrophy and gene expression. 
Similarly adrenergic treatment has been shown to modulate early-response 
gene expression in both the adult heart and isolated myocyte cultures. Thus 
administration of 0-adrenergic agonists in vivo led to a rapid and transient increase in 
the levels of c-fos in the hearts of mice, rats and hamsters (Barka et al., 1987). 
Increased c-fos levels were first observable within 30 min of administration of the drug 
and peaked after 60 min but had returned to near basal levels by 2 h. An increase in 
calcium through voltage-dependent channels appeared not to be required for this 
activation since calcium channel blockers, verapamil, nifedipine and diltiazem had no 
effect. A similar increase in c-fos expression was also obtained following 
administration an a-adrenergic agonist, histamine and prostaglandin (Barka et al., 
1987). In quiescent non-dividing neonatal cardiac myocytes cultures both increased cell 
size and selective up-regulation of several neonatal specific isocontractile genes was 
preceded by a transient increase in c-myc mRNA levels following treatment with 
acadrenergic agents (Starksen et al., 1986). Increased c-myc mRNA levels were 
detectable at 30 min, peaked at 2 h (10 fold above control), and returned to basal by 6 h 
after stimulation. Serum and the phorbol ester promoter PMA (phorbol 12 myristate 15 
acetate) which activates PKC, also enhanced c-myc expression and hypertrophy in these 
cell cultures (Starksen et al., 1986). 
Taken together these studies provide indirect evidence that mechanical load 
and adrenergic administration may be linked to modulation of cardiac mass and 
myocyte size via transduction pathways which act through transcription factors such as 
c-myc and c-fos. In addition, up-regulation of c-myc and c-fos in response to 
hypertrophic stimuli appears to precede a general regression of the heart to the 
developmental phenotype as indicated by the subsequent re-expression of 
neonatal-specific isocontractile genes. Thus the response of adult cardiomyocytes to 
hypertrophic stimulus has similarities to the mitogenic response of other differentiated 
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cell types, which often involves the suppression of the adult phenotype and 
re-expression of the fetal program (Ruoslahi et al., 1984). 
1.5 THESIS AIM 
The central aim of this thesis is to establish whether the expression profile of 
nuclear-acting early-response genes in cardiomyocytes is consistent with their mediating 
aspects of adrenergic initiated cardiac hypertrophy. More specifically, the work in this 
thesis will seek to; 
i) examine in detail the temporal changes in expression of c-myc and c-fos 
and related genes in the heart following both acute and chronic administration of 
catecholamines in vivo and to determine the relative contribution of each type of 
adrenergic receptor to these responses. 
ii) localize the expression of c-myc and c-fos mRNA and protein following 
adrenergic administration, to particular regions and cell types of the heart by gross 
dissection techniques and by in situ hybridization histochemistry and 
immunocytochemistry techniques. 
iii) establish whether the isolated perfused heart system is a suitable model 
in which to study both the early and terminal of stages of gene expression associated 
with cardiac hypertrophy in vivo. and if so to differentiate the possible direct and 
indirect affects of adrenergic hormones on c-myc and c-fos expression using this system. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 EXPERIMENTAL ANIMAL TECHNIQUES 
2.1.1 Drugs and Animals 
2.1.1.1 Drugs 
DL-Propranolol.HC1 	 Sigma 
Heparin 	 CSL 
Methoxamine.HCI 	 Sigma 
Nembutal 	 Bumac Labs. 
Nifedipine Sigma 
(-)Norepinephrine.HC1 	 Sigma 
4a-Phorbol 12b 13a-didecanoate (PDC) 	Sigma 
Phenoxybenzamine.HC1 	 Sigma 
Phentolamine.HC1 	 Ciba-Geigy 
Phorbol 12-myristate 13-acetate (PMA) 	Sigma 
Pyruvate 	 Boehringer 
Fors kolin Sigma 
All other drugs and chemicals were of analytical grade. 
2.1.1.2 Preparation of drugs 
For experiments in vivo, adrenergic agents were prepared freshly each day in 
0.9% saline and 0.1% ascorbic acid. For in vitro perfusion experiments adrenergic 
agents were prepared in perfusion buffer (see section 5.2.1) containing 0.1% ascorbic 
acid. Triiodo-L-thyroxine (T,) was prepared daily in phosphate buffered saline (pH 
11.0). Phorbol esters were prepared as stock 10 mg/ml solution in dimethyl sulfoxide 
(DMSO) and kept at -20°C when not in use. 
2.1.1.3 Animals 
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Male hooded Wistar rats (180-200 g) reared in the animal house, University 
of Tasmania were used for all experiments unless otherwise stated. Rats were 
maintained ad libitum on a standard laboratory chow diet. 
2.2 NORTHERN ANALYSIS 
Specific mRNA transcripts were detected amongst the total RNA extracted 
from the heart by standard northern blotting techniques (Maniatis et al., 1989). Briefly, 
purified RNA extracts were separated according to size by electrophoresis through 
denaturing agarose gels and then transferred by. capillary action to solid support nylon 
membranes. RNA attached to the membrane (which had retained its relative position 
during transfer) was then hybridized to radiolabeled cDNA or oligonucleotide probes 
and the position of any complimentary bands identified by autoradiography. For slot 
blotting, RNA samples were applied directly to the membrane support by suction 
through holding wells in a specially designed apparatus. Membranes were then 
hybridized directly to radiolabeled probes to determine the relative levels of target RNA 
transcripts (Maniatis et al., 1989). 
2.2.1 Materials 
2.2.1.1 Reagents 
[a-"P]dCTP 	 Bresatec 
[y-"P]dATP 	 Bresatec 
8-hydroxyquinoline 	 BDH 
Agarose gel (HGT, LGT) 	 FMC Bioproducts 
Dextran Sulphate 	 Pharmacia 
DNA (type III from Salmon testis) 	Sigma 
Ethidium bromide 	 BDH 
Guanidinium thiocyanate 	 Serva or Fluka 
Morpholinopropane sulfonic acid 	Sigma 
Oligo(dt)-cellulose 	 P-L Biochemicals 
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Phenol 	 BDH 
Proteinase K 	 Boehringer-Mannheim 
Sodium dodecyl sulphate (SDS) 	Serva 
Zeta Probe transfer membrane 	BioRad 
Reagents for bacterial propagation were obtained from Difco, restriction 
enzymes were sourced from Pharmacia, all other reagents were of molecular biology 
grade. 
2.2.1.2 Solutions 
Normal procedures were taken to ensure that solutions were free of 
ribonuclease contamination. All glassware was heated at 180°C overnight whilst heat 
sensitive equipment was soaked in 0.5 M NaOH and then rinsed in Milli Q water. All 
solutions unless otherwise stated were made up in distilled/deionized (Milli Q) water 
and autoclaved. The ribonuclease inhibitor diethyl pyrocarbonate was used to treat 
water in certain instances. 
2.2.2 Extraction of Total RNA and Poly(A) + RNA Selection 
2.2.2.1 Total RNA extraction 
Total RNA was extracted according to the method of Chomcyznslci and 
Sacchi (1987) with slight modification. 1 g of frozen tissue was finely ground under 
liquid nitrogen and transferred to a sterile plastic tube containing 10 ml of 
homogenizing solution (4 M guanidinium thiocyanate, 25 mM sodium citrate pH7.0, 
0.5% sarcosyl, 0.1 M 2-mercaptoethanol) and given two bursts at high speed with an 
ultra-Turrax homogenizer. To the homogenate was added sequentially 1 ml of 2 M 
sodium acetate pH 4.0, 10 ml phenol (saturated with 10 mM Tris-HC1 pH 7.6, 1 mM 
EDTA, 0.1% 8-hydroxyquinoline) and 2 ml of chloroform: isoamyl alcohol mixture 
(49:,1), with thorough mixing after each addition. The final mixture was shaken 
vigorously for 4 min then centrifuged in glass tubes at 10 000 g for 20 min at 4°C. The 
upper aqueous phase was mixed with 10 ml of isopropyl alcohol in a fresh tube and 
cooled at -20°C for 1 h. Total RNA was pelleted by centrifugation at 15 000 g for 10 
min at 4°C, drained and redissolved in 1.5 ml 1 mM EDTA pH 7.4. The RNA was 
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reprecipitated by addition of 2 ml 4.5 M potassium acetate pH 6.0 and incubated at 
-20°C for 1 h. Following centrifugation the RNA pellet was washed consecutively in 
70% and 95% ethanol, dried under vacuum for 1 h and dissolved at 65°C in 200 p.1 of 
0.5% SDS. For smaller amounts of tissue volumes of extraction buffers were adjusted 
accordingly. 
2.2.2.2 Selection of poly(A)* 
mRNA purification was facilitated by virtue of the polyadenylate tail carried 
at the 3' ends of most mRNA species allowing selective retention on oligo(dt) cellulose. 
The method described below is essentially the same as that of Edmonds et al., (1971) 
and Aviv and Leder, (1972). 
A small piece of sterile glass wool was placed in the outlet of a 1 ml syringe 
and 0.1 g of oligo(dt) cellulose saturated with binding buffer (0.01 M Tris-HC1 pH 7.5, 
0.5 M NaC1, 1 mM EDTA, 0.5% SDS) was added. The column was packed down by 
gentle tapping to give a final volume of 0.2-0.3 ml. RNA (1 mg) dissolved in 500 gl of 
binding buffer was heated to 65°C then applied to the column followed by a further 3 ml 
of binding buffer and 1.5 ml of wash buffer (0.01 M Tris-HC1 pH 7.5, 0.5 M NaC1, 1 
mM EDTA). Bound poly(A) + RNA was eluted with 1.5 ml of elution buffer (0.01 M 
Tris-HC1 pH 7.5, 1 mM EDTA) and adjusted to a final concentration of 0.5 M NaC1, 
and the binding, washing and elution repeated as before. Poly(A) + RNA in the final 
eluate was recovered by precipitation with 2 volumes of 95% ethanol at -20°C 
overnight. After centrifugation at 15 000 g for 10 min poly(A)+ RNA pellets were 
drained, dried under vacuum for 1 h and dissolved at 65°C in 0.5% SDS. 
2.2.2.3 Analysis of extracted RNA 
Integrity of total RNA and poly(A) + RNA was determined visually by 
ethidium bromide fluorescence after separation on 0.75% agarose slab gels. RNA was 
quantified by spectrophotometric analysis at 260 - nm against reagent blanks. An optical 
density (0.D) reading of 1 corresponds to 40 gg of RNA (Maniatis et al., 1989). 
2.2.3 Northern and Slot Blotting 
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2.2.3.1 Northern blotting 
i) denaturing gels 
Denaturing formaldehyde gels (1.2%) were prepared by dissolving the 
appropriate amount of HGT agarose in distilled water, 5 x MOPS running buffer (0.1 M 
morpholinopropane sulfonic acid pH 7, 40 mM sodium acetate and 5 mM EDTA) and 
formaldehyde (12.3 M) to give 1 x and 2.2 M final concentrations, respectively. Gels 
were poured in a large gel apparatuses (20 x 20 cm) as described by Maniatis et al., 
• (1989) and once set were submerged in 1 x MOPS running buffer ready for 
electrophoresis. RNA samples (10-50 u.g in 10 1) were mixed with 5 j.tl of 10 x MOPS, 8 
gl of formaldehyde, and 22.5 p.1 of formamide and then incubated at 65°C for 15 min, 
cooled on ice and mixed with 1/5 volume of loading dye (50% glycerol, 1 mM EDTA, 
0.4% bromophenol blue and 0.5 mg/ml ethidium bromide). After samples were loaded 
into the appropriate wells the gel was electrophoresed at 15-30 V overnight before being 
photographed on a U.V light box and transferred to a solid support membrane as 
described below. In some instances standard RNA molecular weight ladders (BRL Cat. 
5620SA) were also included in the same gel as the experimental RNA in order to 
determine the relative size of hybridizing transcripts. 
ii) northern transfer 
RNA was quantitatively transferred from denaturing gels to nylon 
membranes .(Zeta Probe) by capillary action under mildly alkaline conditions by 
standard methods. Mild alkaline conditions were chosen since they facilitate elution of 
RNA from agarose by promoting partial hydrolysis of large RNA species and also 
induce binding of RNA to the nylon membrane (Vrati et al., 1987). After transfer, 
usually between 5-6 h, membranes were briefly rinsed twice in 2 x SSC (0.3 M NaC1, 
0.03 M trisodium citrate pH 7.0), blotted dry and then baked at 80°C for 2 h to ensure 
covalent binding of the RNA to the membrane. Membranes prepared in this manner 
were directly hybridized to radiolabeled probes (see section 2.5.6), or alternatively, 
stored between dry filter paper in sealed plastic bags at room temperature. 
2.2.3.2 Slot blotting 
Slot blotting of extracted RNA was performed using a Milliblot-S system 
(Millipore) and Zeta Probe nylon membranes (Maniatis et al., 1989). After assembling 
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the apparatus according to the manufacturers instructions, RNA samples (50 ng-50 us) 
were diluted to 500 p.1 with 30 inM NaOH and heated to 65°C for 15 min before being 
cooled on ice. Samples were then applied to the appropriate wells of the apparatus and 
transferred to the nylon membrane by means of suction from a vacuum pump. When 
completed the apparatus was disassembled and the nylon membrane rinsed briefly in 2 x 
SSC to neutralize the NaOH and then blotted dry and baked at 80°C for 2 h. Membranes 
prepared in this manner were directly hybridized to radiolabeled probes. 
2.2.4 cDNA Clones 
cDNA clones used as probes for northern analysis and slot blotting included a 
1.06 kb Pstl fragment from v-fos, a 1.5 kb (HindIII) fragment from 13-rat-tubulin, and a 
2 kb Hind III fragment from rat c-myc supplied by Dr. R. Crawford (Howard Florey 
Institute), a 1.5 kb EcoR1 fragment from mouse fra-1, a 1.2 kb EcoRI fragment from 
mouse fra-2, supplied by Dr. D Cohen (John Curtin School of Medical Research) and a 
1.4 kb HindIIVEcoRI fragment from human c-jun supplied by Professor M. Karin 
(U.C.S.D). 
2.2.4.1 Amplification of cDNA clones 
Plasmids containing cDNA clones were transformed into competent E.coli 
(strain MC1061) cells by standard techniques and propagated in normal L-broth 
medium containing appropriate antibiotics as described by Maniatis et al., (1989). 
Plasmid DNA was subsequently isolated by the alkaline lysis method (Birnboim and 
Doly, 1979) and following restriction . digests with the appropriate enzymes, cDNAs 
were purified from plasmid DNA by electrophoresis through 1.5% LMP agarose gels 
(Maniatis et al., 1989) and purified by silica bead adhesion using a commercially 
available kit ("Gene Clean", Bio 101 Inc). cDNA inserts prepared in this manner were 
used directly in the preparation of radiolabeled probes (section 2.2.5). 
2.2.5 Synthetic Oligonucleotides 
Atrial natriuretic peptide- and calcitonin gene-specific oligonucleotide 
probes were a kind gift from Mrs Jenny Penschow and Dr. J. Haralambidis (Howard 
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Florey Institute). The metallothionein (Mt) probe was obtained from Dr. A. K. West 
(University of Tasmania). The 40 mer exon 1 specific c-fos probe (rat-c-fos PR-1) and 
the 40 mer exon 2 specific c-myc probe (rat-c-myc PR-1) were obtained from Oncogene 
Science, USA. The remaining oligonucleotide probes described below, were 
synthesized by the author on a Pharmacia Gene Assembler Plus synthesizer by the solid 
phase method using phosphoramidite chemistry. Probes were synthesized on 0.2 nmole 
scale and the base protecting groups removed by treatment with ammonia at 60°C for 16 
h. Following removal of solvent by vacuum the residue was redissolved in 1 ml of 0.2 
mM EDTA and purified by PAGE according to the method of (Current Protocols). 
Purified oligonucleotides were precipitated and adjusted to 50 ng/R1 in 0.2 mM EDTA 
before radiolabeling. 
FOS2130: 
30 mer exon 2 specific c-fos probe (rat) 
5' GGG CTG CAC CAG CCA CTG CAG GTC TGG GTC 3' 
FOS2230: 
30 mer exon 2 specific c-fos probe (rat) 
5' TCT GGT CTG CGA TGG GGC CAC GGA GGA GAC 3' 
FOS4130: 
30 mer exon 4 specific c-fos probe (rat sense strand) 
5' GGC AGG GTG AAb GCC TCC TCA CAC CTC GGG 3' 
MYC2130: 
30 mer exon 2 specific c-myc probe (rat) 
5' CCT GTT GGT GAA GCT AAC GTT GAG GGG CAT 3' 
MYC3130: 
30 mer exon 3 specific c-myc probe (rat, sense strand). 
5' CGC ACA AGA GTT CCG TAG CTG TTC AAG TTT 3' 
45 
a-SkA20: 
20 mer a-skeletal actin specific probe (rat) (Gustafsen et al., 1986). 
5' GCA ACC ATA GCA CGA TGG TC 3' 
a-MHC20: 
20 mer a-myosin heavy chain specific probe (rat) (Gustafsen et al., 1985). 
5' TTG TGG GAT AGC AAC AGC GA 3' 
2.2.6 Labeling cDNA and Oligonucleotide Probes 
2.2.6.1 cDNA restriction fragments were labeled to a high specific activity 
(-1 x 10-9 cpm/lig) by the random-primed method of Feinberg and Vogelstein (1989) 
using a commercially available kit (OLK, Bresatec) as described below. 
50-100 ng (5-100) of DNA was heated for 5 min at 95°C, cooled on ice and 
briefly centrifuged to bring down condensation. To this was added 12.5 ill of 
nucleotide/random primer buffer (20 p.M dATP, dGTP, dTTP, 50 mM Tris HC1 pH 7.6, 
50 mM NaC1, 20 mM MgCl„ 100 jig/m1 gelatin, 12.5 lig hexanucleotide primers) and 4 
jil of [a-"P]dCTP (4000 Ci/mM, Bresatec) and the solution mixed well. The reaction 
was initiated by the addition of 5-10 units of DNA polymerase I (Klenow fragment) and 
after incubation at 37°C for 20 min, unincorporated nucleotides were separated from the 
labeled strand by exclusion chromatography using a Sephadex G-50 column as 
described by Maniatis et al., (1989). 
2.2.6.2 Labeling oligonucleotide probes 
Oligonucleotide probes were 5' end labeled to a high specific activity (0.5-1 
10-9 cpm/ps) using a commercially available kit (TKK-1, Bresatec) as described 
below. 
Oligonucleotide DNA, generally (50-200 ng) was heated for 5 min at 70°C 
then cooled on ice. After briefly centrifuging 2 gl of buffer (60 mM Tris-HC1 pH 7.6, 
90 mM MgCl2), 2 gl dithiothreitol (100 mM), 2 molar equivalents of [y-"P]clATP, i.e., 
10 1.11 of a 10 mCi/m1 solution of [y- 3211dATP (4000 Ci/mmol) for 100 ng of a 30 mer 
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oligonucleotide (average MW=9207), 5 U of polynucleotide kinase and distilled water 
to 20 RI were added. After mixing well the tube was incubated at 37°C for 15 min after 
which the unincorporated nucleotides were separated from the labeled oligonucleotide 
probe using exclusion chromatography through a Sephadex G-25 "spun column" 
(Penschow et al., 1989). 
2.2.7 Hybridization with cDNA and Oligonucleotide Probes 
Nylon membranes containing immobilized RNA were sandwiched between 
two sheets of hardened filter paper (Whatman no. 54) and soaked in 25 ml of cDNA 
hybridization buffer (Vrati et al., 1987), (50% deionized formamide, 0.5% milk powder, 
1% SDS, 50% dextran sulphate, 50 tnM phosphate buffer pH 6.5, 4 x SSC, 0.5 mg/ml 
salmon sperm DNA sheared and denatured) or oligonucleotide hybridization buffer, 
(20% deionized formamide, 5 x SSC, 50 mM phosphate buffer pH 6.8, 1 mM 
pyrophosphate, 0.1% BSA, 0.1% polyvinylpyrollidone, 0.1% ficoll, 2% SDS and 100 
i.ig/m1 salmon sperm DNA sheared and denatured) and then placed in a pre-made 
polyethylene plastic bag. The remaining hybridization solution (25 ml) containing the 
radiolabeled probe (denatured immediately before adding to the hybridization mixture 
by heating to 95°C for 5 min) was poured into the bag which was then heat sealed being 
careful to exclude any air bubbles. The bag was then placed between two glass plates 
and incubated at 37°C to 42°C (depending on the homology of the probe and the 
stringency required) overnight. After hybridization membranes were removed from the 
bags and non-specific "background" hybridization removed by consecutive washings in 
the following buffers: 
(1) 2 x SSC at room temperature for 5 min 
(2) 2 x SSC, 0.1% SDS at room temperature for 15 min 
(3) 0.2 x SSC, 1% SDS at 65°C (cDNA), 42°C (oligo) for 15 min 
(4) 0.2 x SSC at room temperature for 5 min 
Membranes were subsequently blotted dry on filter paper, covered in plastic 
cling wrap and placed immediately next to a sheet of Kodak X-OMAT x-ray film 
between two CaW0 4 intensifying screens (Cronex Lightning Plus, Dupont) in an x-ray 
cassette. Following exposure at -80°C between 8 h and 1 week, films were developed 
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for 5 min in standard Kodak developer and fixed for 5 min in Kodak fixer and then 
rinsed and dried. 
Membranes could be rescreened several times with additional probes after 
removal of the previously hybridized probe. This was achieved by incubating 
membranes at 98°C in 0.1 x SSC and 0.5% SDS twice for 15 min and then briefly in 0.2 
x SSC after which membranes were re-baked at 80°C for 2 h (Vrati et al., 1987). 
2.2.8 Treatment of Results 
For graphical representation of results, autoradiograms were quantified 
using a scanning laser densitometer and corrected for loading by comparison to readings 
for the control probe I3-tubulin. Results in each case were expressed relative to control 
values and expressed +/- standard error mean (SEM) when number of experiments was 
greater than 3. For n=2 results were expressed as standard deviation (SD). 
2.3 In situ HYBRIDIZATION HISTOCHEMISTRY 
In this study in situ hybridization was used in an attempt to localize 
early-response gene mRNA to discrete cell populations and regions of the heart 
following hypertrophic stimulus. The principal nucleic acid probes used in this study 
were synthetic oligonucleotides since they were readily synthesized by the author using 
phosphoramidite chemistry (see chapter 3) and could be designed to exploit regions of 
maximum difference between closely homologous mRNAs whilst "sense" probes could 
be prepared and used as highly specific negative controls. Furthermore, due to their 
relatively short length, problems associated with tissue penetration and self 
hybridization, encountered with other probe systems, could be largely avoided 
(Penschow et al., 1989). 
In addition to oligonucleotide probes, the use of cDNA probes 
complimentary to early-response genes was also attempted since they were readily 
available and had been well characterized in terms of gene specificity by northern 
analysis (see section 2.2.6). The choice of labeling for oligonucleotide and cDNA 
probes was via "P since it has a high specific activity and permits rapid visualization on 
x-ray film and with liquid emulsion with resolution to single cells in some cases 
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(Penschow et al., 1989). Although [ 31-I] labeling can potentially give much higher 
resolution than "P the low energy of this radioisotope makes x-ray film exposure less 
practical and limits sensitivity of the signal. Similarly "S gives higher resolution than "P 
but requires longer exposure times and has greater potential for background even under 
reducing conditions (Penschow et al., 1989). Numerous nonradioisotopic labels such as 
photobiotin/avidin were available at the time of study however it was considered that 
their sensitivity and ease of use was not yet equal to that achievable with "P labeling 
and were consequently not used. 
Effective tissue fixation is one of the most important steps towards 
obtaining satisfactory in situ hybridization results (Moench, 1987; Hofler, 1987; 
Angerer et al., 1987; Cumming and Fallon, 1988). In these studies crosslinking 
fixatives such as formaldehyde and gluteraldehyde were used due to their superior 
ability to prevent loss of target mRNA and to preserve tissue morphology in comparison 
to precipitative fixers such as acetone or methanol (McAllister & Rock, 1985). 
Crosslinking fixatives are limited in that they tend to hinder tissue penetration of long 
probes (Penschow et al., 1989) such as labeled cDNA. In such circumstances it is 
necessary to employ secondary permeabilization steps such as mild enzymatic digestion 
with proteinases to ensure probe access to target mRNA sites. Fixation and 
permeabilization tend to work in opposition and thus achievement of optimal conditions 
can only be measured in terms of final hybridization signal (Penschow et al., 1989). 
Of the considerable variety of in situ hybridization protocols attempted 
during the course of these studies, only those used on a routine basis with some degree 
of success are outlined below. 
2.3.1 Reagents 
3-aminopropyltriethoxy-silane 	 Aldrich 
Amersham LM-1 Liquid Emulsion 	Amersham 
D.P.X mountant 	 BDH 
Eosin Y 	 Sigma 
Ethylene glycol 	 Sigma 
Formaldehyde 	 Merc 
Gelatin 	 BDH 
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Glutaric dialdehyde 	 Merc 
Hematoxylin 	 Sigma 
Hexane 	 Ajax 
Ilford K-5 Liquid Emulsion 	 Ilford 
0.C.T 	 Miles Inc. 
Pronase E Sigma 
Xylene 	 BDH 
Other reagents were of molecular biological grade. 
2.3.2 In situ Hybridization Protocol 
2.3.2.1 In situ hybridization with oligonucleotide probes 
The oligonucleotide hybridization procedure described below is essentially 
the same as that described by Penschow etal., (1989) with minor modification. 
i) tissue preparation, fixation and prehybridization 
Tissue was removed from experimentally treated or control animals and 
immediately embedded with tissue-Tek in a dry ice/hexane bath and stored at -80°C 
until processed. Control tissue was similarly treated and in some cases was included on 
the same block as experimental tissue. When processed, embedded tissue was allowed 
to warm to -15°C in a cryostat and then sectioned to 5 gm. Sections were picked up onto 
slides (pre-coated with gelatin or poly-lysine (Penschow et al., 1989)) and immediately 
laid on dry ice for 30 min to freeze the section rapidly (this reduces the risk of mRNA 
degradation and improves cell morphology, (J. Penschow, personal communication). 
Slides were subsequently transferred to fixative (4% gluteraldehyde, 0.1 M phosphate 
buffer pH 7.4, 20% ethylene glycol) and fixed at 5°C for 4 min and then rinsed twice in 
2 X SSC and prehybridized by immersion in oligonucleotide in situ hybridization buffer 
(600 mM NaC1, 50 mM phosphate buffer pH 7.0, 5 mM EDTA, 0.02% Ficoll, 0.02% 
BSA, 0.02% polyvinylpyrollidone, 0.01% sheared/denatured DNA, 40% deionized 
formamide) at 40°C for 1 h. After pre-hybridization sections were dehydrated through 
50%, 70% ,95%, 100%, 100% ethanol containing 300 mM ammonium acetate, at which 
stage they were either stored at -20°C for several weeks in moisture proof containers or 
hybridized immediately. 
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ii) probe preparation and hybridization 
Prior to hybridization radiolabeled probes were precipitated by the addition 
of 0.01 volume of tRNA (10 mg/ml in TE buffer pH 7.4), 0.1 vol 3 M sodium acetate 
pH 7.4 and 2 volumes of 100% ethanol. After incubation overnight at -20°C, probe 
DNA was collected by centrifugation at 10 000 g, washed consecutively in 70% and 
95% ethanol and vacuum dried for 30 min before being dissolved at 65°C in the 
appropriate volume of hybridization buffer. Probe concentrations for hybridization 
were determined empirically but were usually in the range of 0.5 to 10 ng/u.l. 
Immediately prior to hybridization probes were denatured by boiling at 95°C for 5 min 
and then chilled on ice. Approximately 25 to 30 gl of probe was then spotted onto clean 
glass cover slips (25 x 24 mm) and picked up onto experimental slides which were 
subsequently placed on a plastic grid and overlaid with plastic wrap. After incubation 
overnight in a humidified chamber at 37°C cover slips were removed from slides by 
gentle agitation in 4 x SSC after which non-specific probe binding was removed by 
incubating the slides in 2 x SSC at 40°C for 1 h with occasional agitation and then in 1 
X SSC at 40-50°C for a further hour. Finally slides were dehydrated through 50%, 70% 
,95% and 100% ethanol and processed for autoradiography (see section 2.3.3.3). 
2.3.3.2 In situ hybridization with cDNA probes 
The cDNA hybridization described below is a modification of that described 
by Closs et al., (1990). 
i) tissue fixation and prehybridization 
Tissue was sectioned as described above and thawed onto slides pre-coated 
with 2% 3-aminopropyltriethoxy-silane (Penschow et al., 1989) and immediately placed 
on a heated plate at 50°C for 5 min (to remove endogenous ribonuclease activity) before 
being fixed at room temperature for 30 min in 0.1 M phosphate buffered saline (PBS) 
containing 4% formaldehyde. Slides were then thoroughly rinsed in PBS and incubated 
in 0.2 M HC1 for 20 min at room temperature and then rinsed again in 2 X SSC. Slides 
were then subjected to mild protease treatment by incubation in 1 X SSC containing 125 
pg/m1 pronase E (this buffer had been autodigested for 2 h to remove potential 
ribonucleases) after which they were rinsed in PBS and fixed again in formaldehyde as 
before. After rinsing again in PBS slides were prehybridized by immersion in cDNA in 
situ hybridization buffer (600 mM NaC1, 10 mM Tris.HC1 pH 7.4, 1 mM EDTA, 0.02% 
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Ficoll, 0.02% BSA, 0.02% polyvinylpyrrollidone, 0.01% sheared denatured DNA, 
0.01% tRNA, 0.1 mg/m1 polyadenylate, 50% deionized formamide) at 40°C for 1 h. 
After pre-hybridization sections were dehydrated through 50%, 70% ,95%, 100%, 100% 
ethanol containing 300 inM ammonium acetate, at which stage they were either stored 
at -20°C for several weeks in moisture proof containers or hybridized immediately. 
ii) probe preparation and hybridization 
The hybridization for cDNA probes was essentially the same as that 
described for oligonucleotide probes. Hybridization temperatures varied between 37°C 
and 42°C depending on percentage homology of the cDNA probes. Following 
hybridization non-specific probe binding was removed by incubating the slides in 
formamide buffer (50% formamide, 0.6 M NaC1, 10 mM Tris HCI pH7.4, 1 mM EDTA) 
at room temperature for 1 h followed by washing in 2 x SSC at 40°C for 1 h with 
occasional agitation and then in 0.1 X SSC at 60-65°C for a further 2 h. After 
dehydration through 50%, 70%, 95%, 100%, 100% ethanol, slides were processed for 
autoradiography as described below. 
2.3.2.3 Probe detection by autoradiography 
i) regional analysis using high resolution film 
Slides prepared in section 2.3.3.2 were taped to a piece of 3MM filter paper 
and exposed in an x-ray cassette to Amersham high. resolution 0-max film. After the 
appropriate exposure time films were processed as usual (section 2.2.6). 
ii) microscopic analysis using liquid emulsion. 
Under dark room conditions Ilford K-5 or Amersham LM-1 nuclear 
emulsion gel was diluted 1 in 2 with distilled water and warmed to 40°C for 2 h. Slides 
were briefly dipped into the prewarmed emulsion and excess liquid allowed to drain 
away by standing slides vertically. When the emulsion had dried slides were loaded 
into racks and placed in light proof boxes over silica gel and exposed for 1 to 4 weeks. 
Exposure time was approximately 10 times that required to give a medium gray image 
following exposure next to fast (low resolution) x-ray films such as Amersham MP or 
Kodak K5. Following exposure slides were developed and fixed in filtered Kodak fixer 
and developer, rinsed in 3% acetic acid, hardened in formalin for 1 min and 
counter-stained with Haematoxylin/eosin (Penschow et al., 1989) and then dehydrated 
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through graded ethanol, cleared into xylene and mounted with D.P.X mountant. Slides 
were photographed between 100 and 400 time magnification under blue light using a 
standard photomicroscope system. 
2.3.2.4 Probe specificity and controls. 
in situ hybridization results may be misleading due to unexpected 
homologies or to short regions within a probe hybridizing to unknown target sequences. 
Similarly interactions between proteins and probes may occur whilst a variety of 
autoradiographic artifacts can provide convincing hybridization signals or alternatively, 
reduce genuine hybridization signals. In an attempt to counter any potential spurious 
results an array of experimental controls were used in the present in situ hybridization 
experiments and these are outlined in table 2. 
Table 2. In situ hybridization controls 
Factor of interest 	 Procedure 
Non-specific probe binding 	Sense DNA probe 
Nonhomologous probe 
Digestion of target RNA 
Non-expressing tissue 
Probe specificity 	 Northern blot 
Autoradiography 	 No probe 
Tissue only 
Blank slide 
Target distribution 	 Irrununocytochemistry 
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2.4 IMMUNOCYTOCHEMISTRY 
c-myc and c-fos protein products were localized to specific cardiac regions 
and cell types by immunocytochemistry using both monoclonal and affinity purified 
polyclonal antibodies. A variety of immunodetection systems were experimented with 
including peroxidase-antiperoxidase (PAP) (Sternberger et al., 1970), alkaline 
phosphatase-antialkaline phosphatase (APAAP) (Cordell et al., 1984), avidin-biotin 
complex (ABC) (Hsu and Soban, 1982), and labeled avidin-biotin (LAB) technique 
(Guesdon et al., 1979) in an attempt to obtain the highest sensitivity and lowest 
background possible. In these studies the technique which consistently gave the best 
results was the LAB method. In this immunostaining procedure, target tissue sections, 
either frozen or formalin-fixed and paraffin-embedded, were first incubated with a 
monoclonal antibody or affinity-purified polyclonal antibody (primary antibody) to the 
antigen of interest. Specifically bound antibody was then visualized by incubation with 
a biotinylated second-step antibody (link antibody) against irrununoglobulins of the 
relevant species (i.e. biotmylated goat anti-mouse IgG for a primary antibody raised in 
mice), followed by incubation with a streptavidin-enzyme conjugate and 
chromagen-substrate. Two different enzyme/chromagen systems, the calf intestinal 
alkaline phosphatase fast red TR and the horseradish peroxidase/ diaminobenzidine 
(DAB) systems were used in the course of these studies. The former of these systems 
gives a brilliant red end product which is easily detectable to the human eye even in low 
concentrations (Rainbow, 1988) but is soluble in alcohol which means it must be 
mounted with aqueous mountants. The latter system gives a brown end product which 
can be mounted in both aqueous and organic mountants and its sensitivity can be 
enhanced with salts of heavy metals such as nickel, silver or osmium (Hsu and Soban, 
1982; Johannson and Beckman, 1983; Rodriguez et al., 1984). 
A number of fixation methods were experimented with in an endeavor to 
obtain the best antigen preservation whilst retaining morphological detail of the 
specimen. In this author's hands fixation of fresh frozen tissue with cross linking 
fixatives (i.e. formaldehyde) or paraffin embedded tissue gave no or very poor 
immunostaining for Myc and Fos protein, possibly because these conditions either 
altered or destroyed the Myc and Fos epitopes. In contrast, although the tissue 
morphology was of lower quality than that using cross linking fixatives, fresh frozen 
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sections fixed with precipitative fixers (i.e. acetone, methanol, ethanol) resulted in 
relatively strong immunostaining for both the anti-Myc and -Fos antibodies. Due to the 
lower resultant background, methanol fixation in conjunction with peroxidase /DAB 
was routinely used for the majority of studies with anti-Myc and -Fos early-response 
gene antibodies. For detection of tissue marker proteins such as a-smooth muscle actin 
formaldehyde fixation in conjunction with alkaline phosphatase/ fast red TR was 
routinely used with satisfactory results. 
2.4.1 Materials 
2.4.1.1 Reagents and chemicals 
Aqueous Mounting medium 	BioGenex 
Crystal/Mount 	 Biomed Corp. 
D.P.X Mountant 	 BDH 
Diaminobenzidine 	 Sigma 
Gelatin 	 Davis Gelatin 
Imidazole 	 Sigma 
Levamisole 	 Sigma 
N,N Dimethyl Formamide 	 Sigma 
Napthol AS MX Phosphate 	Sigma 
Osmium tetroxide 	 Sigma 
Potassium Dichromate 	 BDH 
Protease type XXIV 	 Sigma 
Thymol 	 BDH 
2.4.1.2 Immunological-link and -labels 
Immunological-link and -labels were obtained from BioGenex (USA) and 
are listed below. 
Alkaline phosphatase-conjugated streptavidin (HK350-5K) 
Biotinylated anti-mouse immunoglobulins 	(HK335-5M) 
Biotinylated anti-rabbit immunoglobulins 	(HK336-5R) 
Normal Goat Serum 	 (HK112-5K) 
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Peroxidase-conjugated streptavidin 	(HK330-5K) 
.2.4.1.3 Primary antibodies 
Primary antibodies were obtained from commercial sources and are outlined 
below. 
1)Fos 
For detection of Fos and related proteins a rabbit, affinity purified 
polyclonal antibody raised against the peptide (S GFN ADYE A S SSR C) 
corresponding to residues 4 to 17 of human fos (Oncogene Science, USA, Cat # HCS17) 
was used at a concentration of 2.5 jig/ml. This antibody potentially cross-reacts with all 
members of the fos gene fatnilly. In addition, polyclonal antibodies specific for Fos, 
Fra-1 and Fra-2 were obtained as a kind gift fom Dr. D. Cohen (A.N.U) and were used 
in some preliminary studies. These antibodies were raised to non-conserved regions 
within each protein and therefore are unlikely to cross-react with other members of the 
fos gene family (Dr. D. Cohen, pers. comm.) 
2) Myc 
Myc protein was detected using a mouse monoclonal antibody from ascites 
fluid raised against the peptide (A PS EDIW KKFEL C) corresponding to residues 
44-55 of rat c-myc (Cambridge Research Biochemicals, UK, Cat. # 0M-11-904) and 
was used at a concentration of 25 jig/mi. 
3) Smooth muscle Actin 
Vascular smooth muscle was detected using a mouse monoclonal antibody 
from ascites fluid corresponding to a conserved decapeptide region of human and rat 
a-smooth muscle actin (Skalli et al., 1986) (ICN ImmunoBiologicals, Israel, Cat. # 
63-793) and was used at a dilution of 1:400. 
2.4.2 Immunodetection Procedure 
2.4.2.1 Immunodetection of early-response gene proteins by the 
LAB-immunoperoxidase method 
This method is a modification of the original method of Guesdon et al., 
(1979). 
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Experimental hearts embedded in OCT compound as described in section 
2.1.4 were warmed slowly to -22°C, mounted on a chuck in a freezing microtome and 
sectioned to 5 gm. Sections were then immediately thawed onto gelatin-dichromate 
coated slides (Penschow et al., 1989) and fixed at once in 95% methanol for 2 min and 
then air dried for 2 h at room temperature. Sections prepared in this manner were stored 
in moisture proof containers at -20°C for several weeks or at -80°C for up to several 
months without any apparent decrease in immunosensitivity. For immunodetection 
sections were allowed to thaw to room temperature and then incubated in methanolic 
11202 (0.5%) for 30 min to remove endogenous peroxidase activity. After rinsing in 
PBS they were then incubated successively in 0.1% avidin in PBS pH 7.4 and then 
0.01% biotin in PBS for 20 min to remove endogenous avidin binding activity (Wood 
and Warnke, 1981). After rinsing in PBS sections were incubated in 0.1% Triton X-100 
in order to permeabilize the tissue and then non-specifically blocked by incubating in 
normal goat serum (1%) for 30 min. Sections were subsequently incubated with the 
primary antibody overnight at 4°C at the appropriate dilution in diluent (PBS pH 7.4, 
0.1% BSA). After rinsing in PBS, sections were incubated for 1 h at room temperature 
with biotinylated anti-rabbit immunoglobulin or biotinylated anti-mouse 
immunoglobulin for polyclonal and monoclonal primary antibodies respectively. After 
rinsing, sections were incubated for 1 h at room temperature with peroxidase-conjugated 
streptavidin. After rinsing again with PBS, peroxidase activity was visualized by 
incubating slides in DAB/ifnidazole (0.02% DAB, 0.135% imidazole in PBS) for 2 min 
and then in DAB/imidazole containing 0.005% H202 for 3 min. Sections were then 
rinsed with distilled water and incubated in freshly prepared Osmium tetroxide ( 0.002% 
in PBS) for 3 min and rinsed in distilled water, dehydrated through ethanol, cleared into 
xylene and mounted with D.P.X. mountant. Slides were photographed as described in 
section 2.3.3.3. 
2.4.2.2 Immunodetection of cell marker proteins by the LAB-alkaline 
phosphatase method 
This method is a modification of the original method of Guesdon et al., 
(1979). 
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Fresh frozen tissue was sectioned as described previously and immediately 
fixed by incubating in tri-fixative (2% formaldehyde, 49% methanol, 49% acetone) for 
90 s at 5°C and then rinsed in tris buffered saline (TBS) for 5 min. Sections were then 
incubated successively in 0.1% avidin in TBS ( 0.1 M Tris.HC1 pH7.6, 0.9 g/1 NaC1) 
and then 0.01% biotin in Tris-saline for 20 min to remove endogenous avidin binding 
activity. After rinsing in TBS sections were incubated in 0.1% Triton X-100 in order to 
permeabilize the tissue and then non-specifically blocked by incubating in normal goat 
serum (1%) for 30 min. Sections were subsequently incubated with the primary 
antibody overnight at 4°C at the appropriate dilution in diluent (TBS pH 7.6, 0.1% 
BSA). After rinsing in TBS, sections were incubated for 1 h at room temperature with 
biotinylated anti-rabbit immunoglobulin or biotinylated anti-mouse immunoglobulin for 
polyclonal and monoclonal primary antibodies respectively. After rinsing, sections 
were incubated for 1 h at room temperature with alkaline phosphatase-conjugated 
streptavidin. following rinsing with TBS once again, phosphatase activity was 
visualized by preincubating sections in 0.1 M Tris.HC1 pH 8.2 for 2 min then in 
developing solution (Napthol AS MX 0.2, mg/ml, Fast red TR 0.75 mg/ml, levamisole 
0.2 mg/ml (an inhibitor of endogenous phosphatases) in 0.1 M Tris HC1 pH 8.2) for a 
further 20 min. After rinsing with water sections were protected with crystal mount, 
dried at 45°C and then mounted with D.P.X. Slides were photographed as described in 
section 2.3.3.3. 
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CHAPTER 3 
EFFECTS OF HYPERTROPHIC AGENTS ON EARLY-RESPONSE 
GENE EXPRESSION IN VIVO 
3.1 INTRODUCTION 
Studies by Simpson's group and others have demonstrated that NE acting 
via the occadrenergic receptors is capable of directly and independently inducing 
hypertrophy of neonatal cardiac myocytes in vitro and that this process is qualitatively 
similar to that observed in adult hearts following pressure overload (reviewed in 
Simpson, 1990). It has been speculated that the intracellular pathways linking 
occupancy of the adrenergic receptors to qualitative changes in protein synthesis 
observed during hypertrophy might be transduced by one or more members of a group 
of nuclear-acting early response genes (Simpson, 1988 A). This notion is consistent 
with the observations that elevated expression of some of these genes is an early event 
which occurs during NE-mediated neonatal myocyte hypertrophy (Starksen et al., 1986; 
Iwaki et al., 1990). However, cardiac myocytes isolated from neonatal hearts have 
demonstrable physiological, pharmacological and metabolic differences compared to 
adult cells (for an inclusive list see table 3.1) and results from studies with these 
immature, artificially cultured cells may not be directly applicable to the adult heart in 
vivo (Bugaisky and Zak, 1989). 
In addition it is possible that other cells may modify the response of 
adjacent cardiac myocytes by the release of growth factors. In support of this it has 
been shown that acidic and basic fibroblast growth factors can modify isocontractile 
gene expression and increase expression of c-fos and c-jun in isolated neonatal 
myocytes (unpublished data from Parker and Schneider, 1991) and it is possible that 
their release from fibroblasts may be enhanced by adrenergic agents. Accordingly it is 
of considerable interest to determine if NE might also modulate a similar program of 
early response gene expression in, myocytes of the adult heart in situ. As a first step in 
this direction the work in this chapter has examined the expression of common and 
distinct members of the early-response gene program including c-myc , c-fos, c-jun, fra-1 
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and fra-2 in whole adult rat hearts following acute and chronic administration of 
adrenergic agonists in vivo. For comparison the effects of the hypertrophic hormone T, 
on cardiac early-response gene expression was also analyzed since this hormone results 
in a qualitatively different form of hypertrophy to that observed in response to 
occadrenergic agents. 
Table 3.1 Comparison of cultured embryonic/neonatal and adult cardiac myocytes. 
Embryonic/neonatal 
	
Adult 
Initial striated structure 
Striated structure regained 
Morphology 
T-tubule system 
Beating rate 
Mass beating 
Isozymes 
PAS positive 
Cell division 
DNA synthesis 
Epinephrine responsive 
Resting potential 
Immediately lost 
Yes 
Unique 
Rudimentary 
70-100 
Synchronous 
V I : V3 1:1 
Yes 
Yes 
Yes 
Yes 
-38.2 mV 
Lost with time 
Yes 
Unique 
Well-developed 
175-220 
Asynchronous 
initially; becomes 
synchronous in time 
V, Only (during 1 week) 
Yes 
No 
Yes 
Yes 
-76.3 mV 
(Adapted from Bugaisky and Zak, 1989) 
3.2 EXPERIMENTAL PROTOCOLS 
3.2.1 Acute Administration of Hypertrophic Agents in vivo 
Rats were administered a single 0.5 ml intraperitoneal (i.p.) injection of the 
appropriate drug dissolved in vehicle (see section 2.1.2). Each animal received an 
equivalent dose per kilogram of body weight and control animals were injected with an 
equal volume of vehicle alone. Where used, adrenergic antagonists were injected twice, 
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1 h and again 10 min before NE administration. At the appropriate time after 
administration of drugs, rats were anaesthetized with an i.p. injection of 0.4 ml sodium 
pentobarbitone, 0.2 ml heparin and 0.4 ml of 0.9% saline and the hearts quickly excised 
and rinsed in ice-cold saline. Hearts for northern analysis were left whole or dissected 
into the various chambers and snap frozen in liquid nitrogen to await RNA extraction 
(section 2.2.2). 
3.2.2 Chronic Administration of Hypertrophic Agents in vivo 
3.2.2.1 Norepinephrine administration 
Alzet mini-osmotic pumps purchased from Alzet Corporation (U.S.A. 
Model 2002) were filled according to the accompanying instructions with NE in vehicle 
or vehicle alone (see section 2.1.2). Pumps were then equilibrated for 24 h in 0.9% 
saline before use and implanted in animals as follows. Rats were anaesthetized in an 
ether box and unconsciousness maintained by use of a nose cone. The intrascapular 
region was shaved, swabbed with antiseptic and a 1 cm incision made by blunt 
dissection to accommodate the pump. Following insertion of the pump, the wound was 
closed with surgery clips and the animals were allowed to recover from surgery and 
thereafter maintained as usual. At the appropriate time after surgery animals were 
anaesthetized, hearts removed and weighed and prepared for analysis as described in 
section 2.2. 
3.2.2.2 T3 administration 
Rats were injected subcutaneously every 24 h with T, and weighed on a 
daily basis. Control animals received an equivalent volume injection of vehicle alone 
(see section 2.1.2). After the appropriate number of days rats were anaesthetized and 
hearts removed, blotted dry and weighed. Hearts were then immediately prepared for 
analysis as described in section 2.2.2. 
3.3 RESULTS 
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3.3.1 Acute Effect of Adrenergic and Thyroid Hormones on Early-Response Gene 
Expression in vivo 
3.3.1.1 Adrenergic agents 
Total RNA was extracted from hearts and analyzed for early-response gene 
expression by northern blotting as described in the methods. Basal levels of c-myc but 
not c-fos mRNA could be detected in the hearts of both untreated and saline-injected 
animals, although this required over-exposure of the appropriate autoradiographs (Fig 
3.1-3.4). A single injection of NE (2.5 mg/kg) however, greatly elevated both c-fos and 
c-myc mRNA levels, with c-fos transcripts increasing 15 min after injection to peak at 
1-2 h and returning to basal by 6 h (Fig 3.1, Lanes 3-10). Elevated c-myc mRNA was 
observed at 30 min after injection of NE, peaked at 2-3 h and returned to basal levels 
after 6 h (Fig 3.1, Lanes 3-10). Thus, the increase in mRNA levels of these two genes 
in response to NE was both transient and sequential. Similar but lesser increases of 
c-fos and c-myc were observed following single doses of NE at levels as low as 2.5 
[is/kg, indicating that this response is not restricted to extremely high doses of the 
hormone (Fig 3.2). 
In order to determine which component of NE action was responsible for the 
change in c-myc and c-fos mRNA levels, rats were treated with the a-adrenergic agonist 
phenylephrine (2.5 mg/kg) or the p-adrenergic agonist, isoproterenol (2.5 mg/kg). Both 
agents caused an increase in c-fos and c-myc mRNA which was similar in magnitude to 
that due to NE (Fig 3.3 & 3.4). Minor crossover affinity of phenylephrine for 
P-adrenergic receptors was not responsible for the observed gene inductions in response 
to this agent since animals were co-treated with the selective P-adrenergic antagonist 
propranolol (50 mg/kg). Interestingly, the time required for c-myc mRNA to reach 
maximal levels appeared to be dependent on which agent was administered, peaking at 1 
h, 2 h, 3 h following treatment of rats with NE (a13), phenylephrine (a) and 
isoproterenol (P) respectively (Fig 3.5). 
Recent studies indicate that c-fos is one of a related family of rapidly 
inducible genes including fra-1 (Cohen and Curran, 1988) and fra-2 (Yoshida et al., 
1993) whose products form heterodimers with products of the c-jun gene family and 
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Lane 	1 2 3 4 5 6 7 8 9 10 
Time 	lh 3h 15' 30' 45' lh 2h 3h 6h 12h 
c-fos 
c-Inyc 
0-tubulin 	00004101111141141P111411411 
	
JJ 	  
Control 	Norepinephrine 
(saline) (2.5 mg/kg) 
Fig 3.1. Cardiac expression of c-fos and c-myc in response to a single injection  of norepinephrine. 
Total RNA was extracted from rat hearts removed at the various times indicated following an i.p. injection 
of 0.9% saline (Lanes 1 & 2) or norepinephrine (2.5 mg/kg, Lanes 3-10). After electrophoresis and 
northern blotting, the RNA (50 rig) was hybridized to c-fos (upper tracks), c-myc (middle tracks) and 
13-tubulin (lower tracts). 
111 
Li 1 	  
CTL NE 
(2.5 pg/kg) 
c-fos 
Lane 	1 2 3 	4 5 
Time 	1 hr 1 hr 2 hr 	1 hr 2 hr 
Fig 3.2. Cardiac expression of c-fos and c-myc in response to a single low dose injection of 
norepinephrine. 
Total RNA was extracted from rat hearts removed at the various times indicated following an i.p. injection 
of 0.9% saline (Lane 1) or norepinephrine (2.5 mg/kg, Lanes 2 & 3) and 50 lig  was hybridized to c-fos or 
c-myc. In addition, 7 Rg of poly(A) * RNA was isolated from the 1 h and 2 h total RNA samples for 
norepinephrine-treated rats and hybridized to c-fos (Lane 4) and c-myc (Lane 5) probes respectively. 
Lane 	1 2 3 4 5 6 7 8 9 
Time 	1 h 15" 30' 45• 1h 2h 3h 6h 12 h 
c-fo s 
I L 46410ww• 
IMF 
c-myc 4 =Mb it 
d-tubulin 
1--I 	  
Control 	Phenylephrine 
(Saline) 	(2.5mgikg) 
Fig 3.3. Cardiac expression of c-fos and c-myc in response to a single injection of phenylephrine. 
Total RNA was extracted from rat hearts removed at the various times indicated following an i.p. injection 
of 0.9% saline (Lane 1) or phenylephrine (2.5 mg/kg, Lanes 2-9). c-fos, c-myc and 13-tubulin transcripts 
were analyzed as described previously. 
NMI* 
Lane 	1 2 3 4 5 6 7 8 9 
Time 
c-fos 
c-mvc 
1h 	15 30' 45' lh 2h 3h 6h 12h 
IMPIMPOSPOS0 0-tubulin I 11. 
L_I I 	  
Control 	Isoproterenol 
(Saline) 	(2.5mg/kg) 
Fig 3.4. Cardiac expression of c-fos and c-myc in response to a single injection of isoproterenol. 
Total RNA was extracted from rat hearts removed at the various times indicated following an i.p. injection 
of 0.9% saline (Lane 1) or isoproterenol (2.5 mg/kg, Lanes 2-9), c-fos , c-myc and 13-tubulin transcripts 
were analyzed as described previously. 
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bind to AP-1 like regions of target genes to modulate their transcription (Reviewed in 
Angel and Karin, 1991). Accordingly it was of interest to determine whether these 
genes were also expressed in the heart following NE administration. c-jun and fra-2 but 
not fra-1 mRNA was endogenously expressed at low levels in the hearts of both adult 
untreated and saline-injected animals (Fig 3.6, Lanes 1-3). Injection of NE (2.5 mg/kg) 
however, greatly elevated the mRNA for all three genes: increased fra-1 mRNA 
appeared maximal after 1 h but remained elevated above control levels up to 6 h 
following administration of NE. Increased fra-2 and c-jun mRNA reached maximal 
levels after 2 h and had returned to near basal levels by 12 h and 6 h respectively 
following NE treatment. Interestingly, a second transcript of lower molecular weight (4 
kb) appeared for fra-2 following NE stimulation which is not detectable in basal tissue 
(Fig 3.6, Lanes 4-8). These results indicate that an array of early-response genes are 
induced in a sequential fashion in the rat heart following acute administration of NE. 
In order to determine the percentage contribution of the a- and 13-receptors 
to NE mediated early response gene expression, rats were exposed to selective a- or 
13-adrenergic blockade during NE administration (Fig 3.7 & 3.8). Co-treatment with 
propranolol (50 mg/kg), a synthetic I3„ 132-antagonist, did not attenuate the induction of 
any early-response genes investigated. In fact in most cases (c-fos, c-fun, fra-1 and 
fra-2) the observed induction was increased by 5-30% with respect to animals treated 
with NE alone. In contrast co-treatment with phentolamine (25 mg/kg) a synthetic a 1 , 
oyadrenergic antagonist, significantly attenuated, but did not abolish the induction of 
c-fos and c-jun whilst the mRNA levels of c-myc, fra-1 and fra-2 where not 
significantly reduced. It was noted again that the time of maximal c-myc expression and 
also fra-1 expression was altered in response to a specific component of NE action; thus 
I3-blockade resulted in greatest c-myc and fra-1 levels at 1 h compared to 3 h with 
a-blockade. Blockade with both a- and I3-adrenergic antagonists significantly reduced 
NE induction of all early-response genes to near basal levels indicating that the hormone 
indeed acts via the adrenergic receptors (Fig 3.7). 
3.3.1.2 T 3 administration 
63 
Lane 	1 2 3 4 5 6 7 8 
Time 	lh 3h 6h lh 2h 3h 6h 12h 
011. 	 ego op so 
fra-1 
fra-2 
q-tubulin •a, 41,0110.000111 
II  
CTL 	NE 
(saline) 	(2.5mg/kg) 
Fig 3.6. Cardiac expression of c-jun, fra-1 and fra-2 in response to a single injection of norepinephrine. 
Total RNA was extracted from rat hearts removed at the various times indicated following an i.p. injection 
of 0.9% saline (Lanes 1-3) or norepinephrine (2.5 mg/kg, Lanes 4-8). After electrophoresis and northern 
blotting, the RNA (5014) was hybridized to c-jun, fra-1, fra-2 and P-tubulin . 
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Fig 3.7. Cardiac expression of c-fos and c-myc, c-fun, fra-1 and fra-2 in response to a- or I3-adrenergic 
blockade prior to NE administration. 
Total RNA was extracted from rat hearts removed 1 h and 3 h following an i.p. injection of 0.9% saline 
(CTL, Lanes 1 and 2) or norepinephrine (2.5 mg/kg, Lanes 3 & 4). The 13-antagonist propranolol (PROP, 
50 mg/kg, Lanes 5 & 6) or a-antagonist phentolamine (PHT, 25 mg/kg, Lane 7  & 8) or a combination of 
both (lanes 9 & 10) were given twice, 1 h and 10 min prior to norepinephrine administration. c-myc, c-fos, 
c-jun, fra-1, fra-2 and I3-tubulin transcripts were analyzed as described previously. 
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Fig 3.8.Quantification of c-fos, c-myc, c-jun, fra-1 and fra-2 expression following a- or P-adrenergic blockade of NE-stimulated rats. 
The hybridization signals obtained by northern blotting in figure 3.7 were quantitated via laser densitometry and, after standardization to 13-tubulin levels 
in each track, were expressed as the fold increase over control (basal) signals observed in hearts from rats treated with vehicle. Basal signals for c-fos and 
c-jun were arbitrarily assigned the value of one. a=NE (2.5 mg/kg) + propranolol (50 mg/kg). f3=NE (2.5 mg/kg) + phentolamine (25 mg/kg). Vertical 
bars indicate standard error mean (S.E.M.), n=3. 
Rats were administered a single injection of the thyroid hormone T, (0.25 
mg/kg) and hearts were removed for analysis as described in the methods. No 
significant increase in c-myc, c-fos, or fra-1 expression compared to vehicle injected 
animals was observed up to 12 h following hormone administration (Fig 3.9). In 
contrast fra-2 mRNA levels (6.0 kb transcript) appeared to be slowly upregulated by T, 
administration. Elevated fra-2 friRNA was first observable 3 h following treatment and 
by 12 h mRNA levels were similar to that observed following NE treatment. Cardiac 
c-jun transcripts in response to T, administration were not assessed. 
3.3.2 Chronic Administration of Hypertrophic Agents in vivo 
3.3.2.1 Chronic norepinephrine administration 
Continued infusion of NE (100 lig/kg/h) by means of mini-osmotic pumps 
implanted in the intrascapular region of rats led to observable cardiac hypertrophy 
(assessed by wet weight of the whole heart) within 3 days (Fig 3.10). These results are 
comparable with those of others (Johnson et al., 1983). No evidence of fibrous scar 
formation was immediately obvious in any region of the heart following this treatment 
(Jiang and Downing, 1990). Increased heart to body weight ratios were also 
accompanied by increased expression of the neonatal-specific isocontractile gene 
a-SlcA, with increased transcript levels appearing after 2 h of infusion, rising to a 
maximum after 24 h and declining, but still above basal, after 72 h of NE infusion (Fig 
3.11 & 3.12). Similarly, mRNA levels for the early-response genes c-myc, c-fos, c-fun, 
fra-1 and fra-2 were also elevated in response to NE infusion (Fig 3.11, Lanes 1-12 & 
Fig 3.12), although their expression profiles differed with respect to each other and were 
of lesser intensity than the corresponding levels following a single injection of NE (2.5 
mg/kg) in vivo (Fig.3.11, Lanes 12-13). Elevated c-fos transcripts appeared within 1 h 
of NE infusion, peaking at 3 h and had returned to basal by 6 h of infusion. In contrast 
c-myc, c-jun, fra-1 and fra-2 exhibited more complex expression profiles. Elevated 
c-myc mRNA levels demonstrated an initial minor peak between 1 and 4 h of infusion 
after which transcript levels declined to basal values by 6 h before increasing again by 
12 h of infusion to reach a second, more sustained peak of greater intensity between 24 
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Fig 3.9. Cardiac expression of c-nzyc, c-fos, fra- I and fra-2 in response to a single injection of 
triiodo-L-thyronine. 
Total RNA was extracted from rat hearts removed at various times following an i.p. injection of vehicle 
(Lanes I & 2) or triiodo-L-thyronine (0.25 mg/kg, T„ Lanes 5-12). c-myc, c-fos, fra-1, fra-2 and 13-tubulin 
transcripts were analyzed as described previously. As a positive control, cardiac  RNA obtained from rats 
treated i.p. I h or 3 h previously with norepinephrine (2.5 mg/kg, NE, Lanes 3 &  4) have been included. 
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Fig 3.10. Induction of cardiac hypertrophy during chronic norepinephrine infusion. 
Rats were infused continuously with norepinephrine (100 gg/lcg/h) via implanted mini-osmotic pumps and after the times indicated the animals were 
sacrificed and heart and body weights measured. Vertical bars indicate standard error mean (S.E.M.). 
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Fig 3.11 Cardiac expression of c-myc, c-fos, c-jun, fra-1, fra-2 and a-skeletal actin during continuous 
infusion of norepinephrine. 
Rats were infused chronically with saline or norepinephrine (100 jig/kg/h, Lanes 1-10) for the times 
indicated, following which their hearts were removed and RNA isolated. c-myc, c-fos, c-jun, fra-1, fra-2 , 
a-skeletal actin and p -tubulin mRNA levels were analyzed as described previously. As a positive 
control, cardiac RNA obtained from rats treated i.p. 1 h or 3 h previously with norepinephrine (2.5 mg/kg, 
NE, Lanes l2& 13) have been included. 
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Fig 3.12 Quantification of cardiac c-myc, c-fos, c-jun, fra-1, fra-2 and a-skeletal actin induction during continuous infusion of norepinephrine. 
The hybridization signals obtained by northern blotting in figure 3.11 were quantitated via densitometry and, after standardization to 13-tubulin levels in 
each track, were expressed as percentage of the equivalent signal observed 1 h (c-fos, c-fun) or 3 h (fra-1, fra-2, c-myc) after acute norepinephrine 
administration (2.5 mg/kg). Vertical bars indicate standard error mean (S.E.M.), n=3. 
h and 48 h. By 72 h of NE infusion c-myc transcript levels had returned to near basal 
values. fra-1 and fra-2 and c-jun also exhibited initial transitory peaks between 1 and 6 
h of infusion of NE after which the level of these genes declined but remained above 
basal even after 72 h of infusion. Animals infused with saline did not exhibit increased 
heart to body weight ratios, nor were the transcript levels for a-SlcA or the 
early-response genes elevated significantly above levels observed in untreated animals. 
3.3.2.2 Chronic T, administration 
Rats administered a daily injection of T, (0.2 mg/kg) exhibited significant 
increases in heart weight and heart to body weight ratios within 2-3 days (Fig 3.13) and 
these results are similar to those obtained by others (Sanford et al., 1978; Clarke and 
Ward, 1983). Increased cardiac mass was accompanied by increased expression of the 
isocontractile gene a-MHC (Fig 3.14), an event which can be used as a marker for the 
hyperthyroid state and is characteristic of thyroid hormone-induced cardiac hypertrophy 
in the rat (Everett et al., 1984; Dillmann et al., 1989). Similar increases in a-MHC 
transcripts were also observed following daily administration of T3 at doses as low as 
2-20 jig/kg/day although changes in cardiac mass were not analyzed at these doses of 
T,. However, no change in the level of c-fos and c-myc mRNA was observed compared 
to control animals at any of the time points studied during T, administration (Fig 3.14). 
c-jun fra-1 and fra-2 mRNA levels were not assessed following chronic treatment with 
T,. 
3.4 DISCUSSION 
The nuclear-acting, early-response genes encode known or putative 
transcription factors, the induction of which are thought to modulate gene transcription 
during normal growth and differentiation (reviewed in Angel and Karin, 1991). 
Recently it has been proposed that these genes may also play an active role in the 
postnatal growth of the heart (Simpson, 1988 B), a process in which myocytes increase 
in size without concomitant cell division (Clubb and Bishop, 1984; Zak, 1974 A and B). 
This study has examined whether hormonal agents such as NE and T3 which promote 
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Fig 3.13. Induction of cardiac hypertrophy in response to daily injections of triiodo-L-thyronine. 
Rats were administered a daily injection of T3 (0.2 mg/kg) and at various times indicated body and heart 
weights were measured and expressed as a ratio of heart weight to body weight. Vertical bars indicate 
standard error mean (S.E.M.), n=3. 
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Fig 3.14. Cardiac expression of c-myc, c-fos, and myosin a-heavy chain in response to various doses of triiodo-L-thyronine. 
Total RNA was extracted from rat hearts removed at the various times indicated following daily injections of triiodo-L-thyronine of 0.2 mg/kg/day (Lanes 
1-7), 0.02 mg/kg/day (Lanes 8-13) and 2 gg/kg/day (Lanes 14-19). c-myc, c-fos, and myosin heavy chain transcripts were analyzed as previously 
described. As positive controls cardiac RNA extracted from rats treated with an i.p. injection of vehicle (CTL, Lanes 20 & 21) or norepinephrine ( NE, 
2.5 mg/kg, Lanes 22 & 23) was included. 
cardiac hypertrophy will influence the expression of early response genes in the adult 
heart in vivo. 
i) induction of the early-response gene program in response to NE 
administration. 
In this study c-myc, c-jun and fra-2 mRNAs were constitutively expressed 
at very low levels in the hearts of untreated adult rats. It is possible that this basal 
expression is localized to cells that are actively and continuously dividing such as 
fibroblasts or endothelial cells since c-myc, and the fos-related gene family have been 
associated with cellular proliferation (Angel and Karin, 1991). Interestingly expression 
of c-fos and fra-1 mRNAs were not observed in untreated adult hearts and taken with 
the above results is clear evidence that differential expression of the early-response gene 
program contributes to the function of adult hearts during normal growth. 
However the administration of a single injection of the hypertrophic agent 
NE (2.5 mg/kg) led to a rapid and transient increase in the cardiac mRNA levels for all 
of these genes with respect to control animals. The observed responses were not due to 
stress of the injection since little or no elevation in early-response gene expression was 
observed following an intraperitoneal (i.p.) injection of isotonic saline. Similarly 
increased gene expression cannot be explained simply as a result of the relatively large 
NE administration since the expression of some of these genes was characterized 
following doses of NE as low as 2.5 jig/kg. The majority of experiments however, were 
conducted with the higher dose of adrenergic agents since the responses were 
qualitatively similar to that of the lower dose, and also because others have shown that 
significant cardiac hypertrophy can result following repeated daily injections of 
adrenergic agents in the range 2.5-5 mg/kg (Clarke and Ward, 1983). These results are 
consistent with the hypothesis that early-response gene expression might play an 
important role in the adaptive response of the heart to NE stimulation. 
The sequential pattern of early-response gene expression following NE 
administration (e.g. c-fos preceding c-myc induction) was generally similar to that 
observed in other cell systems in response to mitogen stimulation (reviewed in Curran et 
al., 1989). However the duration of these responses appeared to be slightly longer than 
has been observed previously in response to acute stimulus (Angel and Karin, 1991). 
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For instance, the transient c-fos mRNA response peaked around 1-2 h rather than 30-60 
min as is commonly observed in other systems. Similarly, fra-1 and fra-2 mRNA levels 
were still significantly elevated above basal 6 h following NE treatment. The reason for 
this relatively sustained response is not clear since it can be expected that NE injected 
i.p. would be rapidly turned over and cleared from the animals system. These findings 
may indicate that multiple cell types are contributing to this response and demonstrates 
that even brief exposure of the heart to the trophic hormone NE, can have a lasting 
effect on this tissue in terms of gene expression. This finding is in accordance with the 
notion that these nuclear-acting genes couple short term signals elicited by cell surface 
stimuli to long term alterations in cellular phenotype (Curran, 1991) and is supportive of 
the proposed role for these genes in NE-mediated cardiac hypertrophy (Starksen et al., 
1986; Lee et al., 1988). 
There are no previous reports demonstrating expression of fra-1 and fra-2 
expression in the heart or cardiac myocyte preparations and the observations here are of 
particular significance since different members of the fos and jun families have distinct 
transcriptional properties (Angel and Karin, 1991), thus changes in the composition of 
their protein heterodimer complexes (AP-1) in the heart may be one means by which the 
sequential and diverse expression of target genes involved in the hypertrophic response 
are coordinated. In this regard it is of interest to note that at least two different fra-2 
tnRNA transcripts are observed during northern analysis and this has been observed in 
other tissues previously (Yoshida, et al., 1993). The higher molecular weight fra-2 
transcript but not the lower molecular weight transcript is detectable at low levels in 
basal heart tissue but both transcripts are readily induced following acute NE 
administration. The size difference between the two transcripts is attributable to the 
heterogeneity of the 3'-end, probably reflecting utilization of different polyadenylation 
sites (Yosida, et al., 1993). It will be interesting to to determine their physiological 
relevance in terms of cardiac function. 
In the present studies a single administration of NE caused transient 
increases in the cardiac levels of early-response genes. However a continuous exposure 
of NE is required for up to 24 to 48 h before overt hypertrophy can be observed in vivo. 
It is likely then that if early-response genes play a trans-activating role in this process, 
that they should also be expressed either during, or immediately prior, to this 
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hypertrophic growth period. Accordingly early-response gene expression was 
examined in rat hearts actively hypertrophying as a result of chronic infusion of NE. 
Rats were infused at a rate of 100 1.1g/kg/h since this treatment is a commonly used 
model producing cardiac hypertrophy within 24-48 h (Johnson et al., 1983), a finding 
which was confirmed in the present experiments. Cardiac hypertrophy was preceded by 
transient increases in all early-response genes examined and this response was 
qualitatively similar to that observed in response to a single administration of NE 
further supporting the conclusion that early-response gene expression was not limited to 
a bolus, high dose injection of NE. In addition, a second significant and sustained 
increase in c-myc mRNA levels was observed between 24 h and 72 h of NE infusion and 
this was of particular interest since it coincided with observable increases in cardiac 
mass and increased expression of the isocontractile gene a-SkA. In neonatal cardiac 
myocytes elevated c-myc expression has been associated with increased expression of 
the fetal gene program including reexpression of a-SkA and P-MHC (Simpson, 1990) 
and taken together with the present results, suggests that induction of the early-response 
gene and fetal isocontractile gene programs are a conserved response of both the 
neonatal myocytes and the adult heart to NE stimulation. 
However induction of the early-response gene program is not associated 
with all forms of cardiac hypertrophy (Izumo et al., 1987; Izumo et al., 1988). For 
example, treatment of rats with a single injection of T, did not increase cardiac mRNA 
levels for c-myc, c-fos, or fra-1 although continued daily injections of this dose of T, 
caused significant cardiac hypertrophy and up regulation of a-MHC. It is important to 
note in this respect that T, is removed from the body at a much slower rate than NE and 
thus repeated daily injections can be considered as a single chronic treatment rather 
than a series of acute treatments These results are in agreement with those of a later 
study which also found no increase in myocardial c-myc levels following T, 
administration (Green et al., 1991). In direct contrast, acute T, administration resulted 
in a gradual upregulation of the constitutively expressed fra-2 transcript. The 
physiological significance of this is not known but it is interesting to speculate that this 
gene may play a transducing role in thyroid hormone-induced hypertrophy. Further 
studies are needed to confirm this preliminary and intriguing result. 
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ii) early-response gene expression is primarily an a -adrenergic response 
In addition to temporal differences in expression, these genes also exhibited 
differential responses to the a- and 0-components of NE action. For instance, elevation 
of c-fos and c-jun following a-adrenergic stimulation was significantly greater than that 
induced by 0-adrenergic agents as shown by blockade of the a-and 0-components of NE 
respectively. c-fos has previously been reported to be expressed in cardiac tissue in vivo 
following a- and 0-adrenergic stimulation (Moalic et al., 1989; Barka et al., 1987), 
however these experiments did not establish the relative contribution of the a- and 
13-receptors to this response or characterize the temporal pattern of expression of this 
gene. 
In contrast to the above, c-myc, fra-1 and fra-2 also have a significant 
0-adrenergic component to their response. Elevation of c-myc in response to 
a-adrenergic stimulation in the adult, in vivo model is not unexpected since both 
hypertrophy and c-myc expression can be induced in cultured neonatal myocytes by an 
a,-adrenergic mechanism (Starksen et al., 1986). However, c-myc levels in cultured 
neonatal myocytes are not increased by 13-adrenergic agents (Starksen et al., 1986) 
therefore the increased c-myc expression observed in these experiments following 
13-stimulation may indicate that the gene induction is occurring via a secondary 
mechanism or in a non myocyte cell type. Alternatively the discrepancy may be due to 
the well documented differences in a- and 13-receptor numbers between adult and 
neonatal cardiac tissue (Graham and Lannier, 1986; Schaffer and Williams, 1986; 
Longbaugh et al., 1986). 
It is interesting to note that the time course of c-myc and fra-1 expression is 
dependent on the particular component of adrenergic action: maximal c-myc and fra-1 
mRNA levels were observed at 1 h, 2 h and 3 h in response to a-, a13- and 0-adrenergic 
treatment. This differential response might be due to the distinct intracellular signaling 
mechanisms activated by the a- and 13-adrenergic receptors (Brown and Jones, 1986; 
Homcy and Graham, 1985; Tomlinson et al., 1985) or alternatively might be a further 
indication that the 0-adrenergic response of c-myc and fra-1 involves a secondary 
pathway perhaps involving several cell types and growth factors. Another possibility is 
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that c-myc and fra-1 transcription is elevated by a-adrenergic stimulation, an event that 
would produce a rapid rise in c-myc and fra-1 mRNAs, whilst 0-adrenergic agents 
increase c-myc and fra-1 inRNA accumulation by reducing their degradation. 
Regulation of c-myc expression in other systems at least, is known to include both 
transcriptional and post-transcriptional mechanisms (Alitalo et al., 1987) and resolution 
of these possibilities will require a detailed examination of c-myc and fra-1 transcript 
synthesis and turnover. Finally, it is conceivable that a significant proportion of the 
early response gene expression following 0-agonist treatment is actually mediated by 
increased release of NE from sympathetic nerve endings induced by stimulation of the 
presynaptic 02-receptors (Simpson, 1985), and consequently would depend on 
postsynaptic a-adrenoceptor stimulation. However in these studies early-response gene 
expression was observed during p-adrenergic stimulation even when the oc-adrenergic 
receptors were blocked with the a-antagonist phentolamine. It is possible but unlikely 
that this treatment did not adequately block the a-adrenergic receptors during NE 
administration since all animals were pretreated twice, 1 h and 10 min prior to NE 
administration with a 10 fold excess of a-adrenergic blocker. 
iii) NE and pressure-overload hypertrophy: common and distinct effects on 
early-response gene expression 
Recent studies with cell cultures indicate that c-myc, c-fos and c-jun are 
inducible in neonatal myocytes following NE treatment (Starksen et al., 1986; Iwalci et 
al., 1990). Thus it is possible that at least part of the responses observed in the present 
in vivo experiments with adult rats are a result of direct NE activation of cardiac 
myocyte adrenergic receptors (Bruckner et al., 1985; Buxton and Brunton, 1986; 
Kauman and Lemoine, 1987; Brodde, 1987). However, in addition to cardiac myocytes, 
a,- and 0-receptors are located on a number of other cell types including smooth muscle 
of the coronary and peripheral vascular systems where they mediate vasoconstriction 
and vasodilation respectively (Hyman, 1986). It is well established that high doses of 
NE or moderate doses of acagonists lead to increased vascular resistance and pressure 
load on the heart (Zierhut and Zimmer, 1989) and pressure overload itself can cause 
increased cardiac expression of c-myc, c-fos, c-jun during aortic stenosis (Black et al., 
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1991; Rodman et al., 1991; Izumo et al., 1988). It is not possible in the present study 
to determine whether the a-adrenergic stimulated early-response gene expression is 
mediated in part or wholly by a secondary pressure response and further experiments in 
which changes in hemodynamic parameters are controlled need to be conducted. 
Nevertheless the fact that continuous subcutaneous infusion of NE at the dose used in 
these chronic infusion experiments, leads to a rapid and sustained elevation of systolic 
blood pressure (Johnson et al., 1983) is supportive of a pressure component in the 
early-response gene program. 
However, it is important to note that although the activation of the 
early-response gene program following NE administration appears to be similar to that 
documented in response to pressure-overload, significant temporal and qualitative 
differences in this induction process are observable. For instance, c-fos induction 
following chronic NE infusion is similar to that observed following a single 
administration of NE with mRNA levels returning to basal by 3-6 h. In contrast, c-fos 
levels in pressure overloaded hearts remain elevated for up to 24 h following aortic 
stenosis (Yazalci et al., 1989). The results presented here thus indicate that continued 
expression of c-fos is not necessary for NE mediated cardiac hypertrophy and 
re-expression of the neonatal gene program to occur. Furthermore, pressure overloaded 
rodent hearts do not express fra-1 (Rodman et al., 1991) yet this gene is upregulated in 
animals treated with both acutely and chronically with NE. Thus the adrenergic 
induction of this gene observed here is probably a direct response to cardiac a- and 
13-receptor stimulation independent of load. c-myc expression also differs between 
pressure overloaded hearts and NE-treated hearts since expression of this gene is 
bi-phasic during chronic NE infusion whereas only one sustained peak is observed 
following aortic stenosis (Yazaki et al., 1989). Again this stimulus-specific behavior 
may reflect different physiological outcomes of each treatment. Clearly, to resolve 
these differences, further in vivo studies are needed in which early-response gene 
expression and subsequent phenotypical changes (e.g. isocontractile genes) are 
examined in response to subhypertensive doses of adrenergic agents and compared to 
those changes which occur in response to high doses of these hormones or pressure 
overload. 
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In summary the results presented in this chapter demonstrate that an array of 
early-response genes are rapidly and sequentially induced in the adult rat heart 
following adrenergic stimulation and that this response occurs via both the a- and 
P-adrenergic receptors. Furthermore, the expression of some of these genes is not 
transient but is sustained at high levels during the period when overt cardiac 
hypertrophy occurs and at the same time that the neonatal gene program is reactivated. 
These results are supportive of the hypothesis that induction of the early-response gene 
program is associated with, and may be necessary for, the modulation of the program of 
late response gene expression (e.g. isocontractile genes) that is characteristic of 
adrenergic-, but not thyroid hormone-mediated cardiac hypertrophy. Since some of the 
early response genes such as c-myc and c-fos are modulated by both NE and 
pressure-overload but others such as Ira-1 are only sensitive to NE treatment, these 
studies also provide the first evidence that adrenergic agents and pressure-overload can 
activate both common and distinct subsets of these trans-activating genes. 
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CHAPTER 4 
REGIONAL AND CELLULAR LOCALIZATION  OF 
EARLY-RESPONSE GENE EXPRESSION IN VIVO  
4.1 INTRODUCTION 
Results presented in the previous chapter clearly demonstrated that 
administration of NE in vivo leads, either directly or indirectly, to a rapid activation of 
the early-response gene program in the rat heart. It is likely that at least part of this 
response can be attributed to the cardiac myocytes since others have shown that 
early-response genes are expressed in neonatal myocyte cultures following adrenergic 
treatment (Lee et al., 1988; Starksen et al., 1986). However, at least 70% of the cells in 
the heart are not myocytes, but those associated with neuronal, vascular and fibroblastic 
tissue of which any or indeed all may contribute to the cardiac early-response gene 
expression observed in vivo. For instance, it has been shown that c-myc and c-fos are 
induced in vascular smooth muscle cells during culture and whole aorta by vasoactive 
agents including NE and ANG II indicating that an analogous response may occur in the 
intact heart (Naftilan et al, 1989; Moalic et al, 1989). One necessary step then, in the 
establishment of a direct association between early-response gene expression in the 
heart• and NE mediated hypertrophy of adult myocytes is to localize the rnRNAs for 
these genes to specific cell types following adrenergic treatment and to demonstrate that 
they are translated to their cognate protein products. Further evidence might stem from 
the ability to correlate regional localization of this expression with the differential 
growth of the cardiac chambers during NE mediated cardiac hypertrophy. Already 
preliminary evidence for such a correlation has been obtained from pressure-overload 
models of cardiac hypertrophy since experimental aortic stenosis leads to not only a 
greater cardiac muscle growth of the left ventricle but also increased early-response 
gene expression in this chamber (Mulvagh et al., 1987; Komuro et al., 1988). 
In an attempt to address some of these points, the work in this chapter has 
assessed regional and cellular expression of the early-response gene families in the heart 
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following NE stimulation, utilizing a combination of hybridization histochemistry (in 
situ hybridization) and immunocytochemical techniques. In addition, regional 
expression of early-response gene mRNA was also detected on a gross scale by 
dissecting hearts obtained from experimental animals into the various component 
chambers and analyzing their mRNA levels separately by northern analysis. 
4.2 EXPERIMENTAL PROTOCOLS 
4.2.1 Hybridization Histochemistry 
For detection of metallothionein gene (Mt) expression rats were 
administered a single injection of either cadmium chloride (Cd, 10 lig/kg) or 
dexamethasone (DEX, 1 jig/kg) dissolved in 0.9% saline. Control animals were 
similarly injected with saline alone. After 4 or 6 h animals were sacrificed and livers 
were removed and prepared for northern analysis or hybridization histochemistry as 
described in section 2.3. ANP and calcitonin mRNA was detected in hearts removed 
from untreated adult rats as described in section 2.3. For detection of c-myc and c-fos 
mRNA, animals first received a single injection of NE (2.5 mg/kg) or saline and were 
sacrificed 1 to 3 hours later. Hearts were subsequently removed and processed for 
northern analysis and hybridization histochemistry as before. 
4.2.2 Regional Localization of Early-Response Gene Expression by Northern 
Analysis. 
Rats were treated with a single injection of NE (2.5 mg/kg) or saline as 
described previously and sacrificed after the appropriate time. Hearts were immediately 
removed and quickly dissected into the various chambers, rinsed in saline and 
snap-frozen in liquid nitrogen to await RNA extraction and northern analysis (section 
2.2). Due to their small mass, left and right atria from up to five animals were 
combined for each experimental time point. Results presented are representative of at 
least 3 separate experiments. 
4.2.3 Cellular Localization of Myc and Fos Protein by Immunocytochemistry. 
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Rats were administered a single injection of NE (2.5 mg/kg) as described in 
section 3.2.2.2. After the appropriate time animals were sacrificed, hearts removed and 
processed for immunocytochemistry using anti-early-response gene antibodies as 
described in section 2.4. Results are representative of at least 3 separate experiments. 
4.3 RESULTS 
4.3.1 Hybridization Histochemistry 
Since hybridization histochemistry had not been performed previously in the 
present laboratory, a suitable protocol was devised using a number of trial 
oligonucleotide and cDNA probes which had been successfully used for in situ detection 
of mRNA by other laboratories Detection of Mt was chosen as a suitable experimental 
trial since; 1) it is easily induced to high levels in the kidney and liver of rats in response 
to heavy metal or glucocorticoid treatment; 2) its mRNA remains induced for a 
relatively long period of time giving plenty of opportunity for its detection and finally; 
3) specific Mt-specific oligonucleotide and cDNA probes were readily available. The 
second trial experiment was designed specifically to optimize conditions for the 
detection of mRNA in cardiac tissue in situ. Atrial naturetic peptide (ANP) was an 
obvious choice for this study since its expression in the atria of the heart has been well 
characterized and its relative absence from adult ventricles means that these chambers 
may act as internal negative control tissue. For a negative control probe, the calcitonin 
gene was chosen since its expression is not detectable in the rat heart (J. Penschow, 
personal communication.). 
4.3.1.1 Detection of Metallothionein mRNA in rat liver 
Mt oligonucleotide and cDNA probe specificity was confirmed by northern 
analysis. Mt mRNA was not detectable in basal liver tissue but was rapidly induced 4 to 
6 h following a single injection of Cd (10 lig/kg) or DEX (1 gg/kg) (Fig. 4.1). Both 
oligonucleotide and cDNA radiolabeled probes were specific for Mt mRNA since they 
hybridized to the expected 300 nucleotide transcript. However the cDNA probe 
exhibited the more intense hybridization signal even though both probes were 
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Fig 4.1 Hybridization of metallothionein-specific cDNA and oligonucleotide probes to rat liver following 
a single injection of cadmium chloride or dexamethasone. 
Total RNA was extracted from rat liver at the various times indicated following an i.p. injection of 0.9% 
saline (Lane I), cadmium chloride (10 pig/kg, Lanes 2 & 3) or dexamethasone (1 1.1.g/kg, Lanes 4 & 5). 
After electrophoresis and northern blotting, the RNA (50 lig) was hybridized with a metallothionein 
specific oligonucleotide probe (upper track) or a cDNA probe (lower track). 
radiolabeled to approximately the same specific activity (1 x 109 cpm/fig, Fig. 4.1). It is 
possible that these differences in intensity of signal could be explained by sub-optimal 
hybridization conditions for the oligonucleotide-probe. Nevertheless, these results 
established that both Mt cDNA and oligonucleotide probes were potentially suitable for 
in situ detection of Mt mRNA. Cd administration was used for subsequent in situ 
studies since this treatment increased Mt expression in the liver to a greater extent than 
did DEX. 
Mt-specific probes were subsequently hybridized in situ to tissue sections of 
liver removed from animals previously treated with Cd as described in the methods. 
Typical results from one such an experiment are presented in Fig. 4.2 which shows 
expression of Mt mRNA in liver sections detected by exposure to high resolution 
autoradiographic film. Hybridization is significantly greater in tissue from animals 
treated with Cd (lower section) compared to saline (upper section) for both 
oligonucleotide (Fig. 4.2, Lanes 1 & 2 ) and cDNA (Fig. 4.2, Lanes 3 & 4) probes. The 
hybridization signal is due to specific binding to mRNA rather than DNA or protein 
since signal accumulation is prevented •when tissue is pre-incubated with a broad 
spectrum RNase enzyme (Fig. 4.2, Lanes 5 & 6). These experiments establish that the 
present experimental protocols are suitable for the in situ detection of specific mRNA in 
rat tissue using both cDNA and oligonucleotide probes. 
4.3.1.2 Detection of ANP mRNA in rat heart 
Hybridization histochemistry protocols were further optimized for cardiac 
tissue using oligonucleotide probes specific for rodent ANP and by comparison to a 
negative control probe specific for the calcitonin gene. Two ANP oligonucleotide 
probes were used for this study and their specificity for ANP was tested by northern 
analysis (Fig. 4.3). Both rat-specific and rat/mouse-specific probes hybridized strongly 
to atrial RNA extracts and this regional distribution is in accordance with the results of 
others (J. Penschow pers. comm.). Subsequent hybridization of the negative control 
probe, calcitonin, to the same RNA gave no hybridization signal and this was expected 
since transcripts of this gene are not detectable in heart tissue (Fig. 4.3; J Penchow 
pers. comm.). These results establish that the ANP and calcitonin probes are suitable 
positive and negative probes respectively for in situ analysis of cardiac mRNA. 
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Lane 	 1 	2 	3 	4 	5 	6 
CTL (6 h) 
Cd (6 
	 & 
1/5 	1/10 	1/5 	1/10 	1/5 	1/5 
1  Ii 	 1 I 	II 
Mt (oligo) 	 Mt (cDNA) 
RNased 
Fig 4.2 Effect of cadmium on expression of metallothionein in rat liver. 
Liver was removed 6 h following treatment with either 0.9% saline (upper section) or cadmium chloride 
(10 pt.g/kg, lower section) and prepared for in situ hybridization (section 2.3). The sections were 
hybridized in situ with metallothionein specific oligonucleotide (Lanes 1 & 2) or cDNA (Lanes 3 & 4) 
probes at a 1/5 or 1/10 dilution. As a control the same probes were incubated with liver tissue 
pre-incubated with RNase A (Lanes 5 & 6). 
Mt (oligo) Mt (cDNA) 
Lane 	 1 2 3 4 
Rat ANP #507 
Rat/mouse ANP #257 
Rat Calcitonin #210 
Whole Heart Atria 
Fig 4.3 Analysis of ANP and calcitonin oligonucleotide probes in rat heart. 
Total RNA was extracted from rat ventricle (Lanes 1 & 2) or rat atria (Lanes  3 & 4) and 50 i.tg of RNA 
was hybridized to two oligonucleotide probes (Rat ANP #507 and Rat/Mouse  ANP #257). As a negative 
control the same RNA samples were hybridized to Rat calcitonin #210, a gene  not expressed in the heart. 
ANP-specific probes were subsequently hybridized in situ to sections of 
heart tissue. Both rat-specific and rat/mouse-specific ANP probes hybridized strongly 
to atrial tissue (Fig. 4.4 & Fig. 4.5) but not to ventricular, skeletal or liver tissue (Fig. 
4.4). The results cannot be explained as non-specific hybridization of probes to atrial 
tissue since no hybridization was observed for the negative control probe calcitonin, in 
this tissue (Fig. 4.4). These results established that the current in situ hybridization 
protocols were potentially suitable for the detection and localization of specific mRNA 
species within the , rat heart and accordingly were used for the detection of 
early-response gene expression in this tissue. 
4.3.1.3 Detection of c-myc and c-fos mRNA in rat heart 
Anti-sense and sense probes to the expressed regions of c-myc and c-fos 
were designed and synthesized by the author as described in the methods. In addition, 
oligonucleotide probes specific for c-myc and c-fos were purchased from commercial 
sources and were used for comparison. Specificity of the probes was determined by 
hybridization to cardiac RNA extracted from animals treated with NE. Both c-myc 
anti-sense probes designed by the author hybridized to a 2.3 kb mRNA transcript 
indicating that they were indeed specific for this gene (Fig. 4.6, upper 2 tracks). The 
intensity of the observed hybridization signal was relatively weaker than similar 
hybridization with c-myc cDNA probes (results not shown). This difference in 
hybridization may once again be due to sub-optimal hybridization conditions for the 
oligonucleotide probes. In contrast a commercially obtained c-myc oligonucleotide 
probe did not hybridize to c-myc mRNA transcripts (Fig. 4.6, bottom track). This may 
have been due to the difficulty experienced with labeling this oligonucleotide to a high 
specific activity and seemed to be a problem intrinsic with this particular probe since no 
similar difficulty was experienced when labeling other oligonucleotide probes. As 
expected no hybridization was observed for the sense c-myc probe. 
Specificity of c-fos oligonucleotide probes was similarly determined by 
northern analysis. All c-fos probes hybridized to a 2.2 kb mRNA transcript indicating 
that they were specific for this gene (Fig. 4.7, upper two tracks). In addition, the 
temporal pattern of the observed expression was similar to that observed following 
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Rat ANP #507 A= Left ventricle 
B= Left Atrium 
C= Liver 
D= Skeletal Muscle 
Rat/mouse ANP #257 
• 
Rat Calcitonin #210 
Fig 4.4 in situ hybridization of ANP in rat heart, liver and skeletal muscle. 
Tissue sections of the left ventricle (A), left atrium (B), liver (C) and skeletal muscle (D) were prepared as 
described previously and hybridized in situ to the following oligonucleotide probes rat ANP #507 (upper 
panel), rat/mouse ANP #257 (middle panel) or rat calcitonin #210. 
AlNP #507 
1/5 
	1/2 
	1/1 
A= Right Atrium 
B= Right Ventricle 
C= Left Ventricle 
D= Left Atrium 
Fig 4.5 Regional localization of ANP expression in the rat heart. 
Whole tissue sections of the rat heart were prepared as described previously and hybridized in situ to rat 
ANP #507 at various dilutions (1/5, 1/2, 1/1). 
Lane 
Time 	 lh 3h lh 3h 
myc 2130 
myc 2230 
myc 3130 
(sense) 
myc Pr-1 
CTL NE 
(saline) (2.5 mg/kg) 
Fig 4.6 Analysis of c-myc oligonucleotide probes. 
Total RNA was extracted from rat hearts at the various times indicated following an i.p. injection of 0.9% 
saline (Lane 1 & 2) or norepinephrine (2.5 mg/kg, Lanes 3 & 4). c-myc transcripts were analyzed using 
two anti-sense probes (myc 2130 and myc 2230), a sense probe (myc 3130) and a commercially available 
anti-sense probe (myc Pr-1). 
Lane 	1234 
Time 	lh lh 2h 3h 
fos 2130 	• 
fos 2230 
fos 4130 
(sense) 
fos Pr-i 
CTL NE 
(saline) 	(2.5 mg/kg) 
Fig 4.7 Analysis of c-fos oligonucleotide probes. 
Total RNA was extracted from rat hearts at the various times indicated following an i.p. injection of 0.9% 
saline (Lane I) or norepinephrine (2.5 mg/kg, Lanes 2-4). c-fos transcripts were analyzed using two 
anti-sense probes (fos 2130 and fos 2230), a sense probe (fos 4130) and a commercially available 
anti-sense probe (fos Pr-1). 
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hybridization with a c-fos cDNA probe. Hybridization signals varied considerably 
between probes (all probes in Fig. 4.7 were exposed for the equivalent period) with the 
commercially obtained fos Pr-1 probe consistently giving the highest sensitivity (Fig. 
4.7, bottom track). As expected no hybridization was observed with the sense c-fos 
probe. 
Specific c-myc and c-fos oligonucleotide probes were subsequently 
hybridized to sections of heart tissue obtained from animals treated previously for 1-3 h 
with NE. Results from a typical experiment are presented in Fig. 4.8 which shows 
tissue sections of experimental and control tissue which have been hybridized to myc 
and fos oligonucleotides and exposed to autoradiographic film. No increased 
hybridization was observed for NE-treated tissue (lower tissue section) compared to 
control tissue (upper tissue section) for any of the anti-sense c-myc or c-fos 
oligonucleotides synthesized by the author and this was despite considerable 
manipulation of the experiment protocol. As expected, no hybridization was observed 
for the sense probes. Since c-myc and c-fos mRNA have relatively short half-lives it 
was possible that the fixation technique used here allowed mRNA degradation during 
tissue processing. To test this possibility, previously fixed NE-treated tissue was 
scrapped off slides, processed for RNA extraction and northern analysis and 
subsequently hybridized to radiolabeled c-myc and c-fos cDNA probes. Results in Fig. 
4.9 indicate that intact and hybridizable transcripts for both c-myc and c-fos were 
obtained from the tissue sections, thus the inability of the synthesized oligonucleotides 
to hybridize to c-myc and c-fos in situ is not due to degradation of their respective 
mRNA during tissue processing. Alternatively it is possible that in fact hybridization of 
oligonucleotide probes to target mRNA in situ had occurred but the hybridization signal 
was so weak that it was masked by the background non-specific binding. This 
possibility is especially likely given the weak hybridization signals observed for these 
probes during northern analysis. Finally it is possible that the target sequences in the 
transcript RNA's may not have been available for hybridization in situ due to secondary 
structure of the mRNA or due to associated proteins. Such problems would not be 
observable during northern analysis since RNA is stripped of any associated protein and 
-efficiently linearized by the RNA extraction and northern blotting procedures. 
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Fig 4.8 Cardiac in situ hybridization of c-myc and c-fos following a single injection of norepinephrine. 
Two hours following a single i.p. injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) hearts were 
removed, sectioned and then hybridized in situ with the c-myc probes (upper panel) utilized in Fig 4.6 or 
with c-fos probes (lower panel) utilized in Fig 4.7. 
Lane 	1 2 3 
Time 	2h lh 2h 
C-MVS 
c-fos 
  
CTL NE 
(saline) (2.5 mg/kg) 
Fig 4.9 Northern analysis of c-myc and c-fos expression in cardiac tissue processed for in situ 
hybridization. 
Tissue samples used in figure 4.8 were scrapped from the slide and total RNA extracted. After 
electrophoresis and northern blotting, the RNA was hybridized with c-myc (upper panel) or c-fos (lower 
panel) cl)NA probes. 
Due to the poor results obtained with these oligonucleotide probes, two 
commercially available oligonucleotide probes myc Pr-1 and fos Pr-1 specific for c-myc 
and c-fos respectively, were purchased and used for in situ analysis (see Figs. 4.6 & 4.7, 
bottom tracks) for northern analysis. NE-treated sections of heart tissue were 
hybridized as before to the commercially obtained myc and fos oligonucleotide probes 
(Fig. 4.10). Once again no difference between NE-treated and control hearts was 
observed for the myc Pr-1 probe (results not shown) but this was not unexpected in light 
of the difficulties experienced with this probe during northern analysis (see Fig. 4.6, 
bottom track). In contrast, after considerable manipulation of the experimental protocol, 
specific hybridization of the fos Pr-1 probe to fos mRNA in situ compared to control 
tissue was achieved (Fig. 4.10) The temporal pattern of this expression was similar to 
that observed for c-fos induction during northern analysis with maximal expression after 
2 h. Hybridization was specific for mRNA since signal accumulation was prevented by 
preincubation of tissue with RNase A. The regional expression of c-fos was not uniform 
throughout the heart but greatest in the left ventricle and septum. Hybridization in atrial 
sections was variable and this was probably due to the Problems encountered with this 
tissue partially coming off slides during extended post-hybridization washes. The 
inherent background problems encountered severely restricted the interpretation of these 
in situ results and for this reason further in situ hybridization was conducted using 
labeled cDNA probes. 
The results from one such in situ experiment using cDNA probes for c-myc 
and c-fos are shown in Fig. 4.11. Increased hybridization is observed for both c-fos and 
c-myc in NE-treated tissue compared to control tissue. The temporal pattern of this 
expression is similar to that observed during northern analysis and is specific for mRNA 
since signal hybridization is prevented by preincubation with RNase. Regional 
distribution of c-myc and c-fos mRNA was less clearly discernible following 
hybridization to cDNA probes and this may have been due to the high background. 
Indeed this high background made localization of the responses to specific cells using 
liquid emulsion film impossible despite a number of attempts. 
Because of these above described experimental problems encountered 
during in situ analysis and also due to time constraints, this work was not pursued 
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Fig 4.10 in situ hybridization of c-fos in the rat heart after a single injection of norepinephrine. 
At various times after an injection of saline (CTL) or norepinephrine (NE,  2.5 mg/kg) rat hearts were 
removed, sectioned and hybridized in situ with fos Pr- l . As a control some heart sections were also 
treated with RNase A before hybridization with the fos probe. 
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Fig 4.11 in situ hybridization of c-myc and c-fos in the rat heart after a single injection of norepinephrine. 
At various times after an injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) rat hearts were 
removed, sectioned and hybridized in situ with cDNA probes for c-myc and c-fos. As a control some 
heart sections were also treated with RNase A before hybridization with the probes. 
further and subsequent regional and cellular analysis of c-myc and c-fos and other 
early-response genes was determined using northern analysis of mRNA obtained from 
separate heart chambers and by immunocytochemistry on whole cardiac sections. 
4.3.2 Regional Northern Analysis 
Hearts were removed from animals treated with NE or saline and dissected 
into the various chambers and early-response gene expression assessed by northern 
analysis (Fig. 4.12). All chambers of the heart contributed to the basal expression of 
c-myc, c-jun and fra-2 although this required considerable over-exposure of the 
appropriate autoradiographs. Administration of NE significantly increased mRNA 
levels of c-myc, c-jun, fra-1 and fra-2 above that of control tissue. Increased 
early-response gene mRNA levels were transient with maximal expression occurring for 
all genes at around 2 h and had returned to basal by 3 h with the exception of fra-1 and 
fra-2 which remained above basal for up to 6 h (results not shown but see chapter 3). 
The regional expression of early-response genes also differed following NE 
administration. For instance little or no c-fos transcripts were observed in the combined 
atria sample for any of the time points whilst fra-1, a structurally related gene exhibited 
maximal expression in this chamber. In contrast fra-2 expression was relatively 
uniform throughout the various chambers whilst c-myc, c-fos and c-jun expression was 
greatest in the left ventricle with progressively lesser expression in the right ventricle 
and septum. This variation in early-response gene expression is not due to different 
loading levelsor RNA as demonstrated by hybridization to the control probe 13-tubulin. 
Thus early-response gene expression in the rat heart following NE treatment exhibits 
both regional and temporal differences. 
4.3.3 Immunocytochemistry 
Fos and Myc protein products were detected in control and experimental 
hearts by immunocytochemistry using a number of polyclonal anti-Fos antibodies and a 
monoclonal anti-Myc antibody respectively. 
c-fos 
80 
IMP 
 
c-fos 	c-jun 
	II 	I 	I 	
fra-1 
  
fra-2 	fl-tubulin 
	I 	 
    
0 
lh 410110000 °woe wasell1111 
4104111,4101 alba 
ø.. 
*See 001111• 
ease Illesmo 
NE 
(2.5 
mg/kg) 
 2h 
3h 
At RV LV Sp At RV LV Sp At RV LV Sp At RV LV Sp At RV LV Sp At RV LV Sp 
Fig 4.12 Regional localization of c-myc, c-fos, c-jun, fra-1 and fra-2 in the rat heart following norepinephrine administration. 
Total RNA was extracted from rat heart chambers (At: atria, RV: right ventricle, LV: left ventricle, Sp: septum) at various times indicated following an 
injection of saline (0) or norepinephrine (2.5 mg/kg, 1-3 h). After electrophoresis and northern blotting, the RNA (25 lig) was sequentially hybridized to 
c-myc, c-fos, c-jun, fra-1 and fra-2 (6.0 kb transcript only). Hybridization to 13-tubulin was used to confirm that equal amounts of RNA were loaded in 
each track. 
c-fos protein was localized using a polyclonal antibody raised to a 
synthetic peptide (Oncogene science). This antibody potentially cross-reacts with other 
members of the fos gene family (fra-1, fra-2 & fos-B) due to the relatively high 
conservation of the antigenic sequence. Accordingly immunostaining with this antisera 
was termed Fos-like immunostaining (FL!). 
Little if any FLI was observed in any chambers of the hearts from untreated 
animals, although occasionally weak immunostaining was localized to the non- myocyte 
fraction, possibly fibroblasts, in hearts from saline treated animals (Fig. 4.13, Panel A 
and C). However, following administration of a single injection of NE (2.5 mg/kg) ELI 
increased dramatically in most chambers of the heart with greatest expression localized 
to the nuclei of the cardiac myocytes (Fig. 4.13, Panel B). In addition weaker 
expression was also observed in nuclei of smaller non-myocyte cells, presumably 
fibroblast although these cells were not positively identified (Fig. 4.13, Panel D). FLI 
was also observed in the cardiac vasculature, mainly in the vicinity of the smooth 
muscle cells and to a much lesser extent in the adjacent endothelial cells (Fig. 4.14, 
Panels A and C) In most cases immunostaining was restricted to the nuclei and this is 
in accordance with the proposed nuclear function of fos and for-related proteins. On 
occasion weaker cytoplasmic staining was also evident in some myocyte and 
non-myocyte cells (Fig. 4.13, Panel D) but the frequency and intensity of this staining 
seemed to depend largely on the fixation method (see methods for a more detailed 
discussion). Maximal FLI was observed 1-3 h following NE administration although 
immunostaining was observable within 15 min following NE treatment and was still 
detectable in some hearts for up to 5-6 h post-treatment (Table 4.1). Although ELI was 
distributed relatively homogeneously throughout each chamber, the intensity of staining 
and number of nuclei stained per field of view was greatest in the left ventricle (Fig. 
4.15 & Table 4.1) and this is in good agreement with the regional northern analysis data 
presented above. Interestingly, FLI in the left atrium was very high despite the low 
c-fos mRNA levels observed in this chamber during regional northern analysis 
(compare Pig. 4.15, Panel E with Fig. 4.12). This finding strengthens the idea that the 
anti-Fos antibody might cross-react with other proteins structurally related to Fos. For 
example both fra-1 and fra-2 mRNA are expressed at high levels in the atria following 
NE administration and cross-reactivity of the Fos antibody with these proteins may 
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Fig 4.13 Cellular localization of Fos-like immunoreactivity in the left ventricle of rat hearts following 
norepinephrine administration. 
After a single injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) the left ventricle of rat hearts 
were removed and immunostained for Fos-like immunoreactivity as described in "materials and methods". 
Results are representative of 3 independent experiments. Panels A & C, CTL 2 h left ventricle; Panels B 
D, NE 2 h left ventricle. Arrows in Panels B & D show myocyte nuclear and non-myocyte nuclear 
staining respectively. 400 X magnification. 
Fig.4.14 	Cellular localization of Fos-like immunoreactivity in cardiac -,scular tissue following 
norepinephrine administration. 
After a single injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) the left ventricle of rat hearts 
were removed and immunostained for Fos-like immunoreactivity as described in "materials and methods". 
Results are representitive of 3 independent experiments. Panels B & D, CTL 2 h left ventricular vascular 
tissue; Panels A & C, NE 2 h left ventricular vascular tissue. Arrows in Panels A & C show staining of 
smooth muscle and endothelial nuclei. 400 X magnification 
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Fig 4.15 Regional localization of Fos-like immunoreactivity in rat heart following norepinephrine 
administration. 
After a single i.p. injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) rat hearts were removed 
and immunostained for Fos-like immunoreactivity as described in "materials and methods". Results are 
representative of 3 independent experiments. Panel A, CTL 2 h left ventricle; Panel B, NE 2 h septum; 
Panel C, NE 2 h left ventricle; Panel D, NE 2 h right ventricle; Panel E, NE 2 h left atrium; Panel F, NE 2 
h right atrium. 200 X magnification. 
Table 4.1 Cardiac Fos-like immunostaining following norepinephrine administration. 
CTL 	- 
1 h 	-H- 	 -H- 	+ 	+ 
NE 	2h 	mi 	+ 	Hit 	-H- 	+++ 
2.5 mg/kg 3 h 	+ -H-+ 	+ 	-H- 
6 h + + 
LA 	RA 	LV 	RV 	Sp 
Following a single i.p. injection of norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and stained 
for Fos-like immunoreactivity as described in "materials and methods". Relative immunostaining in three 
representative fields was scored as non-detectable (-) up to maximal (++++) as described elsewhere 
(Snoecicx et al., 1991). LA: left atrium, RA: right atrium, LV: left ventricle, RV: right ventricle, Sp: 
septum. Type of labelled cell (muscle/non-muscle) was not considered. 
Table 4.2 Cardiac Fos-specific immunostaining following norepinephrine administration. 
• 
CTL 
	
1 h 	 -H- 	+ 	+ 
NE 	2 h 	+/- 	- 	im 	++ 	+++ 
2.5 mg/kg 3h -H- 	+ 	+ 
6h 	 +1- 
LA 	RA 	LV 	RV 	Sp 
Following a single i.p. injection of norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and stained 
for Fos-specifc immunoreactivity as described in "materials and methods". Relative immunostaining in 
three representative fields was scored as non-detectable (-) up to maximal (++++) as described elsewhere 
(Snoecicc et al., 1991). LA: left atrium, RA: right atrium, LV: left ventricle, RV: right ventricle, Sp: 
septum. Type of labelled cell (muscle/non-muscle) was not considered. 
account for the high itrununoreactivity observed in these chambers. In order to further 
explore this possibility preliminary immunostudies were performed using antibodies 
raised to peptide regions specific to c-fos, fra-1 and fra-2 (gift from Dr. D. Cohen). 
Fig. 4.16 demonstrates immunostaining with an anti-Fos-specific antibody 
in sections of rat heart 2 h following treatment with saline or NE. Sections have been 
counter-stained with haematoxylin (blue nuclei) in order to demonstrate the relative 
proportion of cells expressing c-fos protein. Little inununostaining was observable in 
saline treated cells (Fig. 4.16, Panel D) however, Fos rapidly accumulated in the 
myocyte nuclei and cytoplasm following NE treatment (Panels B and C). Lesser 
expression was also observable in fibroblast-like nuclei and those of the vasculature 
(not shown). Greatest immunostaining was found in the left ventricle 2-3 h following 
treatment (Table 4.2) and in marked contrast to the expression pattern obtained with 
FLI, little expression is observed in the atria (Fig. 4.16, Panel A) at any time point. 
These results are in good agreement with those obtained by northern analysis (Fig. 
4.12). 
As with Fos, little Fra-1 immunoreactivity was observed in saline treated 
hearts when immunolabelled with the Fra-1 specific antibody (Fig. 4.17, Panel A). 
However following treatment with NE, fra-1 protein accumulated in myocyte nuclei 
and to a lesser extent non-muscle cells (Fig. 4.17, Panels B and C). Both nuclear and 
perinuclear expression was observed. Weaker Fra-1 immunostaining of cells of the 
vasculature system was also observed following NE administration (results not shown). 
In contrast to Fos-specific antibody, significant Fra-1 protein accumulation was 
observed in the left atria (Fig. 4.17, Panel C & Table 4.3), and this is in close agreement 
with distribution of fra-1 mRNA observed during regional northern analysis (Fig. 
4.12). Fra-1 protein remained elevated for up to 6-12 h (results not shown) and this is 
also in accordance with the northern analysis results. 
In contrast to Fos and Fra-1, immunostaining with an anti-Fra-2 specific 
antibody exhibited significant immunostaining in cardiac tissue from control and saline 
treated animals (Fig. 4.18, Panel A). Expression was restricted mainly to the smaller 
non-myocyte nuclei, perhaps fibroblasts and to a much lesser extent in the myocytes. 
These results were in accordance with the observation of fra-2 mRNA in hearts of 
control and saline treated animals (Fig. 3.6). Following treatment with NE, Fra-2 
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Fig 4.16 Regional and cellular localization of Fos-specific immunoreactivity in rat heart following 
norepinephrine administration. 
After a single injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and 
immunostained with an anti-Fos specific antibody and then counter stained with hematoxylin (blue nuclei) 
as described in "materials and methods". Results are representitve of 3 independent experiments. Panel A, 
NE 2 h left atrium; Panel B, NE 2 h right ventricle; Panel C, NE 2 h left ventricle; Panel D, CTL 2 h left 
ventricle. Arrows in Panel C indicate myocyte nuclear staining. 200 X magnification. 
Br 
Fig 4.17 Regional localization of Fra-1 immunoreactivity in rat heart following norepinephrine 
administration. 
After a single i.p injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and 
immunostained for Fra-1 immunoreactivity and then counter stained with hematoxylin (blue nuclei) as 
described in "materials and methods". Results are representative of 3 independent experiments. Panel A, 
CTL 2 h left ventricle; Panel B, NE 2 h left ventricle; Panel C, NE 2 h left atrium. Arrows in Panels B & 
C indicate nuclear staining of myocytes. 400 X magnification. 
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Fig 4.18 Regional localization of Fra-2 immunoreactivity in rat heart following norepinephrine 
administration. 
After a single i.p injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and 
immunostained for Fra-2 immunoreactivity and counter stained with hematoxylin (blue nuclei) as 
described in "materials and methods". Results are representitve of 3 independent experiments. Panel A, 
CTL 2 h left ventricle; Panel B, NE 2 h left ventricle; Panel C, NE 2 h left atrium. Arrows in Panel A 
indicate basal non-myocyte nuclear staining. Arrows in Panel B indicate myocyte nuclear staining. 400 
X magnification. 
Table 4.3 Cardiac . Fra-1 immunostaining following norepinephrine administration. 
CTL 	 -/+ 	 - 
1 h 	-H- 	+ 	-H- 	+ 	+ 
NE 	2 h 	-H-+ 	+ 	 1 	1 1 1 	-H- 	-H- 
2.5 mg/kg 3 h 	-H- 	+ 	-1—H-1- 	-H—F 	-H- 
6 h 	+/- + 	-H- 	+/- 
12 h 	+/- 	 + 	-H- 	+1- 
LA 	RA 	LV 	RV 	Sp 
Following a single i.p. injection of norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and stained 
for Fra-1 inununoreactivity as described in "materials and methods". Relative immunostaining in three 
representative fields was scored as non-detectable (-) up to maximal (++-1—F) as 'described elsewhere 
(Snoecloc et al., 1991). LA: left atrium, RA: right atrium, LV: left ventricle, RV: right ventricle, Sp: 
septum. Type of labelled cell (muscle/non-muscle) was not considered. 
Table 4.4 Cardiac Fra-2 immunostaining following norepinephrine administration. 
CTL 	+ 	+ 	+• 	+ 	+ 
1 h 	+ 	+ 	+ 	+ 	+ 
NE 	2h 	-H- 	+ 	-H- 	+ 	+ 
2.5 mg/kg 3 h 	-H-1- 	+ 	-H-1-+ 	-H- 	-H-+ 
6h 	+/- 	+ 	, 	-H-+ 	+ 	-1—F 
12h 	+ 	+ 	++ 	+ 	+ 
LA 	RA 	LV 	RV 	Sp 
Following a single i.p. injection of norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and stained 
for Fra-2 immunoreactivity as described in "materials and methods". Relative immunostaining in three 
representative fields was scored as non-detectable (-) up to maximal (++++) as described elsewhere 
(Snoecloc et al., 1991). LA: left atrium, RA: right atrium, LV: left ventricle, RV: right ventricle, Sp: 
septum. Type of labelled cell (muscle/non-muscle) was not considered. 
protein accumulated to a much greater extent in myocyte nuclei (Fig. 4.18, Panel B) and 
to a lesser extent in the smaller fibroblast-like nuclei and those of the vasculature (not 
shown). As with Fos and Fra-1 immunostaining, maximum expression occurred in the 
left ventricle 2-4 hr following NE treatment with lesser staining elsewhere including the 
atria (Fig. 4.18 C and Table 4.4). Stained nuclei were still observable 6-12 h following 
treatment (Table 4.4 and results not shown). 
c-myc 
c-myc protein was immunostained with a monoclonal antibody as described 
in the materials and methods. Weak Myc immunostaining was observed in hearts from 
untreated and saline injected animals in the non-myocyte cell population, probably 
fibroblasts (Fig. 4.19, Panel A) but little in the vascular cells or myocytes (Fig. 4.19, 
Panel C). This basal expression was homogeneous throughout all chambers of the heart 
although the intensity varied from animal to animal. The cells in Figure 4.19 have been 
counter-stained with haematoxylin (blue nuclei) in order to demonstrate the relative 
proportion and size of cells expressing c-myc protein. Administration of a single 
injection of NE resulted in rapid accumulation c-myc protein throughout all chambers of 
the heart. Importantly, and in significant contrast to FLI staining, Myc immunostaining 
was greatest in non-muscle cells, probably fibroblasts, with much lesser staining 
apparent in the larger myocyte nuclei (Fig. 4.19, Panel B and Fig. 4.20, Panels B-F). 
Significant increase in Myc expression was observed in the coronary vasculature cells, 
presumably the endothelium and to a lesser extent smooth muscle cells (Fig. 4.19, Panel 
D). Smooth muscle staining (red staining) was confirmed by staining of adjacent slides 
with an anti-smooth muscle actin antibody (compare Fig. 4.19, Panel D with Panel E). 
Myc protein was first observable within 30 min following treatment, rising to a peak 
after 1-3 h and had returned to basal levels by 6-12 h (see Fig. 4.20, Panels A-F, Table 
4.5 and results not presented). These result indicates that c-myc may be associated with 
the hyperplastic response of cardiac non-myocyte cells rather than the hypertrophic 
response of cardiomyocytes following NE stimulation. 
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Fig 4.19 Cellular localization of Myc immunoreactivity in the left ventricle of rat hearts following 
norepinephrine administration. 
After a single injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) the left ventricle of rat hearts 
were removed and immunostained for Myc or smooth muscle actin (red cytoplasmic staining) 
immunoreactivity and counterstained with hematoxylin (blue nuclei) as described in "materials and 
methods". Results are representative of 3 independent experiments. Panel A, CTL 2 h left ventricle; 
Panel B, NE 2 h left ventricle; Panel C, CTL 2 h left ventricle vascular tissue; Panel D, NE 2 h left 
ventricular vascular tissue; Panel E, serial section from Panel D stained with anti-smooth muscle actin. 
Arrows in Panel A show basal non-myocyte nuclear staining. Arrows in Panel  B indicate the majority of 
myocyte nuclei are not stained with the anti-Myc antibody. Nuclei that stain positively for Myc are 
probably due to inter-cardic fibroblasts . Arrows in Panel D show staining of nuclei associated with 
vascular tissue. Arrows in Panel E confirm that Myc immunostained nuclei in Panel D probably belong 
to vascular endothelial and smooth muscle cells. 400 X magnification. 
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Fig 4.20 Regional localization of Myc immunoreactivity in rat heart following norepinephrine 
administration. 
After a single i.p injection of saline (CTL) or norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and 
immunostained for Myc immunoreactivity as described in "materials and methods". Results are 
representative of 3 independent experiments. Panel A, CTL 2 h left ventricle; Panel B, NE 2 h septum; 
Panel C, NE 2 h left ventricle; Panel D, NE 2 h right ventricle; Panel E, NE 2 h left atriim; Panel F, NE 2 
h right atrium. 200 X magnification. 
Table 4.5 Cardiac Myc immunostaining following norepinephrine administration. 
CTL 	+/- 	+/- 	+ 	+/- 	+ 
1 h 	+ 	+ 	+ 	+ 	+ 
NE 	2h 	-H- 	-H- 	-H—F 	-i—F 	d—l- 
2.5 mg/kg 3 h 	-H- 	+ 	-I—H—F 	-H- 	-i—H- 
6 h 	+ 	+/- 	+ 	+/- 	+ 
12 h 	+/- 	+/- 	+/- 	+/- 	+1- 
LA 	RA 	LV 	RV 	Sp 
Following a single i.p. injection of norepinephrine (NE, 2.5 mg/kg) rat hearts were removed and stained 
for Myc immunoreactivity as described in "materials and methods". Relative inununostaining in three 
representative fields was scored as non-detectable (-) up to maximal (++-H-) as described elsewhere 
(Snoeclot et al., 1991). LA: left atrium, RA: right atrium, LV: left ventricle, RV: right ventricle, Sp: 
septum. Type of labelled cell (muscle/non-muscle) was not considered. 
4.4 DISCUSSION 
Studies from chapter 3 established that induction of the early-response genes 
occurred rapidly in the heart following NE administration in vivo. These experiments 
however, did not shed light on the specific cell types or areas within the heart that were 
responsible for this expression or reveal whether their corresponding protein products 
were produced. The work in this chapter has sought answers to these questions using a 
combination of in situ hybridization, northern and immunohistochemical approaches. 
i) detection of c-myc and c-fos mRNA by hybridization histochemistry 
Hybridization histochemistry (in situ hybridization) is a molecular technique 
which has been used widely for the detection and localization of gene expression in 
tissue samples. In this study the technique was employed in an attempt to characterize 
the regional, cellular and temporal expression of two early-response genes, c-myc and 
c-fos in the rat heart following acute NE administration. 
While it was possible to demonstrate competency in the detection and 
localization of mRNA for some control genes (ANP and Mt) in both cardiac and liver 
tissue sections respectively, results obtained for the c-myc and c-fos analysis in the 
heart were not satisfactory. Complete resolution of these problems was compounded by 
the inherently long period which elapsed between the initial animal treatment and final 
interpretation of data and this was largely due to the extended exposure times needed to 
obtain adequate autoradiographic results. However, after considerable manipulation of 
the established experimental protocol, results were attained using a commercially 
obtained fos oligonucleotide (fos Pr-1) and c-myc and c-fos specific cDNA probes. 
These results demonstrated that c-myc and c-fos mRNA accumulated mainly in the left 
ventricle with lesser expression elsewhere and that the temporal pattern of this 
expression correlates with that observed during northern analysis. Thus c-fos induction 
preceded c-myc with maximal expression at 1-2 and 2-3 h respectively. Hybridization 
within the atria was variable and this was probably due to experimental difficulties 
involved in fixing this chamber to the slide. Analysis of c-fos and c-myc expression at a 
cellular level was inconclusive due to persistent background problems which made 
localization of mRNA to specific cell types impossible. 
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It is likely that the reasons for the poor results achieved with this method 
were due to the particular c-myc and c-fos probes and further studies using in situ 
hybridization would require the preparation and testing of more c-myc and c-fos specific 
oligonucleotide probes. Alternatively, riboprobes might be employed due to their 
greater hybridization stability. Further regional and cellular localization of 
early-response genes was undertaken by northern analysis or RNA extracted from 
individual heart chambers or by inununocytochemistry. 
ii) regional localization of early-response gene expression by northern 
analysis. 
Early-response gene expression was further examined in the various 
chambers of the heart by northern analysis following a single injection of NE (2.5 
mg/kg). Constitutive expression of c-myc, c-jun and fra-2 mRNA observed previously 
in whole myocardial extracts, was localized to all chambers of the heart with only slight 
variation in regional intensity. Thus elements which control the constitutive expression 
of these genes do not appear to be chamber specific. 
Following acute administration of NE, rnRNA of all early-response genes 
investigated, was rapidly and transiently induced above basal levels, however each gene 
displayed a distinct regional and temporal pattern of distribution. For instance c-fos 
expression was barely detectable in the combined atrial sample, at any time point, in 
contrast to the structurally and functionally related gene fra-1 which exhibited near 
maximal expression in this chamber at 2 h. In a further example c-fos and c-jun mRNA 
levels were only transiently increased with mRNA levels back to basal levels by 3-4 h 
whilst fra-2 mRNA remained elevated for up to 6 h. These results, taken together with 
those of the previous chapter, indicate that the cardiac induction of early-response gene 
expression following NE administration is not only temporally and stimulus-specific, 
but also a tissue-specific phenomenom and further supports the idea that differential 
expression of these genes is a mechanism by which diversity and specificity of the 
hypertrophic response to trophic stimuli might be achieved. 
The differences in regional distribution of these genes following acute NE 
treatment is suggestive that these genes have a different threshold for the same signal 
and/or are triggered by different signals. For instance the effect of NE on the heart in 
vivo is complex involving both direct receptor-mediated and secondary hemodynamic 
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events both of which are likely to contribute to the differential expression of 
early-response genes observed here. Thus the maximal expression of c-myc and c-fos 
observed in the left ventricle might be a function of the increased pressure that this 
chamber is exposed to as a result of peripheral vasoconstriction during NE treatment 
(see chapter 1). Indeed preliminary data from this laboratory (Eldridge, Hannan and 
West unpublished data) demonstrate that c-myc accumulates primarily in the left 
ventricle following chronic infusion of rats with hypertensive levels of a cadrenergic 
agents. This pattern of expression is similar to that observed in pressure-overloaded rat 
hearts following aortic stenosis and may support the hypothesis that c-myc and c-fos 
products mediate qualitative changes in protein synthesis which occur in the left 
ventricle during this growth process. For example ANP, TGF-13 and a-SkA are all 
expressed at high levels in the left ventricle in pressure-overloaded rat hearts and 
contain potential AP-1 binding sites in their promoter regions (Parker et al., 1991). 
Thus these observations in combination, are suggestive that increased pressure in the 
left ventricle is a major stimulus directing c-myc and c-fos expression in the heart 
following a single high dose injection of NE. 
In contrast however, fra-2 rnRNA levels are similar in the left and right 
ventricle and only slightly less in the septum and combined atrial sample despite the 
different pressures to which these regions might be transiently exposed following high 
dose NE treatment. Thus at least part of this response is probably due to direct cardiac 
NE receptor-mediated events independent of changes in pressure loading. These 
findings are interesting, in light of a recent study reporting that cats chronically 
administered doses of NE similar to those used in these experiments, exhibited cardiac 
hypertrophic growth which was of similar magnitude in both the left and right 
ventricles and which was physiologically similar to that observed following volume 
overload (Mariano et al., 1991). It is intriguing to speculate that fra-2 may be involved 
in the modulation of quantitative or qualitative processes which occur in both the left 
and right sides of the heart during this form of hypertrophy. In support of this, it was 
observed earlier (chapter 3) that T, administration, a treatment which leads to volume 
overload hypertrophy, also produced an upregulation of fra-2 mRNA 
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fra-1 mRNA exhibits greatest expression in the left ventricle and combined 
atrial sample following NE treatment and like c-fos and c-myc described above, this may 
be due to the pressor effect of the treatment. However, fra-1 expression has been 
reported to be unresponsive to pressure in rodents (Rockman eta!, 1991) and if true, 
this would seem to indicate that although all chambers of the heart are presumably 
exposed to the same circulating amounts of NE, their sensitivity to this stimuli differs. 
Clearly further studies are needed to determine which of these two hypotheses is 
correct. 
Further explanation of the regional distribution of early-response gene 
mRNA in the heart is complicated by a number of factors. Firstly, both a- and 
11-components of NE appear to modulate early-response gene expression independently, 
thus the regional distribution of these genes following stimulation by these two 
components of NE action needs to be examined in detail. To this end, preliminary data 
from this laboratory (Hannan and West, unpublished data) indicates that infusion of 
a-adrenergic agents leads to expression of c-myc predominantly in the left side of the 
heart whilst infusion with P-adrenergic agents results in distribution of mRNA evenly in 
both the left and right ventricle. Secondly, it is possible that the observed 
early-response gene induction may occur in different cell types which themselves may 
also exhibit differential sensitivity to the direct or indirect effects of NE, or 
alternatively, they may release factors which may differentially modify the expression 
of early response genes in adjacent myocytes. For instance b-FGF is present in heart 
tissue and has been demonstrated to induce c-fos, c-jun and jun-B in cardiac muscle 
cells (Parker et al., 1991), but while cell-type contribution to early-response gene 
expression can be assessed by immunohistochemistry (see below), elucidation of the 
possible role of autocrine and paracrine growth factors in this process will probably 
require the use of adult cardiac cell co-cultures. 
iii) cellular localization of early-response genes by immunocytochemistry 
Cellular localization of NE-induced early response gene expression was 
achieved by immunocytochemistry using commercially available monoclonal anti-Myc 
antibody and a polyclonal anti-Fos antibody. The anti-Fos antibody had been raised to a 
peptide sequence in the amino terminus which is conserved within the fos gene family. 
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Thus this antibody potentially cross-reacts with other members of the fos gene family 
and consequently positive immunostaining was termed Fos-like immunoreactivity 
(FLI). 
Fos-like immunoreactivity (FLI) was not observed in any cell type in hearts 
removed from untreated animals but weak immunostaining was localized to the 
occasional myocyte of saline treated animals. Thus it is unlikely that the Fos antibody 
used in this study cross reacts to any significant degree with Fra-2 since mRNA for this 
gene was clearly observable in control cardiac tissue. These results are in agreement 
with the recent study of (Schunkert et al., 1991) who also did not observe Fos 
hnmunostaining in untreated rat hearts (Schunkert et al., 1991), but once again, differed 
to those of Rappaport's group who demonstrated significant basal Fos expression in the 
smooth muscle cells of the cardiac vasculature system. However Rappaport's study did 
not discuss the specificity, or lack there of, of their anti-Fos antibody with respect to 
other members of the Fos protein family. Thus it is possible that in fact their anti-Fos 
antibody strongly cross reacts with other Fos like proteins which are observed in basal 
cardiac tissue or alternatively, it may cross-react nonspecifically with some unrelated 
protein in smooth muscle. In addition the results of Rappaport's group differed further 
from the those presented here since they observed significant induction of Fos following 
anesthesia which they attributed to stress of the injection and/or alterations in cardiac 
pressure that this treatment might cause (Snoecicx et al., 1991). However this response 
appeared to be age dependent since less FLI was observed in 12 week old rats than in 3 
week old rats. The animals used in the present study were between 8 to 12 weeks old 
which may explain why little or no FLI was observed in anesthetized animals. More 
over, it appears that a decreased sensitivity to certain types of stress is a common 
feature of the maturing heart in terms of early-response gene expression since it has 
been demonstrated that aortic constriction leads to increased c-myc mRNA in both the 
left ventricle and in both atria of 28 day old rats but only the atria in similarly treated 80 
day old rats (Mulvagh et al., 1987). It will be interesting to see if NE-mediated 
early-response gene expression is similarly down regulated in the hearts of older 
animals and to determine whether this affects the ability of older animals to adapt to 
physiological effects of this hormone. 
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Low level endogenous expression of c-myc characterized previously in this 
study at the RNA level, was observed in all chambers of the heart, in non-muscle cells 
nuclei, possibly fibroblasts but to a much lesser extent in vascular smooth muscle or 
cardiac myocytes. In a recent study by Rappaport's group (Snoeckx et al., 1991), Myc 
immunostaining was similarly observed in the non-muscle cells of the left ventricle of 
control animals and in addition, in the endothelium of large coronary arteries (Snoecicx 
et al., 1991). The reason for the failure to observe similar Myc immunostaining in the 
endothelium by the present study is puzzling but may indicate that the 
immunofluorescence detection system employed by Rappaport's group is more sensitive 
than the immunodetection system used here. 
Acute administration of NE led to the rapid and transient accumulation of 
c-fos like proteins and c-myc protein in the nuclei of heart cells. FLI was primarily 
restricted to the nuclei to the striated muscle cells and this is in accordance with results 
obtained from cultured myocyte cells following treatment with NE. In further support 
of these results, Schunkert's group (Schunkert et al., 1991) demonstrated that c-fos 
proteins accumulate in the myocyte nuclei of pressure-overloaded hearts and taken 
together they give further support for the idea that c-fos and structurally related genes 
may play an active role in NE and pressure mediated hypertrophy of adult myocytes 
Interestingly c-fos expression following NE administration was not 
restricted to the cardiac myocytes alone since increased FLI staining was also observed 
in the vascular smooth muscle nuclei which is in good agreement with previous reports 
of expression of c-fos mRNA in these cells and in whole aorta in response to NE 
treatment (Naftilan et al., 1989; Moalic et al., 1989). In addition much weaker 
accumulation of FLI relative to control was observed throughout the heart in smaller, 
presumably non-myocyte nuclei, a response that was also observed in the pressure 
overload studies of Rappaport's group (Snoeckx et al., 1991). This weaker expression 
was possibly due to activity of these genes in a subset of cardiac fibroblasts or other 
cells, but a much more stringent identification of this cell type is required to confidently 
explore this possibility. It is worthy to note, however, that expression of early-response 
genes in other cell types which are probably actively dividing does not negate a specific 
role for these genes in the hypertrophic growth of differentiated myocytes. For instance, 
it is possible that in response to the same trophic stimuli (i.e. NE), increased 
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early-response gene expression in different cell types may coordinate alternative growth 
responses depending on their post-transcriptional modification, the availability of other 
transcription factors or nuclear chromatin structure. An alternative explanation is that 
increased cardiac myocyte early-response gene expression simply indicates that these 
cells are attempting to re-enter the cell cycle. In corroboration with this is the 
observation that NE administration results in increased rat cardiocyte proliferating cell 
nuclear antigen (PCNA), an auxiliary protein of DNA polymerase gamma which may 
indicate that the cells are capable of DNA synthesis (Marino etal., 1990). 
The temporal and spatial pattern of Fos immunostaining closely correlated 
with that observed during regional northern analysis. For example, increased Fos 
staining was observed in the left ventricle 30 min following NE treatment and preceded 
increases in Myc levels. Interestingly however, although c-fos mRNA was hardly 
detectable in the atria of NE treated animals at any time point, this chamber exhibited 
significant FL! 1-2 h following treatment. These results were interpreted as the result of 
cross reactivity of the anti-Fos antibody with other Fos-like proteins, for example Fra-1, 
since mRNA levels for this gene accumulate to high levels in the atria following acute 
NE stimulation. As a first preliminary step in determining which proteins structurally 
related to Fos that might contribute to the observed FLI, studies were undertaken using 
polyclonal antibodies raised to non-conserved regions between Fos, Fra-1 and Fra-2. 
These experiments demonstrated that c-fos,.fra-1 and fra-2 protein products do indeed 
accumulate in the myocytes and to a lesser extent other cell types of adult hearts 
following NE treatment. In addition, the chamber-specific distribution correlated well 
with that observed during northern regional analysis. For example, protein products for 
all three genes accumulated in the left ventricle following NE treatment but only Fra-1 
and Fra-2 immunostaining was observable in the atria. Thus it would appear that the 
observed FLI in the atria following NE stimulation is the result of cross reactivity of the 
anti-Fos antibody with other members of the Fos gene family (fra-1, fos-B) or 
other as yet undiscovered fos-related genes, although western analysis is required for 
their confident identification. Unfortunately due to time constraints and limitations in 
the availability of the various anti-early-response gene antibodies, Western analysis was 
not able to be performed. 
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In direct contrast to FLI, Myc immunoreactivity following NE 
administration was greatest in non-cardiomyocyte cell types. A definite identification of 
these expressing cells was not made but their localization strongly suggests they are 
cardiac fibroblasts, the cell type that constitutes 90-95 % of the non-cardiomyocyte 
fraction (Eghbali et al., 1991). In addition significant Myc immunostaining was 
observed in the cardiac vasculature. Staining of serial sections with an anti-snooth 
muscle actin antibody indicated that these nuclei were probably of endothelial or smooth 
muscle origin but once again further studies are required to definitively identify these 
cells. Importantly, these results would seem to indicate that prior expression of c-myc in 
cardiac myocytes is not required for NE mediated cardiac hypertrophy in adult rat 
hearts. In direct contrast to these findings Simpson and co-workers demonstrated 
accumulation of c-myc mRNA in neonatal myocyte cultures following NE 
administration and implicated this gene in mediating the growth response of these cells. 
One possible resolution of these differences is that c-myc expression observed in the 
developing heart of neonatal animals represents at least a partial contribution from 
proliferating and or hypertrophying cardiomyocytes. This is not unreasonable since 
evidence exists implicating a role for c-myc in the maturation of neonatal 
cardiomyocytes to terminally differentiated, non-dividing cells (see chapter 1 for a more 
detailed discussion). It is worthy to note however, that the present immunostudies were 
performed in cardiac tissue obtained 1-6 h following acute administration of NE. It will 
be interesting to see if the non-cardiac cell population is also the major site of c-myc 
expression during chronic infusion of NE since, in addition to this transient rise in Myc 
between 1-6 h, this gene also exhibits a second sustained rise in expression after 12 h 
of NE infusion (see chapter 3). It is possible for example that the initial rise in Myc 
observed here represents the proliferation of non-cardiomycytes which is concomitant 
with cardiomyocyte hypertrophy and this hypothesis is supported by the observation that 
c-myc mRNA levels are elevated in proliferating fibroblasts and endothelial cells. By 
analogy the second sustained rise in cardiac c-myc mRNA observed during NE infusion 
might be restricted to hypertrophying cardiomyocytes. Further studies are required in 
order to determine which of these possibilities is correct. 
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Interestingly, in the studies by Rappaport group ( Snoeckx et al., 1991) 
aortic stenosis did not lead to a further increase in Myc in the rat heart in any cell type, 
despite the well documented changes in c-myc mRNA levels during this treatment 
(Izumo et al., 1988; Mulvagh et al., 1987). Such findings are further evidence that 
pressure-load and NE administration lead to both similar and dissimilar responses at the 
cellular level during cardiac hypertrophy and this may correlate with the different 
pathologies which may ultimately arise from each treatment. 
In summary this study provides the first evidence that administration of the 
hypertrophic hormone NE leads to accumulation of an array of similar and distinct 
early-response gene products in the adult heart in vivo. Fos and related gene products 
accumulated primarily in the cardiomyocyte nuclei and this in accordance with 
proposals that this gene family may play a transducing role during the initial stages of 
NE-mediated cardiac hypertrophy. In contrast Myc expression is mainly restricted to 
non-cardiomyocyte cell types such as fibroblasts and endothelial cells and consequently 
may be associated with the proliferation of these cells which is concomitant with 
cardiomyocyte hypertrophy. The regional and temporal pattern of distribution was 
confirmed at both the mRNA and protein levels and was found to be specific for each 
gene. Maximal expression of c-myc, c-fos and c-jun was observed in the left ventricle 
which might correlate with the increased pressure that this chamber is likely to 
experience during high dose NE administration. However the regional expression of 
fra-1 and fra-2 did not seem to correlate with changes in hemodynamics and indicates 
that these genes may be more responsive to the direct effect of NE. Taken together, 
these results provide indirect evidence that certain subsets of the early-response genes 
may play a trans-activating role in the chamber-specific responses observed in the heart 
following high doses of NE or aortic stenosis whilst a distinctly different subset might 
be important in coordinating global responses to hypertrophic growth stimuli. 
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CHAPTER 5 
EXPRESSION OF EARLY-RESPONSE GENES  IN THE ISOLATED 
PERFUSED HEART  
5.1 INTRODUCTION 
It is virtually impossible to dissociate the effects of stimuli that act directly 
on the cardiac myocyte from those that are secondary to systemic alterations. This is 
particularly so for the adrenergic hormones since they are not only capable of altering 
cardiac inotropy, chronotropy and metabolism, but they also increase work-load on this 
organ secondary to an increase in peripheral resistance (see chapter 1 for more in depth 
discussion). As a consequence of this some investigators have turned to cultured 
cardiac myocytes in order to examine the direct effect of NE and other trophic factors on 
myocyte growth independent of systemic influences. As discussed previously, the work 
of Simpson's group and subsequently others established that NE can directly mediate 
cardiac hypertrophy and modulate gene expression in isolated neonatal cardiomyocytes. 
However, it has been questioned whether it is appropriate to extrapolate results obtained 
from immature cells in an in vitro system to describe the responses of the fully mature 
myocyte in vivo (Bugaisky and Zak, 1989). For this reason other investigators have 
attempted to isolate and culture myocytes from the mature heart, but only recently has 
the preparation and culture of these cells been sufficiently advanced to allow for the 
long term study of adequate numbers of cells for biochemical and molecular analysis 
(Bugaisky and Zak, 1989). Even so, the effect of NE on heart cell growth in vitro 
appears to vary, with some groups reporting that adrenergic agents have a general 
anabolic effect on adult cardiac myocytes but do not modulate shifts in isocontractile 
protein synthesis (Dubbus et al., 1990) whilst others have demonstrated specific 
phenotypic alterations following adrenergic treatment (Rupp etal., 1991). Furthermore, 
there have been few reports of the effect of NE on early-response gene expression in 
isolated adult myocytes, possibly because stress of the cell isolation procedure itself has 
been shown to induce substantial early-response gene mRNA levels (Claycomb, 1987; 
Hannan and West unpublished data). 
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However an alternative model for investigating the direct effects of NE or 
other humoral factors on adult cardiac myocyte growth during controlled 
haemodynamic conditions, is the isolated (and therefore denervated) perfused heart 
system. In this model hearts are removed from the animal and perfused in vitro with a 
defined media either in a working or non-working capacity and in such a manner that 
the direct and indirect actions of NE can be studied separately whilst potentially critical 
interactions between different cardiac populations of cells are preserved. For instance, 
simulation of factors thought to be important in the development of cardiac 
hypertrophy, for example inclusion of NE in the perfusate, or elevation of perfusion 
pressure, have been shown to increase RNA, protein synthesis and ribosome formation 
(for review see Morgan et al., 1992 ). If early-response gene expression is involved in 
any of these processes, it should be possible to observe their expression, and to mediate 
this experimentally in isolated perfused hearts. Thus, while overt hypertrophy cannot be 
observed in this system due to the time required for this to occur, it is possible to model 
the biochemical initiation of this event. 
Accordingly the work in this chapter has sought to use the non-working 
perfused heart system in order to explore separately the direct and indirect effects of NE 
on cardiac early-response gene expression and to determine the specific chamber 
contribution to this response. 
5.2 METHODS 
5.2.1 in vitro Coronary Perfused Hearts 
Rats were anaesthetized as described previously (section 3.2.1) and hearts 
removed and placed in ice-cold isotonic saline until contraction had stopped. The aorta 
was stripped of connective tissue and tied directly onto the cannula of the perfusion 
apparatus and the hearts were then perfused at a constant pressure of 60, 90 or 120 
mmHg in the Langendorff (non-recirculating) manner as described by Williamson 
(Williamson, 1964). The perfusion cabinet was maintained at 37°C and a perspex 
surround was placed around the hearts to prevent evaporative cooling. With the 
apparatus available up to four hearts could be perfused simultaneously thus allowing a 
direct comparison to be made between untreated and experimental hearts. All hearts 
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were allowed a 15 min stabilization period and only hearts which had a stable 
contractile activity at the end of this period were accepted for further study. Following 
this period, designated "zero time" the drugs under investigation were introduced 
continuously into the perfusion medium of some hearts by means of a peristaltic pump 
or included directly in the perfusion medium reservoir (see section 5.3). Following 
perfusion, hearts were removed from the apparatus, rinsed in ice-cold isotonic saline and 
prepared for analysis as described in section 2.2. The perfusion medium was modified 
Krebs-Henseleit bicarbonate buffer (Williamson, 1964) containing in addition 1.27 mM 
CaCl„ 0.05 mM EDTA, 5 mM glucose, and 2 mM pyruvate which was filtered through 
a 45 gm Millipore filter and continuously equilibrated against a gas mixture of 95% 0 2 , 
5% CO, and maintained at 37°C by passage through a heated water jacket. See Fig. 5.1 
for a diagram of the perfusion setup. 
5.3 EXPERIMENTAL PROTOCOLS 
5.3.1 Expression of Early-Response Genes in Hearts Perfused at 60 mmHg. 
To assess the basal cardiac expression of early-response genes during 
perfusion, hearts were removed from anaesthetized animals and perfused at a constant 
pressure of 60 mmHg with Krebs-Henseleit buffer. At the end of the appropriate time 
(15 min-5 h), hearts were frozen in liquid nitrogen and processed for northern analysis 
as described in section 2.2. In order to confidently determine the baseline induction of 
early-response genes, 8 or more hearts were perfused at each time point and the results 
quantified by laser densitometry and analyzed statistically as described below (section 
5.3.5) 
5.3.2 Effect of Adrenergic Agents and Second Messengers. 
To study the effect of NE on early-response gene expression independent of 
pressure load, hearts were perfused at a constant pressure of 60 mmHg with buffer 
containing NE at final concentrations between 1 nM and 1 p.M. When used, adrenergic 
antagonists methoxamine (10 gM) and dl-propranolol (20 gM) were introduced into the 
perfusate 15 min prior to NE and thereafter maintained in the perfusate for the duration 
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Fig 5.1 Perfusion apparatus. 
A schematic representation of the non-working isolated perfused heart apparatus. For control 
perfusions (60 mmHg) the reservoir height was 80 cm above the aorta. For perfusions at elevated 
pressures (90 or 120 mmHg) the perfusion reservoir was raised to 120 and 160 cm respectively. 
of the perfusion. In order to establish whether early-response gene expression was 
mediated by increased PKC activity or elevated cAMP levels hearts were similarly 
perfused at 60 mmHg in the presence of phorbol myristate (PMA) or forskolin at final 
concentrations of 20 nM and 2 1.tM respectively. At the end of the perfusion period, 
hearts were processed for northern analysis and analyzed as before. 
5.3.3 Effect of Elevated Perfusion Pressure 
In order to establish whether increased perfusion pressure and thus stretch of 
the ventricular wall, could modulate early-response gene expression independent of NE, 
hearts were perfused at 60, 90 or 120 mmHg for 1 to 3 h in the presence of buffer alone 
and early-response gene mRNA levels were analyzed as before. 
5.3.4 Regional Localization of Early-Response Genes in the Perfused Heart 
In order to assess the regional expression of early-response genes, hearts 
were perfused at 60 mmHg with NE or at 120 mmHg with buffer alone and then 
dissected into the various chambers and analyzed separately for early-response gene 
expression by northern analysis. 
5.3.5 Treatment of Results 
Following northern analysis autoradiograms were quantified by laser 
densitometry. Each sample was corrected for loading by comparison to the 
hybridization with the control probe p-tubulin and results expressed as a multiple of 
basal expression (fold basal). When the experimental number was n=3 or better, error 
bars represent standard error mean (S.E.M) and for n=2 error bars represent standard 
deviation (S.D.) 
5.4 RESULTS 
All hearts were pre-perfused for 15 min following removal from 
anaesthetized animals to allow them to equilibrate with experimental conditions. Low 
levels of c-myc but not c-fos mRNA could be detected in hearts directly after removal, 
although this required over exposure of the appropriate autoradiogram (Fig. 5.2, Lane 
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Fig 5.2 Cardiac expression of c-myc and c-fos in rat hearts perfused at a constant coronary pressure 
(60 mmHg). 
Total RNA was extracted from rat hearts directly after removal from the animal (Basal, Lane 1) or at 
the various times indicated following perfusion at constant pressure of 60 mmHg (Lanes 2-10) with 
modified Krebs-Henseleit buffer. After electrophoresis and northern blotting, the RNA (50 lig) was 
hybridized to c-myc (upper tracks), c-Jos (middle tracks) and 13-tubulin (lower tracts). 
1). However mRNA levels for both genes rose significantly as a consequence of 
perfusion with Krebs-Henseleit buffer at a constant pressure . of 60 mmHg (Fig. 5.2, 
Lanes 2-10). Increased levels of c-myc mRNA could be observed after 15 min of 
perfusion and reached a peak between 2-3 h of perfusion. c-fos mRNA levels 
demonstrated a more complex profile since they reached a peak at 15-45 min and a 
second peak at approximately 2 h. These characteristic patterns for c-myc and c-fos 
expression were determined at each time point in 8 independent experiments with slight 
variation in the time course and intensity of the profile (see Fig. 5.10). Similar 
perfusion with 10 % bovine serum included in the perfusate did not alter the c-myc and 
c-fos expression profiles observed with buffer alone (results not presented). Similarly, 
prior treatment of hearts with a- and 13—adrenergic antagonists before removal from the 
animals, also did not remove basal c-myc and c-fos expression (results not shown). All 
filters were rehybridized to the control probe 13—tubulin to confirm that equal levels of 
mRNA were loaded in each track. 
Inclusion of NE (0.1 [tM, 1 ii,M) in the perfusion buffer significantly 
elevated the levels of c-myc and c-fos mRNA above that observed during perfusion with 
buffer alone at 60 mmHg, although c-fos was more responsive of the two genes (Fig. 
5.3). The observed increase in mRNA levels was dose-dependent with greater 
expression observed with 1 jiM NE than 0.1 1.1,M NE although significant elevation of 
c-myc and c-fos above basal could be observed following perfusion with NE at levels as 
low as 1 nM (results not shown). Expression of some other genes structurally or 
functionally related to c-fos were also examined in hearts following perfusion with 
buffer alone or buffer containing NE (1 1.1.M, Fig. 5.4). As with c-myc and c-fos, 
perfusion with buffer alone elevated mRNA levels of c-jun, fra-1 and fra-2. Inclusion 
of NE in the perfus ate greatly elevated fra-1 and fra-2 mRNA levels however the 
increase in c-jun mRNA in response to NE was less intense with respect to hearts 
perfused with buffer alone (Fig. 5.4). 
In order to determine the relative contribution of the a— and 13-components 
of NE action on early-response gene expression, hearts were co-perfused with NE and 
the 13 -adrenergic blocker propranolol, or with NE and the a—adrenergic blocker 
phentolamine (Fig. 5.5 & Fig. 5.6). c-myc, c-fos and fra-1 were only responsive to 
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Fig 5.3 Induction of c-myc and c-fos in the perfused rat heart in response to norepinephrine. 
Total RNA was extracted from rat hearts directly after removal from the animal (Basal) or at the 
various times indicated following constant perfusion at 60 mmHg with Krebs-Henseleit buffer alone 
(CTL) or with Kreb-Henseleit buffer containing norepinephrine (NE, 10 4 , 10 -6 M). c-myc and c-fos 
transcripts were detected as previously described. 
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Fig 5.4 Cardiac expression of c-fos like genes and c-jun in the perfused rat heart in response to 
norepinephrine. 
Total RNA was extracted from rat hearts directly after removal from the animal (Basal, Lane I) or at 
the various times indicated following constant perfusion at 60 mmHg with Krebs-Henseleit buffer 
alone (Upper panel) or with buffer containing norepinephrine (1 iM, lower panel). c-jutz, fra-1, fra-2 
and I3-tubulin transcripts were detected as previously described. 
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Fig 5.5 Contribution of the a- and 13-components of norepinephrine action to early response gene expression in the perfused rat heart. 
Total RNA was extracted from rat hearts directly after removal from the animal or at the various times indicated following constant perfusion at 60 mmHg 
with Krebs-Henseleit buffer alone (CTL) or with buffer containing norepinephrine (NE,  1 	norepinephrine and propranolol (NE, 1 JI M + PROP. 20 
1.0,4) or norepinephrine and phentolamine (NE, 1 JIM + PHT, 10 1..1M). c- myc. c-fas. c-jun, fm-1, fra-2 and 13-tubulin transcripts were analyzed as 
described previously. 
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Fig 5.6 Quantification of the a- and 13-components of norepinephrine action on early response gene 
expression in the perfused rat heart. 
The hybridization signals generated by northern blotting in figure 5.5 were quantitated via 
densitometry and, after standardization to p-tubulin levels in each track, were expressed as the fold 
increase over control (basal) mRNA levels observed in hearts from untreated rats. NE: 
norepinephrine (10 -6 M); a: NE (10 -6M) + propranolol (2x10 -5 M); 13: NE (10 -6M) + phentolamine 
(10-5 M). 
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a—adrenergic stimulation whilst increased fra-2 mRNA levels were observed following 
both a- and n-stimulation. Interestingly, the pattern and timing of induction of the two 
fra-2 transcripts differed with respect to each other. The higher molecular weight 
transcript (6.0 kb) was responsive to both a- and P-adrenergic agents, rising to a peak at 
1 and 3 h respectively. In contrast the lower molecular weight transcript (4 kb) was 
only sensitive to 13-adrenergic stimulation and exhibited maximal expression at 3 h. 
Once again, relative to hearts perfused with buffer alone, a— and 13-adrenergic agonists 
had little if any additional effect on c-jun expression. Similar perfusion with either a-
or 13-agonists (phenylephrine and isoproterenol respectively) produced similar 
expression of the early-response genes as the analogous experiments with NE + a or 13 
blockers presented here (data not shown). 
The mechanism or mechanisms which might couple the a-adrenergic 
receptors to modification of early-response gene expression in the heart are unknown. 
However recent studies in isolated neonatal myocytes indicate that a cadrenergic agents 
stimulate PKC and that stimulation with PMA, a potent activator of PKC, reproduces 
certain effects of a s -stimulation on myocyte growth and gene expression, including 
induction of c-myc (Starksen et al., 1986). Accordingly then, hearts were perfused in 
the presence of PMA to determine whether activation of PKC-dependent pathways 
might be linked to induction of c-myc in the adult heart (Fig. 5.7, Lanes 1-3). Hearts 
perfused at a constant pressure of 60 mmHg in the presence of PMA (20 nM) exhibited 
increased cardiac levels of c-myc mRNA with respect to hearts perfused with the 
biologically inactive phorbol ester, 4a phorbol 12b 12a-didecanoate (PDC: Fig. 5.7, 
Lanes 4-6). Although translocation of PKC was not directly measured this has been 
shown to occur in rat cardiac tissue following adrenergic stimuli (Allo et al., 1992; 
Henrich and Simpson, 1988). Accordingly, these results provide indirect evidence that 
a s -induction of c-myc occurs via activation of PKC associated pathways. The 
expression of other a s -sensitive early-response genes was not examined in response to 
PMA. 
Similarly, pathways which might link P-adrenergic receptor cellular ' 
occupation to early-response gene transcription in the heart are not known. However 
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Fig 5.7 Cardiac expression of c-myc in response to PMA or PDC. 
Total RNA was extracted from rat hearts removed at the various times indicated following 60 mmHg 
perfusion with modified Krebs-Henseleit buffer containing phorbol myristic acid (PMA, 20 nM; 
Lanes 1-3) or the inactive phorbol ester 4a-phorbol 12b 12a-didecanoate (PDC, 20 nM; Lanes 4-6). 
c- myc and P-tubulin transcripts were analyzed as described previously. 
13-adrenergic agents increase cardiac levels of cAMP and augment protein synthesis and 
transcription of a-MHC. Furthermore, agents such as forskolin which also increase 
cAMP, lead to increased protein synthesis in the perfused heart (Xenophontus et al., 
1989). Accordingly, it was of interest to determine whether 13-mediated induction of 
fra-2 was regulated by pathways linked to cAMP. Hearts perfused at a constant 
pressure of 60 mmHg in the presence of forskolin (21.tM) exhibited increased both fra-2 
mRNA transcript levels (Fig. 5.8, Lanes 1-3) with respect to hearts perfused with buffer 
alone (Fig. 5.8, Lanes 4-6). The observed response was specific for the a-sensitive gene 
fra-2 since similar treatment did not increase expression of the a-sensitive gene c-fos 
(results not shown). Although cardiac cAMP levels were not directly measured, this 
study provides indirect evidence that fra-2 is activated by pathways which may involve 
c AMP. 
5.4.1 The Effect of Increased Perfusion Pressure on Cardiac Early-Response Gene 
Expression 
Pressure overload of the heart in vivo following aortic stenosis is 
accompanied by expression of a panel of early-response genes, quantitative and 
qualitative alterations in isocontractile protein synthesis and cardiac hypertrophy. 
Recent in vitro experiments have suggested that a parameter most related to increased 
protein synthesis in the perfused heart was increased stretch of the ventricular wall, as a 
consequence of increased aortic pressure (perfusion pressure) (Kira et al., 1984). In 
light of this it was of interest to determine whether increased perfusion pressure might 
also augment expression of the early-response gene program in the perfused heart in 
absence of changes in humoral factors, and if so, to compare this response with the 
qualitative and quantitative changes that are observed following perfusion in the 
presence of NE. 
When the hearts were perfused at constant pressure of 120 mmHg, cardiac 
c-myc and c-fos mRNA levels were significantly increased with respect to hearts 
perfused with buffer at 60 mmHg (Fig. 5.9). The level of c-myc expression was directly 
dependent on the perfusion pressure with 120 mmHg resulting in greater induction than 
90 mmHg. The time of maximal c-myc expression occured after 2-3 h of perfusion at at 
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Fig 5.8 Cardiac expression of fra-2 in response to forskolin. 
Total RNA was extracted from rat hearts removed at the various times indicated following 60 mmHg 
perfusion with Krebs-Henseleit bicarbonate buffer alone (Lanes 4-6) or buffer containing forskolin (2 
lafv1, Lanes 1-3). fra-2 and f3-tubulin transcripts were analyzed as described previously. 
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Fig 5.9 Effect of elevated coronary perfusion pressure on c-myc and c-fos expression in the rat heart. 
Total RNA was extracted from rat hearts directly after removal from the animal or at the various times 
indicated following perfusion at a constant pressure of 60, 90, or 120 mmHg. c-myc and c-fos 
transcripts were analyzed as described previously. 
pressures of 90 and 120m although further studies demonstrated that mRNA levels of 
this gene remain elevated above basal perfusion levels for as long as the pressure load 
was maintained (see chapter 6, Fig. 6.1). In contrast the level of c-fos expression was 
approximately equivalent in response to perfusion at 90 or 120 mmHg, however the 
exact timing of maximal induction varied at each pressure: appearing maximal between 
15-45 min for 90 mmHg and 1-2 h for 120 mmHg. In both cases the response was 
transient although expression of this gene was still slightly above baseline levels during 
extended perfusion at 120 mmHg for up to 6 h (see chapter 6, Fig. 6.1). Comparison of 
the relative abilities of pressure load and NE to modulate c-myc and c-fos expression 
indicates that c-myc is more responsive to aortic pressures equivalent to 120 mmHg than 
to NE (1 p.M: Fig. 5.10), although removal of the 13-component of NE raises levels of 
this gene to near those observed in response to 120 mmHg (comparative results not 
shown). In contrast c-fos appears to be equally responsive to both pressure (120 mmHg) 
and adrenergic stimulus (1 gM: Fig. 5.10). 
Similarly, the expression of c-fun, fra-1 and fra-2 was investigated during 
elevated perfusion pressure (Fig. 5.11, autoradiograms not shown). c-fun expression 
was not altered significantly when perfusion pressure was adjusted to 120 mmHg with 
respect to hearts perfused at 60 mmHg, although this lack of relative induction may be 
due to the fact that c-fun was already induced to high levels during perfusion at 60 
mmHg with buffer alone. Similarly fra-1 expression was not altered by the higher 
perfusion pressure and this is in accordance with observations in vivo that this gene is 
not pressure responsive (Rocicman et al., 1991). In contrast the a/13-responsive 
transcript of fra-2 (6.0 kb) was elevated by perfusion at 120 mmHg to levels similar to 
those observed in response to NE. However the 13-responsive transcript of this gene (4.0 
kb) was not significantly altered by this treatment. 
5.4.2 Regional Localization of c-myc and c-fos Expression in the Perfused Heart 
Determination of the regional expression of early-response genes in the rat 
heart in vivo (see chapter 4) following NE administration is potentially complicated by 
the hemodynamic effects of this hormone which can independently modify cardiac 
early-response gene expression (Mulvagh et al., 1987; Komuro et al., 1987; Komuro et 
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Fig 5.10 Quantification of c-myc and c-fos expression in response to elevated perfusion pressure or 
norepinephrine in the rat heart. 
The hybridization signals generated by northern blotting in figures 5.1, 5.3 and 5.9 were quantitated 
via densitometry and, after standardization to 13-tubulin levels in each track, were expressed as the 
fold increase over control (basal) signals observed in hearts perfused at 60 mmHg. Vertical bars 
indicate standard error mean (S.E.M.). 
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• Fig 5.11 Quantification of c-fos like and c-jun gene expression in perfused rat heart in response to 
norepinephrine and elevated pressure. 
The RNA hybridization signals observed by northern blotting in figure 5.4 and results not shown 
were quantitated via densitometry and, after standardization to 13 - tubulin levels in each track, were 
expressed as the fold increase over control (basal) signals observed in hearts perfused with Krebs 
buffer alone at 60 mmHg. 
al., 1991). Accordingly, it was of interest to analyse separately the effect of NE and 
pressure on regional localization of these genes. 
Perfusion at 60 mmHg resulted in greatest expression of c-myc tuRNA after 
3 h and this was located mainly to the combined atrial sample and the septum. 
Similarly, maximal c-fos expression was observed in the combined atrial sample and 
also the right ventricle after 1 h of perfusion and then subsequently, but at lower levels, 
in the septum after 3 h (Fig. 5.12). These autoradiograms were over-exposed relative to 
autoradiograms obtained from hearts perfused with NE (1 RM) or at 120 mmHg, in 
order that the regional expression could be better assessed. 
Perfusion at 60 mmHg with NE (1 i.tM) resulted in maximal expression of 
c-myc and c-fos mRNA after 2 h and 1-2 h respectively and this was mainly localized to 
the left and right ventricle with considerably less expression in the septum (Fig. 5.12) 
and combined atrial samples. By the third hour of perfusion in the presence of NE, 
c-myc and c-fos mRNA were only observable in the left and right ventricle (Fig. 5.12). 
Elevation of the perfusion pressure from 60 mmHg to 120 mmHg resulted in 
maximal c-myc expression after 3 h and this response was approximately of the same 
intensity in each chamber of the heart for each time point (Fig. 5.12). Similarly, c-fos 
mRNA levels were augmented by this treatment appearing maximal between 1 and 2 h 
however, whilst the response was approximately equal in the left and right ventricle and 
septum, little or no c-fos expression was observed in the combined atrial sample (Fig. 
5.12). 
These results are typical of three separate experiments and are not an artifact 
of loading as demonstrated by equal intensity of bands following hybridization to the 
control probe 0-tubulin. 
5.5 DISCUSSION 
Cardiac hypertrophy is a complex process which is initiated and promoted 
by both hemodynamic and hormonal factors, but resolution of these can be difficult in 
whole animal models. For instance, pressure-overload (Komuro et al., 1988; Mulvagh 
et al., 1987) and NE administration (this thesis) have been shown to cause cardiac 
hypertrophy in adult rat hearts and elevate mRNA coding for a number of 
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Fig 5.12 Regional expression of c-myc and c-fos in response to elevated perfusion pressure or 
norepinephrine in the perfused heart. 
Total RNA was extracted from rat heart chambers (At: atria, RV: right ventricle, LV: left ventricle, 
Sp: septum) removed at the various times indicated following 60 mmHg perfusion with 
Krebs-Henseleit bicarbonate buffer alone at 60 mmHg or 120 mmHg or with buffer containing 
norepinephrine (1 RM) at 60 mmHg. c-nzyc, c-fos and 13-tubulin transcripts were analyzed as 
described previously. 
early-response genes. However, elevated pressure load and increased activation of the 
adrenergic system appear to be interrelated processes, for example, pressure overload 
following aortic stenosis has been associated with up regulation of cardiac-adrenergic 
receptors whilst administration of moderate to high doses of NE in vivo can lead to 
pressure overload of the heart. Accordingly the work in this chapter has attempted to 
dissociate the effect of some potential growth signals on cardiac early-response gene 
expression by use of the isolated, Langendorff perfused heart system. This model has 
the advantage over in vivo studies that it is possible to examine separately the effects of 
NE or pressure-load on some of the events in cardiac hypertrophy, such as increased 
protein synthesis and early-response gene expression, whilst still maintaining the 
potentially critical cell-cell interactions within this organ. 
The coronary perfusion pressure for control hearts was selected at 60 mmHg 
since previous studies have indicated that this pressure results in sufficient coronary 
flow rates to ensure adequate oxygenation of isolated rat hearts by the relatively simple 
perfusion medium (Krebs-Henseleit buffer) used in these experiments (Williamson, 
1964). Interestingly this treatment alone was sufficient to elevate cardiac mRNA of 
c-myc, c-fos, c-fun, fra-1 and fra-2 . Increased c-myc expression rose steadily during 
perfusion whilst c-fos, c-fun, fra-1 and fra-2 exhibited more complex profiles reaching a 
number of peaks during the perfusion period. These responses in the apparent absence 
of stimulatory factors are puzzling but may simply be due to "stress" associated with 
removal of the heart from its in situ surrounds and perfusion in vitro. For instance, 
surgery itself may lead to altered catecholamine and other neurotransmitter release 
(Manders and Vatner, 1976; Vatner and Braunwald, 1975; Vatner and Smith, 1974), 
whilst general anesthesia has been shown to depress most aspects of autonomic reflex 
control (Vatner et al., 1971) reduce myocardial contractility and increase baseline heart 
rate (Manders and Vatner, 1976) in mammals. It is possible that any of these factors 
either alone or in combination could initiate early-response gene expression which 
would be observed during subsequent perfusion. The possibility of surgery leading to 
increased catecholamine activity was tested in these experiments by means of prior 
treatment of the animal with both a-and 13-adrenergic blockers before heart removal, but 
this did not attenuate the expression of any of the genes examined. An alternative 
explanation for these results might be that the expression of these putative transcription 
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factors, a process which appears to be tightly regulated in vivo, may become deregulated 
during perfusion in vitro in the absence of possible serum-derived regulatory factors. 
For example, basal expression of c-fos appears to be at least partially regulated by 
binding of a serum response factor (SRF) to a serum response element (SRE) in the 5' 
control region of the c-fos gene (Curran, 1991; Angel and Karin, 1991) In order to test 
this hypothesis, hearts were perfused with Krebs buffer supplemented with freshly 
isolated bovine serum (10%), however no change in the expression profiles or intensity 
of any of the genes examined was observed with respect to hearts perfused with buffer 
alone. A further possibility is that particular regions of the heart are relatively poorly 
perfused at the basal aortic pressures used here (60 mmHg) and subsequent ischemia of 
these areas may lead to stress-related early-response gene expression. This is not 
unreasonable since c-fos, at least, is rapidly induced in tissue surrounding the infarct 
zone following experimental regional ischemia of the heart (author's personal 
observation). One possibility is that cardiac interstitial edema caused by perfusion with 
Krebs buffer may lead to microvascular compression and thus non uniform perfusion of 
the heart. Indeed during perfusion at 60 mmHg regional expression of c-myc and c-fos 
mRNA levels were not uniform but restricted mainly to the atria and right ventricle. 
However further studies are required to ascertain whether or not these regions are 
compromised during Langendorff perfusion at a pressure of 60 mmHg. This possibility 
could perhaps be tested by examining cardiac early-response gene expression in 
perfused hearts in which edema is minimized for instance, by increasing the density of 
the perfusate with substances such as dextran sulfate. Finally, it is entirely possible that 
the observed responses are simply due to stress associated with the higher than normal 
coronary flow rate associated with this in vitro model since the in vivo coronary flow rat 
in rat hearts is 2-4 ml/min/g compared to 6-8 ml/min/g in isolated hearts perfused under 
60 mmHg of pressure. 
i) induction of early-response genes in the petfused heart by NE 
Although hearts exhibited increased expression of a number of 
early-response genes during perfusion at 60 mmHg of pressure with buffer alone, 
significantly greater cardiac expression of many of these genes was observed during 
perfusions in the presence of stimuli associated with cardiac hypertrophy in vivo and 
increased protein synthesis in vitro (Morgan et al., 1991). For example, perfusion at a 
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constant pressure of 60 mmHg with Krebs buffer containing NE (1 nM to 1 RM) 
resulted in a significant increase the cardiac mRNAs of c-myc, c-fos, Ira-1 and fra-2 
with respect to hearts perfused at 60 mmHg with buffer alone. Quantitatively, these 
responses were of similar intensity to those observed following a single injection of NE 
in vivo. Interestingly, c-jun levels were not significantly altered during perfusion with 
NE with respect to hearts perfused with buffer alone. It is possible that this gene is 
already maximally stimulated by perfusion with buffer .alone or that c-jun does not 
respond specifically to NE but rather is simply a marker of cellular stress. Certainly the 
difference in response of this gene with respect to the functionally related gene c-fos is 
interesting and warrants further investigation. 
At least part of the observed early-response gene expression in vivo 
following NE treatment is likely to be attributable to secondary pressure loading 
following vasoconstriction of the peripheral vasculature. In contrast, in these in vitro 
experiments NE-mediated induction of early-response genes cannot simply be ascribed 
to pressure loading of the heart since pressure load was held constant at 60 mmHg. 
Furthermore the responses cannot be due to local vasoconstriction of the coronary 
vasculature since, as the result of local metabolic affects, NE does not mediate 
constriction of the cardiac vasculature (Vatner, 1992 and references there in). It is 
possible, however, that the pronounced effects that NE has on cardiac inotropy and 
chronotropy may indirectly modulate cardiac expression of these putative 
trans-activating factors. In argument against this, studies from this laboratory have 
shown that significant reduction of cardiac contractility by perfusion with buffers 
containing low Ca2* levels, does not significantly alter NE-mediated early-response gene 
expression in the perfused heart (unpublished data). Thus taken together with the 
previous results, these experiments provide the first evidence that NE can activate the 
early-response gene program in adult myocytes (c-fos, c-jun and related genes) and in 
cardiac non myocyte cells (c-myc) independent of the changes in cardiac hemodynamic 
parameters that this hormone causes. Since similar perfusion of hearts with adrenergic 
agents has been shown to augment protein synthesis and ribosomal formation (Morgan 
et al., 1992), the present studies provide further evidence implicating early-response 
genes in the initiation of cardiac hypertrophy in vivo. 
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The regional localization of c-myc and c-fos mRNA during perfusion with 
NE revealed that both early-response genes were expressed to approximately the same 
extent in the left and right ventricle. These results are not unexpected since both 
ventricular chambers should receive equal exposure to the drug, however this 
distribution contrasts significantly with in vivo studies (chapter 4) in which both genes 
were expressed predominantly in the left side of the heart following a single injection of 
NE. It is probable that the significant physiological differences in stimuli to which the 
myocardium is exposed in each of these two model systems is responsible for the 
differing spatial distributions. For instance, pressure overload of the left side of the 
heart following administration of NE in vivo most probably contributes to the increased 
early-response gene expression in this region and such an affect would be absent in 
vitro. 
Interestingly, expression of c-myc and c-fos in the atria and septum of hearts 
perfused in the presence of NE, is significantly less than in the left and right ventricles. 
Such differences suggest that the pathway(s) linking occupation of the adrenergic 
receptors to nuclear expression of c-myc and c-fos in these regions are less responsive 
than in the ventricles. It is possible that this simply reflects tissue distribution of 
adrenergic receptors, or alternatively, the atria and septum may be poorly perfused and 
therefore receive less exposure of NE than regions which might be better perfused such 
as the ventricles. Further studies are required to verify these possibilities. 
ii) a -adrenergic response 
in vivo studies presented in this thesis indicate that a significant proportion 
of NE-mediated cardiac early-response gene expression can be reproduced by 
stimulation of the a-adrenergic receptors. These findings are supported by the present 
in vitro studies since perfusion in the presence of NE and the I3-adrenergic blocker 
propranolol or perfusion with the a-adrenergic agonist phenylephrine led to significant 
elevation of c-myc, c-fos, fra-1 and fra-2 mRNA levels above those observed following 
perfusion with buffer alone. acadrenoreceptor stimulation is thought to stimulate 
phosphoinositide-hydrolysis of membrane phosphatidylinositols which stimulate the 
production of diacylglycerol and inositol phosphate (reviewed in Berridge, 1987). 
Diacylglycerol in turn stimulates protein kinase C to phosphorylate target proteins 
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whilst inositol triphosphate increases cytoplasmic Ca 2+ concentration by stimulating 
release of calcium from intracellular stores. Both of these signaling pathways are likely 
transducing mechanisms of a-adrenergic-mediated early-response gene expression since 
both calcium and PKC regulatory elements have been identified in the promoter regions 
of a number of early-response genes. In these studies acadrenergic induction of c-myc 
could be reproduced by perfusing hearts in the presence of PMA, a potent activator of 
PKC, however no similar response was observed following treatment of hearts with the 
inactive phorbol ester PDC. Although translocation of PKC was not directly studied in 
these experiments, this event has been demonstrated to occur in the heart and isolated 
myocytes following adrenergic stimulation (reviewed in Simpson, 1990). Moreover, 
these results are in close agreement with those of Simpson's group who have 
demonstrated in neonatal myocyte cultures that agents which activate PKC also increase 
myocyte expression of c-myc and cardiac hypertrophy (Starksen et al., 1986). Thus 
considered together these studies are indirectly suggestive that cardiac expression of 
c-myc by NE, in both the adult heart and in neonatal myocytes, is at least partially 
regulated via PKC dependent pathways. Similarly, although not tested in these studies, 
it is likely that other a-adrenergic inducible early-response genes such as c-fos are also 
regulated via PKC pathways in the adult heart, since induction of these genes has also 
been correlated with activation of this second messenger system in neonatal myocyte 
cultures. Further studies will need to determine whether PKC induction is a necessary 
prerequisite for early-response gene expression in the heart following a i -adrenergic 
stimulus and if so, to determine which specific isoforms of PKC are translocated under 
these conditions. It appears that at least some of these points are currently being 
investigated in neonatal myocyte cultures (Simpson, 1991). 
iii) 3 -adrenergic response 
In contrast to a-adrenergic stimulation, perfusion of hearts in the presence 
of P-adrenergic agents resulted in increased expression of fra-2 only, whilst cardiac 
mRNA levels of other genes examined following this treatment were either unchanged 
(c-jun) or even lower (c-myc, c-fos, and fra-1) than observed following perfusion with 
buffer alone. These results are not however, in entire agreement with those from in vivo 
studies (this thesis; Barka et al., 1987). For instance in this thesis, treatment of intact 
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animals with 13-adrenergic agents resulted in small increases in the levels of c-fos c-jun 
and fra-1 and much greater elevation in c-myc and fra-2 with respect to the levels of 
these genes observed in response to acstimulus alone or NE. Similarly Barka's group 
demonstrated cardiac expression of one early-response gene, c-fos following 
administration of both a— and 13—adrenergic agents (Barka et al., 1987). A number of 
interpretations of these results are possible. Firstly, given the ability of 13-adrenergic 
agents to elevate fra-2 expression in the heart both in vivo and in vitro it is likely that 
this putative transactivator is a bona fide I3-adrenergic responsive gene in the adult heart. 
In contrast c-fos, c-jun and fra-1 which exhibited no expression in vitro and only low 
expression in vivo following I3-agents, are probably not directly regulated by 13-receptor 
occupation in target cardiac cells. Rather, in vivo induction of these genes is more likely 
to be the result of cardiac a—adrenergic stimulation following 13-mediated release of NE 
from presynaptic nerve terminals (see chapter 1 for a more in-depth discussion). In 
contrast to the heart in vivo, isolated perfused hearts are denervated and thus are not 
subject to this presynaptic release. 
It is more difficult to explain the apparent inconsistencies with c-myc given 
the intensity of the 13-adrenergic response of this gene in vivo and the absence of 
induction in vitro. Interestingly this in vitro response is in agreement with neonatal 
myocyte culture studies of Simpson which also failed to link 13-adrenergic activation to 
c-myc, albeit in neonatal myocyte cultures (Starksen et al., 1986). It is possible then, 
that c-myc is indirectly stimulated by non-cardiac derived humoral factors following 
I3-stimulation in vivo and consequently cardiac cells would not be exposed to these 
factors during perfusion in vitro or during cell culture. This notion might be tested by 
comparing c-myc expression in cultured cardiac cells following incubation with serum 
derived from normal rats or rats previously treated with 13-adrenergic agents. Further 
studies are clearly warranted to resolve this matter. 
In the heart 13-adrenergic agonists alter a number of ionic and second 
messenger systems and among these responses probably the strongest mechanistic link 
is a rapid increase in cAMP levels and this preceeds such events as cardiac growth. For 
example, Morgan's group has demonstrated that agents such as forskolin that raise levels 
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of cAMP in the perfused heart (Xenophontos et al., 1989), also increase protein 
synthesis and ribosome formation in that tissue whilst other studies have isolated a 
number of cAMP-regulated genes that are responsive to growth factors/hormones 
(Roesler et al., 1988). Furthermore, many early-response genes including those of the 
c-fos family contain cAMP response elements in the 5' control regions. Thus taken 
together, cellular transduction pathways involving cAMP are likely mechanisms by 
which I3-adrenergic agents affect fra-2 expression in the heart. Indeed the present 
studies support this notion since perfusion of hearts with forskolin, a drug known to 
increases cellular cAMP levels, resulted in increased cardiac expression of fra-2, and 
this response was quantitatively and qualitatively similar to that observed in response to 
P-adrenergic agents. Furthermore the observed induction was specific for the 
n-responsive gene fra-2 since similar treatment did not augment cardiac levels of the 
a-responsive gene c-fos. Thus these results demonstrate that cAMP is a possible second 
messenger system linking P-adrenergic receptor stimulation to fra-2 expression in the 
rat heart. Once again further studies will need to determine whether elevation of cAMP 
levels is required for, or merely accompanies 13-adrenergic induction offra-2 in the heart 
and this could perhaps be achieved using specific inhibitors of cAMP formation or 
addition of the cAMP analogue 8-bromo-cAMP. 
iv) the effect of increased perfusion pressure on cardiac early-response gene 
expression 
Recent reports have demonstrated that experimental aortic stenosis in 
rodents leads to a rapid rise in the cardiac levels of a number of early-response genes 
and that this event is followed by increased protein synthesis and cardiac hypertrophy 
(Mulvagh et al, 1987; Izumo et al, 1988; Komuro et al, 1988). However because such 
studies have been conducted in vivo it has not been possible to determine whether 
increased load itself is directly coupled to increased gene transcription and protein 
synthesis or whether in fact these responses are mediated via secondary release of 
humoral factors either from within the heart (paracrine or autocrine) or from non 
cardiac tissue (endocrine). Accordingly, part of the work in this chapter has sought to 
discount the possible contribution of circulating humoral factors to the initial stages of 
pressure-load induced cardiac hypertrophy by examining early-response gene 
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expression in isolated hearts perfused with a serum-free medium (Krebs-Henseleit 
buffer) under increasing aortic pressure loads (60-120 mmHg). This model was 
specifically chosen since Morgan's group using this model have been able to 
demonstrate that increased stretch of the ventricular wall as a direct consequence of 
elevated aortic pressure leads to activation of early events in hypertrophy such as 
increased ribosome formation and protein synthesis (Kira et al., 1984; Morgan et al., 
1987; McDermott and Morgan, 1989). 
When the aortic perfusion pressure was increased from 60 mmHg to 90 or 
120 mmHg a significant increase in cardiac expression of c-myc, c-fos and fra-2 was 
observed with respect to hearts perfused at 60 mmHg. The induction of c-myc and c-fos 
was more rapid than observed in vivo following aortic stenosis (Izumo et al., 1988; 
Mulvagh et al., 1987; Komuro et al., 1988) and this may indicate that the stimulus in 
vitro is greater or more consistent than observed in the in vivo preparation. Interestingly 
the response of c-myc and c-fos to the increased load differed with respect to each other. 
For instance, c-myc expression is proportionally greater at 120 mmHg than 90 mmHg 
whist elevation of aortic pressure from 90 to 120 mmHg had no additional effect on 
c-fos expression. One interpretation of these results is that c-fos has a lower threshold 
of inducibility by pressure than c-myc and is thus already maximally stimulated during 
perfusion at 90 mmHg. During the course of these studies Swynghdauw's group 
published data complimentary to that presented here in which they demonstrated that 
c-myc and c-fos mRNA levels increase in the isolated perfused heart in direct proportion 
to the increase in coronary flow (Bauters et al., 1988). Since coronary flow and 
coronary perfusion pressure are directly related in non-working Langendorff 
preparations, these two studies provide preliminary evidence that increased coronary 
perfusion pressure and/or coronary flow is sufficient stimulus to increase cardiac 
early-response gene levels. 
The cardiac expression of these two genes during elevated perfusion 
pressure was further characterized at the level of each cardiac chamber. Elevation of 
perfusion pressure resulted in an equivalent induction of c-myc in all chambers of the 
heart and this probably indicates that these regions are subjected to similar loading via 
the coronary vasculature system. Regional distribution of c-fos was similar to c-myc 
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with the exception of the atria where mRNA levels of this gene were extremely low 
during elevated perfusion pressures. These results indicate that following pressure load, 
prior expression of c-fos is not a necessary prerequisite for the induction of c-myc, at 
least in the atria. Thus pathways linking pressure load and c-fos induction are either 
absent or down regulated in atrial tissue and given the inducibility of this gene in the 
atria via NE, indicates that pressure load and NE activate c-fos via alternate 
mechanisms. 
In addition to c-fos and c-myc these studies demonstrated for the first time 
that fra-2, a gene structurally related to c-fos, is inducible in the heart following 
increased mechanical load and considered with the results presented previously, they 
establish this gene as a further member of the early-response gene family responsive to 
contrasting types of hypertrophic stimulus (e.g. NE and aortic stretch). However not all 
genes structurally or functionally related to c-fos appear to be responsive to increased 
aortic pressure, since neither c-jun nor fra-1 mRNA levels were increased in the heart 
when aortic pressure was raised from 60 mmHg to 120 mmHg. The failure to observe 
increased expression of fra-1 correlates well with the observation of Chein's group who 
reported that aortic stenosis in mice does not increase cardiac expression of fra-1, 
although this treatment led to increases in cardiac c-fos, and c-jun levels (Rodman et 
al., 1991). Taken together these results provide further evidence of the differential 
responsiveness of c-fos and related families of early-response genes during hypertrophic 
stimulus and strengthens the notion that differential expression of these genes is a means 
to ensure diversity and specificity of cellular responses to extra-cellular stimuli, thus 
allowing for target gene selectivity. In contrast, the lack of responsiveness of c-jun to 
increased aortic pressure is puzzling especially considering that other groups have 
reported induction of this gene both in vivo and more recently in an in vitro study 
similar to this, in which it was shown that increasing left ventricular systolic force gave 
rise to increased ventricular mRNA levels of c-fos and c-jun (Schunkert et al., 1991). 
Such discrepancies might be explained by the differences in the nature of the load 
stimulus between different experiment systems. In the present studies increased 
early-response gene expression can most probably be correlated with the increase in 
passive systolic stretch to which these chambers are exposed. For example, elevation of 
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perfusion pressure has direct effects on the ventricular wall (and presumably the atrial 
wall) to elevate intracoronary blood volume by as much as 60% (Morgenstern et al., 
1973), to increase sarcomere length by 10% and to stretch and thicken the ventricular 
wall (Olsen el al., 1981). In contrast, in the studies of Schunkert et al., (1991) hearts 
were subjected to an acute increase in systolic wall stress by means of inflatable 
balloons in the ventricular space. It was concluded that active systolic tension, but not 
passive stretch was the major factor controlling increased cardiac early-response gene 
levels in this isolated heart model. Obviously the models used in the present studies and 
those of Schunkert and Swynghdauw do not fully mimic events which take place during 
pressure overload in vivo. Clearly further studies are needed to determine the relative 
contribution of active and passive stretch to increased cardiac early-response gene 
expression and left ventricular hypertrophy in vivo following aortic stenosis. In this 
respect however it is worthy to note that the experiments of Morgan's group established 
that intraventricular pressure development, cardiac contraction, oxygen consumption, 
glucose 6-phosphate production, energy availability and coronary flow could be 
dissociated from the stimulatory effect of higher aortic pressures on protein synthesis. 
Rather, they suggested that passive stretch of the ventricular wall as consequence of 
increased aortic pressure, could be the mechanical parameter most closely related to the 
observed increased protein synthesis (Kira et al., 1984). 
Despite the minor differences described above, the in vitro studies described 
here and those of others are supportive of the idea that increased wall stress in general is 
a potent signal for the induction of a subset of early-response genes. 
The results presented here have demonstrated that increases in circulatory 
levels of non-cardiac derived growth factors such as NE are not required for pressure 
mediated increases in cardiac early-response gene expression. Recent studies have 
demonstrated that direct stretching of neonatal myocytes in culture is sufficient to 
induce c-fos expression independent of humoral factors (Komuro et al., 1989; Komuro 
et al., 1991) and therefore it is likely that stretching of adult myocytes as a consequence 
of increased aortic pressure is the primary and direct stimulus for the observed 
early-response gene expression in the present experiments. However, as discussed 
previously, evidence is accumulating to implicate non-myocyte derived cardiac growth 
factors as major regulators of cardiac gene expression and growth. For example 
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endothelin derived from endothelial cells and a number of fibroblast-derived growth 
factors are capable of inducing early-response gene expression and hypertrophy in 
cultured myocytes (Neyses et al., 1991; unpublished data in Parker et al., 1991). 
Further studies will be needed to ascertain whether such paracrine factors are important 
mediators of early-response gene expression and cardiac hypertrophy in adult myocytes 
following pressure overload. 
The intracellular pathways by which mechanical stimulus might directly or 
indirectly stimulate early-response gene expression in the perfused heart were not 
studied in this work although results from others have implicated a number of candidate 
transducing mechanisms including PKC, cAMP, ion fluxes and direct mechanical 
connections between external and nuclear membranes. However the results from such 
studies have been less than definitive and further studies are required to fully understand 
the mechanisms of mechanical force on cardiac growth. 
v) summary 
The studies in this chapter have made use of an isolated perfused heart 
system in order to dissociate the direct and indirect affects of adrenergic hormones on 
cardiac early-response gene expression. With this model it was demonstrated for the 
first time that treatment with NE increases mRNA coding for a number of 
early-response genes in the adult heart, and that this response can be dissociated from 
the systemic hemodynamic effects often associated with this hormone in vivo. These 
results are in agreement with the in vivo studies presented earlier since they confirm 
that the majority of these responses are mediated by the a-adrenergic receptors. 
However one gene, fra-2 was also responsive to 0-adrenergic stimulation, although the 
significance of this is yet to be determined. 
In a complimentary series of experiments it was also shown that increased 
aortic pressure load in hearts perfused in the absence of NE and other growth factors, 
also elevated cardiac levels of a number of early-response genes. However, the exact 
subset of genes and the temporal, spatial distribution of the responses differed to that 
observed following treatment with NE. Taken together, and with those of previous 
chapters these studies clearly illustrate that adrenergic hormones and pressure load can 
independently regulate early-response gene expression in the adult heart. Accordingly 
then it is possible to speculate that particular subsets of these nuclear acting genes may 
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serve as common transcription factors in cellular pathways connecting adrenergic 
stimuli and mechanical activity with cellular enlargement and alterations in phenotype 
in adult cardiac myocytes and other cell types in vivo. 
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CHAPTER 6 
EXPRESSION OF PHENOTYPIC MARKERS OF CARDIAC HYPERTROPHY 
IN THE ISOLATED PERFUSED HEART.  
6.1 INTRODUCTION 
It was demonstrated in the previous chapter that adrenergic agents and pressure 
overload can independently increase early-response gene expression in the isolated 
perfused heart. Previous studies have shown that these trophic stimuli also increase 
rDNA transcription and cardiac ribosome content in the perfused heart and taken 
together they suggest that the isolated perfused heart is a suitable model system in 
which to study at least the initial stages of cardiac hypertrophy. However, cardiac 
hypertrophy is also marked by qualitative changes in the expression of specific 
contractile, and non-contractile genes whose products play important roles in cardiac 
structure and function. Such changes in gene expression appear to be characteristic for a 
particular hypertrophic stimulus. For example, a—SkA. and ANP mRNA levels are 
rapidly down regulated in ventricular tissue following birth but can be restored to levels 
similar to those observed in the neonate following imposition of pressure-overload in 
vivo (Izumo et al., 1988; Schwartz et al., 1986) or acadrenergic stimulus in the adult 
animal (this thesis; Schwartz et al., 1986) or rat ventricular myocardial cells (Bishopric 
et al., 1987). In contrast, during thyroid hormone-induced hypertrophy the expression 
of fetal-specific genes are not altered whilst the relative expression of contractile genes 
associated with the adult phenotype are even further upregulated (e.g. a-MHC: Morkin 
et al., 1983). Consequently it has been suggested (for a more detailed discussion see 
chapter 1) that such alterations in gene expression (cardiac plasticity) might be used as 
phenotypic markers of the presence and extent of particular cardiac pathologies 
observed in response to different hypertrophic stimuli. Studies in this chapter have 
sought to determine whether it is possible to detect such changes in the expression of 
hypertrophic "marker" genes including ANP, a—SkA and a-MHC in the isolated 
perfused rat heart in response to pressure-overload, adrenergic agents and thyroid 
hormone. If so, then this might establish the perfused heart as a suitable in vitro model 
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in which to study pathways that link the immediate responses to hypertrophic stimuli, 
for example, early-response gene expression, to secondary events in this process 
including qualitative changes in contractile and non-contractile genes. 
6.2 METHODS 
6.2.1 in vitro Coronary Perfused Hearts 
Hearts were isolated and perfused in the same manner as described in chapter 5. 
NE and T, were prepared as described in chapter 3 and when used, where included in 
the perfusion medium as described below. Hyperthyroidism was induced in rats by 
treating animals with T3 (0.2 mg/kg/day) for two weeks as described in chapter 3. 
6.3 EXPERIMENTAL PROTOCOLS 
6.3.1 Effect of NE and Perfusion Pressure on ANP and a-SkA Expression 
To determine whether NE alone or in combination with elevated perfusion 
pressure could modulate expression of ANP and a-SkA, hearts were perfused from 15 
min to 6 h at pressures of 60 mmHg and 120 mmHg with buffer alone or, alternatively, 
at 60 mmHg and 120 mmHg in the presence of NE (1 iiM). Following perfusion hearts 
were frozen in liquid nitrogen and processed for northern analysis as described in 
chapter 2. 
6.3.2 Effect of T3 and NE on a-MHC Expression 
To assess the effect of T3 and NE on a-MHC expression, hearts were perfused at 
60 mmHg of pressure from 30 min to 6 h with perfusion media containing T3 (1 nM) or 
a combination of T3 (1 nM) and NE (1 [tM). Following perfusion hearts were processed 
for northern analysis as described above. 
6.4 RESULTS 
6.4.1 a-SkA and ANP Expression 
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In the first series experiment hearts were perfused with Krebs-Henseleit buffer under a 
coronary perfusion pressure or 120 mm Hg for 15 min to 6 h and the subsequent 
changes in expression of c-myc, c-fos, ANP and a-SlcA measured by northern analysis 
(Fig. 6.1). As shown previously (see chapter 5) elevating the perfusion pressure from 
60 mmHg to 120 mmHg increased cardiac mRNA levels of the early-response genes 
c-myc and c-fos. Increased c-myc mRNA levels were maximal after 4-5 h of perfusion 
(Fig. 6.1) and this relatively sustained response is similar to that observed for c-myc in 
pressure overloaded hearts in vivo (Mulvagh et al., 1987). c-fos mRNA expression was 
more transient with maximal levels observable after 2 h and near basal by 6 h of 
perfusion (Fig. 6.1). However, in direct contrast, elevation of perfusion pressure from 
60 to 120 mmHg did not alter mRNA levels of the cardiac isocontractile gene a-SlcA or 
the atrial naturetic gene ANP (Fig. 6.1). These results differ from in vivo studies in 
which acute pressure overload has been shown to markedly increase ventricular mRNA 
levels for both of these genes (Izumo et al., 1988; Schwartz et al., 1986). 
In a second experiment, to establish whether NE might modulate a-SlcA mRNA 
levels, hearts were perfused for 15 min to 6 h at either 60 or 120 minHg in the presence 
of NE (111M). As shown in Fig. 6.2 hearts perfused at 120 mmHg with NE OR M) did 
not exhibit increased cardiac a-SkA mRNA levels relative to the zero time control 
although either treatment results in significant induction of the early-response gene 
program (see chapter 5). Similarly, perfusion at 60 mmHg in the presence of NE did 
not modulate a-SlcA tnRNA levels (results not shown). These results contrast with the 
in vitro studies of Simpson group who showed that cultured neonatal cardiomyocytes 
treated with NE (1 p,M) exhibit a 3-4 fold increase in mRNA levels of this gene within 
3-4 h (Long et al„ 1989). The effect of NE on ANP mRNA levels was not studied. 
6.4.2 a-MHC Expression 
It is well established that thyroid hormone can directly regulate transcription of 
a-MHC in vivo (Mandavi et al., 1989; Nadel-Ginad and Mandavi, 1989) and 
consequently it was of interest to determine whether this might also be observable in the 
isolated perfused heart. In the first experiment the basal expression of a-MHC mRNA 
was assessed in hearts perfused at 60 mmHg with Krebs-Henseleit buffer alone (Fig. 
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Fig 6.1 Expression of c-myc, c-fos, a-skeletal actin (a- Sk-actin) and atrial naturetic peptide (ANP) in rat 
hearts perfused at a constant coronary pressure of 120 mmHg. 
Total RNA was extracted from rat hearts at the various times indicated following perfusion at constant 
pressure of 120 mmHg (Lanes 1-13) with modified Krebs-Henseleit buffer. After electrophoresis and 
northern blotting, the RNA (5() pig) was hybridized to c-myc, c-fos, a-skeletal actin, ANP and 13-tubolin. 
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Fig 6.2 Expression of a-skeletal actin (a-Sk-actin) in perfused rat heart in response to norepinephrine. 
Total RNA was extracted from rat hearts at the various times indicated following perfusion at constant 
pressure of 120 mmHg with Krebs-Henseleit buffer containing 1 p.1 ■4 norepinephrine. 	After 
electrophoresis and northern blotting, the RNA (50 lig) was hybridized to a-skeletal actin and 13-tut5ulin. 
6.3, upper tracks). Hearts perfused in this manner for up to 6 h exhibited a progressive 
reduction in a-MHC expression during the course of the perfusion (5-10 fold less after 6 
h, Fig. 6.4). This was not part of a general down regulation of cardiac isocontractile 
gene expression since a-SlcA naRNA levels were not similarly reduced (results not 
shown). However, hearts perfused at the same pressure with the inclusion of T3 ( 10 nM) 
in the perfusate did not exhibit decreased a-MHC levels, rather this treatment caused a 
transient increase (2 fold) in a-MHC mRNA levels between 2-4 h of perfusion (Fig. 6.3, 
lower tracks and Fig. 6.4). Further experiments established that levels of T, as low as 
0.1 nM were sufficient to prevent a decrease in a-MHC mRNA levels during perfusion 
(results not shown). These experiments demonstrate regulation of a-MHC mRNA 
levels in the isolated perfused heart by thyroid hormones for the first time. 
In contrast to T„ the effect of adrenergic agents on a-MHC expression is less than 
clear. Studies with cultured adult myocytes have been inconclusive with some 
investigators demonstrating a positive effect of NE and 13-adrenergic agonists on 
a-MHC expression whilst others have reported no changes (Dubus et al., 1990; Rupp et 
al., 1991). However, when hearts were perfused in the presence of NE (1 gM) alone a 
progressive reduction in a-MHC mRNA was still observed (results not shown) 
indicating that NE alone is insufficient to prevent down regulation of cardiac a—MHC 
mRNA in the absence of T,. Since any potential NE-mediated regulation of a-MHC in 
the perfused heart may be obscured by the down regulation of this gene observed during 
the absence of T„ hearts were subsequently perfused with NE (1 i.tM) in the presence of 
T, (1 nM) and a-MHC mRNA expression compared to hearts perfused with T, alone 
(perfusion control). As before, hearts perfused with T, exhibited a moderate, transient 
increase in a-MHC mRNA levels (2 fold) after 1-2 hours of perfusion (Fig. 6.5, Lanes 
2-7 and Fig. 6.6). However when NE was also included in the perfusate a-MHC 
mRNA levels were rapidly and transiently increased to levels markedly above those 
observed in response to T, alone but returned to basal by 3 h of perfusion (Fig. 6.5, 
Lanes 8-13 and Fig. 6.6). The level of maximum expression (5-8 fold) was similar to 
that observed in hyperthyroid rats (Fig. 6.5, Lane 1). Perfusion with T, did not elevate 
mRNA levels of c-fos (Fig. 6.4, Lanes 2-7) or c-myc (results not shown) with respect to 
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Fig 6.4 Quantification of a-myosin heavy chain (a-MHC) mRNA levels in the perfused heart in response 
to triiodo-L-thyronine (TO. 
The hybridization signals observed by northern blotting in Fig. 6.3 were quantified via densitometry and, 
after standardization to 13-tubulin levels (not shown) in each track, were expressed as percentage change 
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Fig 6.6 Quantification of a-myosin heavy chain expression in perfused hearts in response to 
triiodo-L-thyronine alone and in combination with norepinephrine. 
The hybridization signals generated by northern blotting in Fig. 6.5 were quantified via densitometry and, 
after standardization to 13-tubulin levels (not shown) in each tract, were expressed as fold induction of 
equivalent signals observed in euthyroid animals. Vertical bars indicate standard deviation. 
hearts perfused with buffer alone and this is in accordance with in vivo observations 
presented earlier (see chapter 3). However, T, was not able to prevent increase in the 
early-response gene program elicited by NE since c-fos levels (Fig. 6.5, Lanes 8-13) 
were significantly elevated within 30 min of co-perfusion with T, and NE and were still 
above basal after 3 h. The expression of other early-response genes during this treatment 
was not studied. 
These results indicate that the continuous administration of NE (1 mM) in the 
presence of T, (1 nM) in the isolated perfused heart leads to a rapid and transient 
accumulation of a-MHC mRNA with respect to hearts treated with T, alone. 
Furthermore, the increased contractile gene expression is preceded by induction of the 
early-response gene program. Further studies are require to determine which 
component of NE action (i.e. a or 13 ) is responsible for induction of a-MHC and 
whether the prior induction of the early-response gene program is a necessary 
prerequisite. 
6.5 DISCUSSION 
Cardiac hypertrophy observed in response to administration of adrenergic agents, 
thyroid hormones or following pressure overload appears to be a coordinate process 
involving both quantitative and qualitative changes in protein expression. Protein 
products that might have pivotal roles in regulating these processes include those of the 
early-response gene families and the induction of some of these putative trans-activating 
factors following hypertrophic stimuli have been clearly demonstrated in the proceeding 
chapters both in vivo and in an isolated perfused heart system. The latter model has the 
distinct advantage in that the complex systemic interactions associated with many 
hypertrophic stimuli can be dissociated, however, it is yet to be formally demonstrated 
whether qualitative changes in expression of cardiac structural or functional genes can 
be observed in this system following treatment with hypertrophic agents. Accordingly 
the studies in this chapter have examined the acute expression of a number of 
structurally or functionally important cardiac genes including ANP, a-SkA and a-MHC, 
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in the isolated perfused heart system in response to NE or T, administration or elevated 
coronary perfusion pressure. 
i) expression of ANP and a -SkA in response to pressure load and/or NE 
ANP and a-SkA naRNA are normally expressed at low levels in the left ventricle 
of untreated adult rat hearts however their mRNAs rapidly accumulate in this chamber 
following imposition of aortic stenosis. a-SkA and ANP mRNA levels have also been 
shown to be rapidly upregulated in neonatal ventricular myocyte cultures (Knowlton et 
al., 1991; Chien, et al., 1991) and in whole hearts in vivo in response to chronic 
administration of NE (this thesis). However in these .experiments elevation of perfusion 
pressure from 60 mmHg to 120 mmHg did not increase mRNA levels of either ANP or 
a-SkA at any time point with respect to zero time control. Similarly inclusion of NE in 
the perfusion buffer for periods up to 6 h did not elevate ANP or a-SkA mRNA levels 
(ANP levels not shown) above those observed in control hearts. 
A reason for this lack response for these two genes in this experimental system is 
not clear although a number of plausible explanations exist. For instance it is possible 
that the length of perfusion time (6 h) was insufficient to allow for any appreciable 
increase in mRNA to be observed. However, other groups have demonstrated that 
a-SkA transcripts, at least, are observable within 1-3 h following the initiation of acute 
pressure overload or following NE treatment (Black et al, 1991). It is important to note 
though, that the acadrenergic mediated induction of a-SlcA observed by Simpsons 
group was studied in a neonatal myocytes culture system, the responses of which may 
differ greatly with myocytes in the adult heart in vivo (for further discussion see chapter 
1). Alternatively the apparent lack of induction may be due to possible quantitative and 
qualitative differences in hypertrophic stimuli experienced by the heart perfused in vitro 
with respect to hearts in vivo. For example it is possible that pressure- or NE-induced 
expression of ANP or a-SkA in adult hearts in vivo requires the presence of a 
permissive serum derived factor that would be absent during in vitro perfusions. 
Finally, since the northern blots presented here represent RNA extracted from whole 
hearts including the atria, the constitutively high level of expression of ANP in atria 
may mask any subsequent changes in expression of this gene in the ventricles. Further 
studies will need to examine the expression of these genes at a regional level either by 
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gross dissection and northern analysis or alternatively by in situ hybridization or 
immunohistochemistry. 
ii) expression of a -MHC in response to NE and/or T3 
A large body of evidence now exists implicating thyroid hormone in the direct 
regulation of a-MHC transcription (see chapter 1) however the role of adrenergic agents 
in modulation of this gene is not known. Part of this lack of understanding probably 
stems from the close interrelationships between these two hormones since recent studies 
have demonstrated that thyroid hormones can directly up regulate 13-adrenergic 
receptors at the level of transcription. Results from cell culture have been conflicting 
and do not always agree with in vivo studies (Buttrick et al., 1993). For instance, it has 
been reported that activation of adenyl cyclase accompanies a-MHC mRNA (Gupta et 
al. 1991) but these studies are contrary to the earlier work of Gustafson (Gustafson et 
al., 1987). Furthermore, contractility has been reported to regulate cardiomyocyte MHC 
content yet many studies are performed variously with beating or arrested cells. Thus it 
would appear that the outcome of such experiments in neonatal and adult myocyte cell 
cultures are dependent in large part on differences in culture conditions. In the present 
experiments the effect of T, and NE on a-MHC mRNA levels was examined in isolated 
perfused hearts. When hearts were perfused in the absence of T, and NE a rapid 
decrease in a-MHC mRNA was observed during the perfusion time course. However 
the reduction in a-MHC mRNA levels could be prevented by the inclusion of T, alone 
but not NE alone, in the perfusate. These findings underline the importance of T, in the 
regulation of basal a-MHC levels in the rat heart and demonstrate that NE by itself is 
insufficient to maintain a-MHC expression in the absence of thyroid hormone. 
Interestingly, when hearts were perfused with T, and NE together a transient rise in 
a-MHC was observed above that seen in response to T, alone. These results indicate 
that NE is able to potentate the effect of T, on a-MHC expression and agree with recent 
work of Leinwands group (Buttrick et al., 1993) suggesting that the thyroid hormone 
response element is not sufficient for complete regulation of a-MHC in vivo. Further 
studies will need to determine which component of NE action (a or 13) is responsible for 
the observed induction of a-MHC and to identify potential cis- and trans-acting 
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elements involved in this process. This might be achieved by transfecting myocytes in 
culture with appropriate vectors or direct gene transfer into adult rat hearts ( Kitis et al., 
1991; Buttrick et al., 1993 ). In addition it will also be important to assess the 
significance of the transient a-MHC mRNA induction since presumably a more 
sustained elevation of this transcript is required in order to significantly affect cardiac 
a-MHC protein levels and subsequent cardiac performance. 
iii) Summary 
a-SkA and ANP are rapidly inducible in the rat heart in vivo following aortic 
stenosis or NE treatment, however no change in expression in either of these genes was 
observed in these experiments in isolated hearts perfused under elevated pressure or in 
the presence of NE. The reason for this apparent conflict in results is not known but 
it may be due to experimental design or temporal restrictions pertaining to the perfused 
heart system. Further studies are required in which the expression of these two genes 
are studied at a regional level either by in situ hybridization or immunohistochemistry. 
In contrast a-MHC mRNA levels rapidly diminish during perfusion with 
Krebs-Henseleit buffer but can be restored to levels similar to control animals in vivo by 
including T, in the perfusate. NE alone had no effect on a-MHC expression but when 
used in conjunction with T, a rapid and transient increase in a-MHC mRNA was 
observed. The mechanism by which NE potentated the effect of T,, on a-MHC 
expression is not know but warrants further investigation. These preliminary studies 
provide the first evidence that the isolated perfused heart system can be used to assess 
not only the primary responses to hypertrophic stimuli (e.g. early-response gene 
expression) but also changes in expression of structural genes which are often used as 
end point markers of different hypertrophic phenotypes. 
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CHAPTER 7  
GENERAL DISCUSSION 
Despite the recent advances with investigative techniques the molecular 
mechanisms which regulate the development and growth of the mammalian heart 
remain poorly understood. This is due in part to the fact that cardiac biogenesis is a 
complicated process involving cell proliferation, cell commitment, cell differentiation 
and chamber diversification. Furthermore, at each of these stages the heart exhibits an 
array of different phenotypes due to alterations in expression of genes thought to be 
critical to cardiac structure and function. 
In contrast to embryonic development in which the myocytes undergo proliferative 
growth (hyperplasia), the major contributor to postnatal enlargement of the mammalian 
heart is an increase in size (hypertrophy) of a fixed number of myocytes. In addition, the 
adult heart can hypertrophy above that normally expected, in response to a diverse range 
of physiological and pathological stimuli including increased pressure and mechanical 
load or in response to changes in hormone levels and following ischemia. In the initial 
stages, the growth is generally seen as an adaptive response of the organism, however, 
during latter stages it may be insufficient to cope with the increased demand or is 
associated with pathological changes, such that the heart ultimately fails. The exact 
reasons why growth of the heart changes from one of compensatory hypertrophy to a 
stage of decompensation are not completely understood although it is known that this 
transition is accompanied by further changes in cardiac phenotype. For example, 
hypertrophy mediated by vasoactive hormones or pressure-overload is characterized by 
re-expression in the left ventricle of a group of genes including ANP, oc-SkA and Ca2+ 
ATPase whose expression is normally restricted to the fetal or neonatal heart (de la 
Bastie et al., 1990; Izumo et a/., 1988; Schwartz et a/., 1986) It is thought that changes 
in the expression of these so called "phenotypic marker genes" are at least partly 
responsible for the different metabolic, contractile and electrochemical properties of this 
organ observed during various cardiac hypertrophic diseases (Reviewed in van Bilsen 
and Chien, 1993). It follows then that the elucidation of the molecular signals which 
regulate these phenotypic changes should allow for a better understanding of the general 
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mechanisms which regulate cardiac growth and development and have far reaching 
implications for clinical treatment of heart disease. Accordingly, the work embodied in 
this thesis has examined the expression of a group of nuclear-acting early-response 
genes including c-myc and c-fos whose actions have been suggested to be pivotal to the 
initiation and maintenance of cardiac hypertrophy and the accompanying phenotypic 
changes, often by analogy to their involvement in growth and differentiation in other 
tissues. The effect of two hypertrophic hormones, NE and T, on cardiac nuclear-acting 
early-response expression was studied since these agents have been shown to cause 
hypertrophy which differs both quantitatively and qualitatively from each other 
suggesting that alternative mechanisms of action may be involved in modulating each 
growth response. 
The results presented in this thesis have demonstrated that c-myc, c-fos and genes 
structurally or functionally related to c-fos including fra-1, fra-2 and c-jun are rapidly 
and transiently induced during NE mediated cardiac hypertrophy. By use of the isolated 
perfused heart system to model the initial stages of adult cardiac growth it was also 
shown that NE can elevate expression of these genes in the absence of elevated pressure 
load, thus supporting results derived from neonatal cell culture studies which have 
demonstrated that adrenergic hormones can effect cardiac growth and early-response 
gene expression independent of mechanical stimuli (for review see Simpson et al., 
1991). Increased pressure load and NE stimulation of adult hearts resulted in the 
induction of both distinct and similar sets of early-response genes indicating that these 
stimuli may share some pathways coordinating cardiac growth whilst others may be 
more specific for each stimuli. Interestingly the induction of these genes in response to 
NE and pressure load showed regional, temporal, cellular and receptor mediated 
specificity thus providing a possible mechanism by which these putative transcription 
factors might coordinate hypertrophic signals at the cell surface to the complex array of 
long term changes observed during cardiac hypertrophy. For example, the observation 
that c-fos expression following NE/pressure stimulation was localized mainly to the 
myocyte nuclei of the left ventricle is in good correlation with the observation that 
myocyte growth and re-expression of the fetal gene program is also greatest in this 
chamber (reviewed by Chien etal., 1991) and supports the hypothesis that this gene may 
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be important in regulating the genetic reprogramming of myocytes following NE 
mediated hypertrophy. 
In direct contrast, c-myc expression was restricted mainly to non-muscle cell types 
following NE administration and pressure overload thus reducing the likelihood that this 
gene plays a direct role in orchestrating the growth and phenotypic changes of adult 
myocytes. It is possible that this gene is involved in coordinating the mitogenic growth 
of non-muscle cell types such as fibroblasts which occurs concomitant with myocyte 
hypertrophy during cardiac growth. It is worthy to note however, that myocytes are not 
the only cardiac cell type which exhibits specific alterations in gene expression 
following trophic stimulation. For example, cardiac fibroblasts can acquire certain 
properties characteristic of the myocyte phenotype such as expression of sarcomeric 
actin and muscle-specific actin filaments following stimulation with peptide growth 
factors and it is possible that both c-myc and c-fos may be involved in regulating such 
gene reprogramming (Eghbali et al., 1991A). Indeed the importance of non-myocyte 
cell types to the regulation of cardiac structure and function is indicated by recent studies 
implicating transforming and fibroblastic growth factors including TGF13, aFGF and 
bFGF released from fibroblasts in the regulation of cardiac myocyte hyperplasia, 
differentiation and hypertrophy (for review see Cummins et al., 1993). More over, one 
of these growth factors, TGFP 1 , appears to be critical to the regulation of collagen 
biosynthesis, the inappropriate accumulation of which, has been implicated in 
hypertrophic myocardial fibrosis (Eghbali et al., 1991B). It remains to be seen as to the 
role of early-response gene expression in regulating this and other non cardiac myocyte 
cell functions although one recent report indicates that collagen biosynthesis in 
hypertrophying hearts may be independent of the fibroblast response to transcription 
factors such c-fos, and c-jun (Eghbali et al., 1991 B). 
Multiple factors have been shown to cause cardiac hypertrophy in vivo including 
administration of thyroid hormones (Sanford et al., 1978; Clarke and Ward, 1983) 
Similarly in this study chronic treatment of rats with thyroid hormone resulted in 
significant hypertrophy within 2-3 days. In contrast to adrenergic administration 
however, thyroxine treatment was not accompanied by increased c-myc, c-fos, c-jun or 
fra-1 levels. In agreement with this the recent study by Green also failed to detect 
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increased c-myc expression following T3 administration (Green et al., 1991) . Taken 
together these results indicate that induction of this particular set of early-response genes 
is not an absolute requirement for the initiation and maintenance of cardiac hypertrophy 
and that alternative pathways must link the thyroid receptor with nuclear events 
regulating myocyte growth and gene transcription. For example, thyroid hormones have 
been shown to directly affect the transcription of a number of genes (e.g. a—MHC, 
13-adrenergic receptor) by interaction of the thyroid receptor with cis-acting elements in 
their 5' regions (Bahouth, 1991; Nadal Ginard and Mandavi, 1989) and it is possible that 
this hormone may affect transcription of other genes important to the cardiac 
hypertrophic response by a similar mechanism. Unexpectedly, and in contrast to other 
early-response genes investigated, administration of thyroxine led to a gradual rise in 
fra-2 mRNA. Whether this early-response gene is a permissive factor for thyroid 
hormone induced hypertrophy is not known and the ability of thyroxine to positively 
modulate expression of members of the c-fos gene family has not been previously 
reported although recent studies suggest that the thyroid receptor can interact with AP-1 
to affect its transcription activity (Lopez et al., 1993). Further studies are required to 
determine if this is a direct transcriptional effect of the activated thyroid receptor on 
fra-2 expression or whether increased fra-2 levels are secondary to T3 mediated 
alterations in cardiac contractility or activity of hormonal factors. 
Thyroid hormone mediated cardiac hypertrophy is phenotypically different to 
pressure/NE mediated growth in that it is not accompanied by re-expression of the fetal 
genes and this is entirely constant with the hypothesis that re-expression of this fetal 
gene program requires prior expression of a certain panel of early-response genes such 
as Fos and Jun. Alternatively, increased early-response gene expression following NE 
treatment or pressure overload may be a coincidence unrelated to myocyte growth or 
qualitative alterations in gene expression. Indeed the evidence presented here and those 
of others implicating a role for Fos and Jun in cardiac myocyte growth and genetic 
reprogramming following NE administration or pressure-overload has come from 
correlative studies. Future studies will need to formally demonstrate both in vitro and in 
vivo that these transcription factors can directly alter cardiac myocyte gene expression. 
With respect to this, some recent evidence supporting such a function has been obtained 
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using neonatal myocyte cultures. In the studies of Bishopric et al., 1992 expression 
vectors encoding c-fos and c-jun were used to analyze the role of these early-response 
genes in mediating the transcriptional induction of a-SkA by adrenergic stimulation. 
They were able to demonstrate that over expression of Fos/Jun trans-activated the fetal 
isoform a-SkA promoter 5 fold but did not affect transcription of the a-MHC promoter, 
an isoform associated with the adult heart. These results suggest a direct role for these 
genes in regulating a-SkA expression and more generally in cardiac actin isoform 
switching. However not all transfection studies with neonatal myocytes cultures 
support a positive role for early-response genes in trans-activating the fetal gene 
program. For example McBride et al., (1993) demonstrated in transient co-transfection 
assays that Jun, Fos, Fra-1, Fos-B and v-Fos trans-repress the ANP promoter 5-10 fold 
in both quiescent and a l -adrenergic stimulated atrial and ventricular myocytes. Deletion 
analysis indicated that repression did not require typical AP-1 binding sites or serum 
response elements but was targeted at a cardiac specific element within the ANP 
promoter. Furthermore, repression by Jun occurred via the N-terminal activation domain 
and did not require the DNA binding domain suggesting that AP-1 repression involved 
interaction with one or more limiting cardiac-specific factors. Thus, although 
stimulation of neonatal cardiomyocytes with acadrenergic agents induces cellular 
hypertrophy and increased AP-1 activity and ANP expression, induction of ANP in this 
model must result from activation of a Fos/Jun independent pathway. The above studies 
have provided the first evidence indicating that Fos and structurally or functionally 
related genes can have both positive and negative effects on the transcription of the 
cardiac gene program. A similar ability of Fos/Jun to both trans-repress and activate has 
been observed in other systems (Shaw et al., 1989; Schule et al., 1990; Gius et al., 1990; 
Lucibello et al., 1990). It remains to be seen however, whether these transcription 
factors are functional in other models of neonatal myocyte hypertrophy (ie: stretch or 
growth factor induced) or indeed if similar mechanisms of action are conserved in the 
more relevant adult myocytes in vivo. As a first step in addressing these questions it is 
important that similar transient transfection assays to those performed in the neonatal 
myocyte system be performed in primary adult myocytes cultures, although the greater 
inherent problems in maintenance of the more mature cells dictates that these 
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experiments will be considerably more difficult. Even so, recent studies have 
demonstrated that recombinant adenovirus can efficiently transfer reporter gene 
constructs into adult ventricular myocytes although the appropriate experiments 
examining the effects of putative regulators have yet to be undertaken (Kirshenbaun et 
al., 1993). Even if such transfection experiments are fruitful it will still be necessary to 
determine their relevance to the physiological and pathological growth of the cardiac 
myocyte in vivo. 
One possible alternative model in which to close the gap between the observations 
of molecular and cellular biologists in vitro and the pathophysiological effects of growth 
pathways on cardiac hypertrophy in vivo is the use of transgenic animals (reviewed by 
Sigmund, 1993). To achieve this it will be necessary to fuse the gene of interest, in this 
case early-response genes such as c-fos, to transcriptional control elements which confer 
myocyte-specific expression. Following integration of this construct into the genome of 
the animal, it will be possible to examine the effect of hypertrophic growth stimulation 
on the expression and function of the target gene in the context of the whole heart. To 
date a diverse panel of cardiovascular genes whose regulatory sequences confer tissue 
and/or inducible expression to a heterologous protein have been identified (for reviews 
see Hunter et al., 1993; Sigmund, 1993). 
Gene "knockout" experiments may also prove to be a powerful approach to the 
study of cardiac hypertrophy. For example, recently mice lacking a functional c-fos 
gene have been created using embryonic stem cells targeted by homologous 
recombination at the c-fos locus (Johnson et al., 1992). Interestingly this mutation is not 
lethal, rather it causes a wide range of phenotypic deficiencies with some of the 
homozygous mutant animals surviving for over 7 months. Such animals would be ideal 
models in which to determine whether c-fos is important in the regulation of genes 
thought to be structurally or functionally important to the hypertrophying heart. 
Similarly mice lacking functional fra-1 or fra-2 genes may become available and 
together these mouse models should become increasingly important in the search for 
regulators of cardiac development, growth and disease in the future. 
One difficulty with the models outlined above is their high cost and excessive 
time required to generate the new animal lines. A possible novel alternative to these 
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systems is the direct injection of expression/reporter constructs into adult hearts in vivo 
(Buttrick et al., 1992; Kitsis et al., 1991; Acsadi et al., 1991; Lin et al., 1990). Indeed 
preliminary reports already exist demonstrating the utility of direct injection technique in 
mapping cis- and trans-acting factors involved in cardiac specific gene expression 
(Buttrick et al., 1993; Kitsis et al., 1991). Using this technique it may be feasible to 
determine the importance of early-response gene expression to the structure and 
function of cardiac myocytes in vivo. 
The studies in this thesis and the majority of those in the current literature have 
focused on the molecular signals linking trophic stimuli to the altered expression of 
specific subsets of phenotypic marker genes seen as being important to the myocyte 
structure and function during hypertrophy. However, for a number of reasons caution 
has to be used in extrapolating the significance of these results to the human situation. 
Firstly, it is now becoming evident that the phenotypic changes in the adult human heart 
following hypertrophic stimuli are not necessarily the same as those in small rodents. 
For example in rats a-SkA is present in extremely low levels in the normal adult left 
ventricle but following pressure overload the rnRNA and protein levels of this gene rise 
dramatically (Schwartz et al., 1986) . In contrast a-SkA remains expressed at quite high 
levels in the human left ventricle throughout life (Gunning et al., 1983; Vandekerckhove 
et al., 1986). Such observations underline the fact that cardiac hypertrophy is 
qualitatively different between species and raises the question as to the relevancy of 
delineating pathways leading to increased a-SlcA in the rat heart in terms of cardiac 
hypertrophy of the adult human heart. Secondly, the use of certain genes traditionally 
seen as being prototypical markers of pathological hypertrophy may have to be revised. 
For example, decompensated hypertrophy associated with chronic pressure overload in 
rats is characterized by re-expression of ANP, a-SlcA and Ca 2+ ATPase in the left 
ventricle (Feldman et al., 1993). However when hypertrophy of the left ventricle is 
reduced to a level similar to that of the normal heart by use of levels of angiotensin 
converting enzyme inhibitors which do not reduce the pressure load on the heart, only 
the level of Cal  ATPase is reduced (Lore11 et al., 1993). Such findings indicate that 
Ca' ATPase closely correlates with decompensated hypertrophy whilst ANP and 
a-SlcA may simply be markers of pressure load per se. These studies clearly 
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demonstrate the importance of defining exactly which sets of genes are important in 
contributing to the altered performance of the heart during physiological and 
pathological hypertrophy so that the ability of putative transcription factors such as c-fos 
and c-fun, to modulate their expression can be tested in the appropriate model systems. 
In addition to the qualitative changes in gene expression discussed above, postnatal 
cardiac growth is also characterized by a general increase in myocyte protein synthesis 
and it is this trophic process which accounts for the increase in myocyte size (reviewed 
by Morgan et al., 1987). Increases in general protein synthesis have been shown to 
occur as the result of raised myocyte cellular capacity to produce protein viz., an 
increase in cellular ribosome content (McDermott and Morgan, 1989; Siehl etal., 1985). 
In turn increased ribosome biogenesis is largely due to elevated ribosomal DNA 
(rDNA) transcription and accelerated rates of transcription can be observed within 12 h 
following hypertrophic stimuli (McDermott et al., 1991 and references there in). The 
mechanisms by which rDNA transcription is controlled are relatively poorly understood 
although recent studies indicate that at least two transcription factors, UBF and SL-1 in 
addition to polymerase 1 are required for efficient transcription from vertebrate rDNA 
promoters (reviewed by Xie and Rothblum, 1993). It is feasible then that early-response 
genes such as c-fos may be involved in coordinating this response by directly binding 
to the promoter region of the 45S gene and interacting with the initiation factors to 
modulate transcription. Indeed, putative AP-1 consensus sequences have been identified 
in the promoter regions of the 45S gene (Rothblum, L. I., pers. comm.). Alternatively 
early-response genes may be involved in trans-inducing the rDNA transcription factors 
themselves. In support of this UBF mRNA and protein is rapidly induced in response to 
hypertrophic stimuli such as norepinephrine in neonatal myocyte cultures and this 
induction is preceded by c-fos expression (Rothblum, L. I., pers. comm.). Further 
studies are require to identify the molecular mechanisms involved in regulating rDNA 
transcription and to determine possible roles of nuclear acting early-response genes in 
this process. It will be interesting to determine whether cardiac rDNA transcription and 
qualitative changes in gene expression are regulated through similar or distinct pathways 
during NE-mediated cardiac hypertrophy. In contrast, the results presented here indicate 
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that c-fos and c-jun are probably not involved in regulating general protein synthesis 
during T3 mediated cardiac hypertrophy. 
In conclusion this thesis has demonstrated that c-fos, c-jun and related proteins of 
the AP-1 complex fullfill the temporal, spatial and cellular-specific requirements 
necessary for transcription factors proposed to be active in the initiation and 
maintenance of NE mediated cardiac hypertrophy in vivo. These physiologically 
relevant studies are of increasing importance in light of recent in vitro neonatal myocyte 
experiments demonstrating that c-fos and c-jun can directly regulate the expression of 
genes thought to be structurally and functionally important to the hypertrophic response 
of the heart following NE administration and pressure overload. Future studies will need 
to examine the ability of the heart to initiate cardiac hypertrophy following inhibition of 
c-fos and/or c-jun expression using transfection studies in vitro or by transgenic and 
direct injection techniques in vivo. In contrast the prototypical early-response gene, 
c-myc is localized to non-myocyte cell types following NE administration making it 
unlikely that this gene has a direct role in regulating adult myocyte hypertrophy. Further 
studies are required to determine if this gene is involved in potentiating the growth and 
function of non-myocyte cell types which occurs concomitant with cardiac myocyte 
hypertrophy. 
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